2 0 1 7 A N N U A L R E P O R T
REWRITING TREATMENTS FOR PATIENTS WITH CANCER
AND OTHER SERIOUS DISEASES
TO OUR SHAREHOLDERS,
I am proud to be reporting to you,
our shareholders, about our many
achievements in 2017 that helped
drive value and moved Epizyme
closer to its mission and the reason
we work so hard each and every
day: bringing new treatments to
patients in need. Based on these
accomplishments and the strength
of our clinical and regulatory
progress with tazemetostat, our
lead anti-cancer investigational
medicine, we are now focused on
evolving Epizyme into a fully
integrated, commercial
biopharmaceutical company.
Tazemetostat is a first-in-class, oral
inhibitor of EZH2, which has been
linked to many forms of cancer.
This product candidate has broad
potential applicability ? in
hematological malignancies and
solid tumors, both as a
monotherapy and as a combination
agent in early and late lines of
treatment. We have a
comprehensive clinical
development program underway,
with our first New Drug Application
(NDA) for tazemetostat in sight.
An estimated 40,000 people in the U.S. and European Union are
treated for FL each year. FL is an incurable and deadly form of cancer
that is most frequently treated with multiple lines of systemic
chemotherapy. As a result, there remains a significant need for an
effective, convenient and tolerable medicine that patients can take for
long durations.
Our Phase 2 trial includes FL patients with and without EZH2
activating mutations. We reported interim data from this trial in June
of 2017, demonstrating tazemetostat?s clinical activity in the vast
majority of patients enrolled with an EZH2 mutation and in a number
of patients without EZH2 mutations. This led to an initial interaction
with the FDA late in the year to begin discussing our FL program.
We plan to complete enrollment of FL patients in the Phase 2 trial and
present updated data at a medical meeting this year. We also plan to
commence our first FL combination study in the second half of the
year. In order to further refine our registration strategy for
accelerated approval, we plan to have additional interactions with FDA
as we progress through 2018, with an NDA submission in this
indication targeted for 2019.
In addition to ES and FL, we are testing tazemetostat?s potential to
benefit patients with:
-
-
-
-
Diffuse large B-cell lymphoma both as a monotherapy and
in three separate therapeutic combinations;
Mesothelioma with BAP1 loss-of-function as a monotherapy;
Other INI1-negative tumors as a monotherapy, both in
adults and children; and
Non-small cell lung cancer in combination with
atezolizumab.
"Tazemetostat
represents an
exciting 'pipeline
in a product'
opportunity for
Epizyme and
our shareholders."
This planned NDA is for a rare solid tumor called epithelioid sarcoma
(ES). An ES diagnosis typically occurs between the ages of 20 and 40,
and for these patients, the situation is dire. There are no treatments
currently indicated specifically for this cancer, and patients with
localized disease tend to undergo numerous surgeries, including
potential amputations, in the hopes of controlling the spread of the
disease. Those with unresectable or metastatic ES are often treated
with chemotherapy, which has shown limited clinical benefit. As a
result, the median survival for ES patients is reported to be only
about 30 months, and less than one year for patients with metastatic
disease.
It is clear that tazemetostat represents an exciting "pipeline in a
product" opportunity for Epizyme and our shareholders. As we
continue its development, we plan to move our next product
candidate, EZM8266, toward the clinic. EZM8266 is a novel G9a
inhibitor we are developing for the potential treatment of sickle cell
disease, a blood disorder that affects approximately 300,000 people
globally. Unlike most of today?s medicines, which tend to treat the
symptoms of sickle cell disease, we believe EZM8266 has the potential
to modify the underlying disease. In 2018, we plan to complete the
necessary work to enable an Investigational New Drug filing, with
clinical development anticipated to begin in early 2019.
We are now well underway in a Phase 2 study evaluating the
potential for tazemetostat as a monotherapy to treat patients with
this devastating cancer. In 2017, we completed enrollment in what is
now the largest clinical program undertaken in ES. The preliminary
data from this trial prompted us to engage with the U.S. Food and
Drug Administration (FDA) to discuss a potential registration for
tazemetostat, and this interaction enabled us to identify a path to
accelerated approval. We intend to present mature data from this
population at a medical meeting in the second half of 2018, and we
are on-track to achieve the most significant milestone in Epizyme?s
history - an NDA submission in the fourth quarter of 2018.
We are also diligently working to bring tazemetostat to much larger
patient populations who are in need of new treatment options. Our
efforts include our Phase 2 study for the treatment of patients with
follicular lymphoma (FL), one of the most prevalent forms of
non-Hodgkin lymphoma (NHL).
In summary, our work in 2017 has positioned us well for what we
believe will be the most milestone-rich period in the company?s
history. I am very proud of the Epizyme team and commend them for
their hard work and steadfast dedication to serving patients. I also am
incredibly thankful to all of the patients, physicians and medical
personnel who participate in our studies and fuel our passion.
I look forward to reporting back to you on our continued progress.
Sincerely,
Robert Bazemore
President and Chief Executive Officer
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2017
or
For the transition period from to
Commission File Number 001-35945
EPIZYME, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of
incorporation or organization)
400 Technology Square, Cambridge, Massachusetts
(Address of principal executive offices)
26-1349956
(I.R.S. Employer
Identification No.)
02139
(Zip code)
617-229-5872
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Common stock, $0.0001 par value
(Title of each class)
NASDAQ Global Market
(Name of exchange on which registered)
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. ☐
Yes ☒ No
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12
months (or for such shorter period that the registrant was required to submit and post such files). ☒ Yes ☐ No
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (229.405 of this chapter) is not
contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☒
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See definitions of “accelerated filer,” “large accelerated filer,” “smaller reporting company”
and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
Non-accelerated filer
☐
☐ (Do not check if a smaller reporting company)
☒
Accelerated filer
Smaller reporting company ☐
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No
The aggregate market value of the registrant’s common stock, par value $0.0001 per share, held by non-affiliates of the registrant on
June 30, 2017, the last business day of the registrant’s most recently completed second fiscal quarter, was approximately $673.1 million
based on the closing price of the registrant’s common stock on the NASDAQ Global Market on that date.
The number of outstanding shares of the registrant’s common stock, par value $0.0001 per share, as of March 1, 2018 was 69,440,282.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s definitive proxy statement that the registrant intends to file with the Securities and Exchange Commission
pursuant to Regulation 14A in connection with the registrant’s 2018 Annual Meeting of Stockholders are incorporated by reference into
Part III of this Annual Report on Form 10-K to the extent stated herein.
Epizyme, Inc.
Annual Report on Form 10-K for the Fiscal Year Ended December 31, 2017
Table of Contents
PART I
Item No.
Item 1.
Business................................................................................................................................................
Item 1A. Risk Factors ..........................................................................................................................................
Item 1B. Unresolved Staff Comments.................................................................................................................
Properties..............................................................................................................................................
Item 2.
Legal Proceedings ................................................................................................................................
Item 3.
Mine Safety Disclosures.......................................................................................................................
Item 4.
PART II
Item 5.
Item 6.
Item 7.
Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases
of Equity Securities ..............................................................................................................................
Selected Financial Data ........................................................................................................................
Management’s Discussion and Analysis of Financial Condition and Results of Operations ..............
..............................................................................................................................................................
Item 7A. Quantitative and Qualitative Disclosures about Market Risk ..............................................................
Financial Statements and Supplementary Data ....................................................................................
Item 8.
Item 9.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure ..............
Item 9A. Controls and Procedures.......................................................................................................................
Item 9B. Other Information.................................................................................................................................
PART III
Item 10. Directors, Executive Officers and Corporate Governance ...................................................................
Item 11. Executive Compensation ......................................................................................................................
Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related
Stockholder Matters..............................................................................................................................
Item 13. Certain Relationships and Related Transactions, and Director Independence.....................................
Item 14. Principal Accounting Fees and Services ..............................................................................................
PART IV
Page
3
40
71
71
71
71
72
74
75
90
90
92
92
93
95
95
95
95
95
Item 15. Exhibits, Financial Statement Schedules..............................................................................................
Item 16. Form 10-K Summary............................................................................................................................
96
99
Signatures ............................................................................................................................................. 100
Epizyme® is a registered trademark of Epizyme, Inc. in the United States and/or other countries. All other
trademarks, service marks or other trade names appearing in this Annual Report on Form 10-K are the property of
their respective owners.
Forward-looking Information
This Annual Report on Form 10-K contains forward-looking statements that involve substantial risks and
uncertainties. These statements may be identified by such forward-looking terminology as “anticipate,” “believe,”
“estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,”
“should,” “continue,” and similar statements or variations of such terms. Our forward-looking statements are based
on a series of expectations, assumptions, estimates and projections about our company, are not guarantees of future
results or performance and involve substantial risks and uncertainty. We may not actually achieve the plans,
intentions or expectations disclosed in our forward-looking statements. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in these forward-looking statements. Our business
and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the
risks and uncertainties inherent in our statements regarding:
•
•
•
•
•
•
•
•
our plans to develop and commercialize novel epigenetic therapies for patients with cancer and other
serious diseases;
our ongoing and planned clinical trials, including the timing of initiation and enrollment in the trials, the
timing of availability of data from the trials and the anticipated results of the trials;
our ability to achieve anticipated milestones under our collaborations;
the timing of and our ability to apply for, obtain and maintain regulatory approvals for our product
candidates;
the rate and degree of market acceptance and clinical utility of our products;
our commercialization, marketing and manufacturing capabilities and strategy;
our intellectual property position; and
our estimates regarding expenses, future revenue, capital requirements and needs for additional
financing.
All of our forward-looking statements are made as of the date of this Annual Report on Form 10-K only. In each
case, actual results may differ materially from such forward-looking information. We can give no assurance that
such expectations or forward-looking statements will prove to be correct. An occurrence of or any material adverse
change in one or more of the risk factors or risks and uncertainties referred to in this Annual Report on Form 10-K
or included in our other public disclosures or our other periodic reports or other documents or filings filed with or
furnished to the Securities and Exchange Commission, or the SEC, could materially and adversely affect our
business, prospects, financial condition and results of operations. Except as required by law, we do not undertake or
plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions,
estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of
this Annual Report on Form 10-K, even if such results, changes or circumstances make it clear that any forward-
looking information will not be realized. Any public statements or disclosures by us following this Annual Report
on Form 10-K which modify or impact any of the forward-looking statements contained in this Annual Report on
Form 10-K will be deemed to modify or supersede such statements in this Annual Report on Form 10-K.
Item 1.
Business
Overview
PART I
We are a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other
serious diseases through discovering, developing, and commercializing novel epigenetic medicines. By focusing on
the genetic drivers of disease, our science seeks to match targeted medicines with the patients who need them. We
are broadly developing our lead product candidate, tazemetostat, an oral, first-in-class selective inhibitor of the
EZH2 histone methyltransferase, or HMT, in a range of cancer types and settings, and developing the lead
development candidate in our novel G9a program, EZM8266, for the treatment of sickle cell disease, or SCD.
We have taken a “pipeline in a product” approach to developing tazemetostat with a broad clinical development
program through company-sponsored studies and collaborations that are evaluating tazemetostat as both a
monotherapy and combination treatment in both hematological malignancies and solid tumors. Tazemetostat has
shown meaningful clinical activity as a monotherapy in indications in both disease areas and has been well tolerated
across clinical trials to date.
In our hematological program, we are conducting global Phase 2 studies evaluating tazemetostat’s treatment
potential in patients with relapsed or refractory follicular lymphoma, or FL, or diffuse large B-cell lymphoma, or
DLBCL, the two most prevalent forms of non-Hodgkin lymphoma, or NHL, both with and without EZH2 activating
mutations. We are continuing to enroll FL and DLBCL patients with EZH2 mutations in our ongoing global Phase 2
monotherapy relapsed or refractory FL and DLBCL study. Based on initial engagement with the U.S. Food and
Drug Administration, or FDA, we believe we have the opportunity to submit for accelerated approval for
tazemetostat as a monotherapy in FL. We plan to continue to engage with the FDA in 2018 to further refine our
registration strategy for FL, and subject to the results of our FL study, are targeting a planned submission to the
FDA of a New Drug Application, or NDA, for tazemetostat for FL in 2019. We also have multiple combination
studies underway through collaborators with both targeted agents and chemotherapy in DLBCL, in both relapsed or
refractory and first-line treatment settings, and plan to commence a combination study of tazemetostat in FL in the
second half of 2018.
In our solid tumor program, we are evaluating tazemetostat’s treatment potential in adults and children with
molecularly defined solid tumors, including INI1- and SMARCA4-negative tumors, which we collectively refer to
as INI1-negative tumors. We are conducting a global Phase 2 trial of tazemetostat in adults with INI1-negative
tumors, including epithelioid sarcoma, malignant rhabdoid tumors, or MRT, other INI1-negative tumors, and
chordoma. Based on positive data that we observed in the epithelioid sarcoma cohort in the ongoing study, we
engaged with the FDA in May 2017. Based on this FDA interaction, we have identified a potential path to
submission for accelerated approval in this indication and we are targeting submission of our first NDA to the FDA
for tazemetostat for epithelioid sarcoma in the fourth quarter of 2018. In connection with this submission, we plan to
commence a clinical trial of tazemetostat for epithelioid sarcoma that could serve as the confirmatory trial required
in connection with any accelerated approval. We are also evaluating tazemetostat in the dose-expansion portion of a
Phase 1 study in pediatric patients with INI1-negative tumors and in a Phase 2 study in adults with mesothelioma
characterized by BAP1 loss-of-function. In addition, as part of a study conducted by our collaborator Genentech,
Inc., or Genentech, tazemetostat is being evaluated in combination with atezolizumab (TECENTRIQ®), a PD-L1
inhibitor, in patients with non-small cell lung cancer, or NSCLC.
We own the global development and commercialization rights to tazemetostat outside of Japan. Eisai Co. Ltd, or
Eisai, holds the rights to develop and commercialize tazemetostat in Japan. Tazemetostat is covered by claims of
U.S. and European composition of matter patents, which are expected to expire in 2032, exclusive of any extensions.
We have announced that the FDA has granted tazemetostat Fast Track designation in patients with relapsed or
refractory FL, with or without activating EZH2 mutations, and relapsed or refractory DLBCL with EZH2 activating
mutations. We have also announced that the FDA has granted orphan drug designation for the treatment of patients
with FL, malignant rhabdoid tumors, or MRT, soft tissue sarcoma and mesothelioma. The orphan drug designation
for the treatment of MRT applies to INI1-negative MRT as well as SMARCA4-negative malignant rhabdoid tumor
of ovary, or MRTO. We also own global rights to EZM8266 targeting G9a.
We have retained commercialization rights in the United States to all of our other programs, except two programs
that are the subject of our collaboration with Glaxo Group Limited, which we refer to as GlaxoSmithKline, or GSK,
and two of the preclinical programs that are the subject of our collaboration with Celgene. We plan to retain
commercialization rights in the United States and possibly in select foreign jurisdictions in connection with any
future collaborations. We intend to build a focused field presence and marketing capabilities to commercialize any
of our product candidates that receive regulatory approval in the United States, as well as the capabilities to lead
global commercial strategy. We have recently begun building the infrastructure necessary to support the successful
launch and marketing of tazemetostat and other product candidates that may receive marketing approval.
Our Corporate Strategy
Our goal is to become a fully integrated biopharmaceutical company developing and commercializing novel
epigenetic therapies for patients with cancer and other serious diseases.
The key elements of our corporate strategy are to:
•
•
•
•
•
•
rapidly advance the clinical development of tazemetostat in molecularly defined solid tumors and NHL;
expand the treatment utility for tazemetostat through a broad development program evaluating different
combinations, in both early- and late-lines of treatment and in additional indications;
establish commercialization and marketing capabilities in the United States;
leverage our drug discovery platform to build a pipeline of chromatin modifying protein, or CMP,
inhibitors;
as necessary, develop companion diagnostics for use with our therapeutic candidates; and
leverage strategic collaborations that can contribute to our ability to rapidly advance our product
candidates and build our company.
Our Pipeline
Overview. The following table summarizes our current pipeline:
1
Eisai holds rights to tazemetostat in Japan
2
3
4
5
Part of Genentech’s MORPHEUS umbrella study
Celgene holds ex-US rights to pinometostat
GSK holds global rights
Celgene holds option to license ex-US rights for one target and global rights for the other two targets
Tazemetostat Clinical Program in Epithelioid Sarcoma and Other INI1-Negative Solid Tumors
Background on INI1-Negative Solid Tumors: INI1 and SMARCA4 are subunits of SWI/SNF, a chromatin
modifying protein complex, that opposes the activity of PRC2, the complex within which EZH2 resides. Loss of
INI1 or SMARCA4 in specific cell backgrounds is believed to cause dysregulation in the balance between SWI/SNF
and PRC2, and thus cause tumors to become sensitive to EZH2 inhibition. This effect was observed in a preclinical
study of tazemetostat in a xenograft model of MRT in which tazemetostat caused a dose dependent regression in
INI1-negative tumors. INI1-negative tumors can appear in many different tissue types, and can present as epithelioid
sarcoma, MRT, extraskeletal myxoid chondrosarcoma, peripheral nerve sheath tumor and myoepithelial carcinoma,
among several others. SMARCA4-negative tumors can also appear as different tumor types, including MRTO.
INI1-negative or certain SMARCA4-negative tumors are typically aggressive cancers with few to no approved
treatments. For example, epithelioid sarcoma is an ultra-rare and aggressive soft tissue sarcoma, characterized by a
loss of the INI1 protein. It is most commonly diagnosed in young adults (20-40 years old) and is often fatal. There is
no established standard-of-care for treating these patients, who are typically resistant to chemotherapy. INI1-
negative tumors are most commonly seen in infants through young adults, while SMARCA4-negative tumors are
most commonly seen in teenagers and young adults. It is estimated that approximately 2,000 new patients (adults
and children) with INI1-negative tumors and certain SMARCA4-negative tumors are diagnosed annually in the
United States and other major pharmaceutical markets; however, we believe that the actual number may be higher,
as these types of molecularly defined cancers are significantly under-reported today.
Phase 2 Clinical Program in Adults: We are conducting a registration-supporting, global Phase 2 trial of
tazemetostat monotherapy in patients with certain molecularly defined solid tumors, including INI1-negative tumors
and synovial sarcoma. This trial is enrolling up to 250 patients. The patients in the trial were previously stratified
into one of five cohorts: epithelioid sarcoma (n=60), rhabdoid tumors (n=30), other INI1-negative tumors (n=30),
renal medullary carcinoma (n=30) and synovial sarcoma (n=30). In 2017, we opened two additional cohorts: INI1-
negative chordoma (n=30) and a cohort to explore the effect of tazemetostat treatment on immune responsiveness by
obtaining paired tumor biopsies in epithelioid sarcoma patients (n=40).
Patients in the Phase 2 trial in molecularly defined solid tumors are dosed at 800 mg twice daily with tablets taken
orally. The primary endpoint for all cohorts, except synovial sarcoma and the paired biopsy cohort, is overall
response rate. The primary endpoint for the synovial sarcoma cohort is disease control, defined as a complete
response, partial response, or stable disease, at 16 weeks. The primary endpoint for the paired biopsy cohort is
assessment of pre- and post-dose biopsies for immune priming (e.g. PD-L1 and CD8 IHC).
Epithelioid Sarcoma Cohort: The epithelioid sarcoma cohort in our Phase 2 trial represents the largest prospective
trial of epithelioid sarcoma with any approved or investigational treatment to date. The cohort was initially designed
to enroll 30 patients and was expanded in December 2016 to enroll an additional 30 patients based on encouraging
early activity. We completed enrollment in the 60-patient epithelioid sarcoma cohort in July 2017, and are enrolling
up to an additional 40 patients in a new cohort to explore the effect of tazemetostat treatment on immune
responsiveness by obtaining paired tumor biopsies in these patients.
In June 2017, at the American Society of Clinical Oncology 2017 Annual Meeting, or ASCO, we presented interim
data from 31 patients in the initial epithelioid sarcoma cohort, as of the data cutoff date of May 1, 2017. In these
patients, tazemetostat treatment resulted in a 32% disease control rate, the primary endpoint at that time. Disease
control rate is comprised of confirmed objective responses measured in accordance with Response Evaluation
Criteria in Solid Tumors, or RECIST 1.1, guidelines for any duration or disease stabilization of 32 weeks or more.
As of the data cutoff date, four patients (13%) had achieved confirmed objective responses (all partial), and the time
to response ranged from two months to six months. The median duration of response was seven months and
ongoing. Prolonged disease stabilization of 32 weeks or more was observed in six patients (19%), including two
patients having stable disease for more than 15 months. Updated data from the 60-patient cohort are expected to be
presented in the second half of 2018.
Due to a lack of treatment options and the severity of epithelioid sarcoma, we believe that this molecularly defined
patient population may represent the fastest potential path to a first NDA submission, approval and commercial
launch for tazemetostat. Based on an interaction with the FDA, we have identified a potential path to submission for
accelerated approval in this indication and we are targeting submission of our first NDA to the FDA for tazemetostat
for epithelioid sarcoma in the fourth quarter of 2018.
Other INI1-Negative Tumor Cohorts: In November 2017, we reported that both the malignant rhabdoid tumor
cohort and other INI1-negative tumor cohorts of the ongoing Phase 2 study surpassed their futility assessment with
objective responses observed in both populations. We are continuing to monitor patients in these cohorts, and plan to
present updated data from these cohorts in 2018. We added the chordoma cohort due to the high rate of enrollment
of these patients in the other INI1-negative cohort and the observed clinical activity with tazemetostat in this tumor
type in both adults and children to date. Enrollment in this cohort in underway.
At ASCO 2017, we presented data from the synovial sarcoma cohort of the trial, which we had fully enrolled.
Unlike the cancers in the other cohorts of the trial, synovial sarcoma is characterized by a functional dysregulation
of INI1, rather than by a complete loss of INI1. The data presented showed tazemetostat treatment resulted in stable
disease as the best response in 10 patients (30%) with five patients (15%) meeting the primary endpoint of disease
stabilization for 16 weeks or longer. Despite these results, we concluded that the activity of tazemetostat in this
cohort was insufficient to continue further investigation of tazemetostat in this population as a monotherapy. In
addition, in the third quarter of 2017, we determined that while activity had been observed in the cohort of patients
with renal medullary carcinoma, we had not seen sufficient activity to warrant further investigation of that as a
monotherapy for this aggressive disease.
Phase 1 Clinical Program in Children: We are conducting a global Phase 1 dose-escalation and expansion trial of
tazemetostat in approximately 110 children with INI1-negative solid tumors. We have completed the dose-escalation
portion and have advanced to the dose-expansion stage of this trial. In the trial, we used an oral suspension formula
of tazemetostat in the dose-escalation portion, and are using both the oral suspension and a tablet formulation in the
dose-expansion portion. The primary endpoint of the trial is safety, with the objective of establishing the
recommended Phase 2 dose in pediatric patients. Secondary endpoints include pharmacokinetics, objective response
rate, duration of response, PFS and overall survival. We anticipate completing enrollment in this study in 2018.
In October 2017, dose-escalation data were presented at the AACR-NCI-EORTC International Conference on
Molecular Targets and Cancer Therapeutics. Objective responses were observed in patients with epithelioid sarcoma
(n=1), poorly differentiated chordoma (n=2) and atypical teratoid rhabdoid tumors (n=1) at dose levels ranging from
520 to 900 mg/m2 twice daily. The recommended Phase 2 dose has been reached and we have advanced to the dose-
expansion stage.
Tazemetostat Clinical Program in Non-Hodgkin Lymphoma
We are executing a broad clinical development program for tazemetostat as both a monotherapy and combination
treatment in relapsed/refractory and first-line NHL, as summarized below.
Background on NHL: Two types of NHL, FL and DLBCL of germinal center origin, are associated with oncogenic
EZH2 mutations. In our preclinical studies, we observed that NHL cells were sensitive to EZH2 inhibitors such as
tazemetostat and that NHL cells bearing EZH2 mutations were particularly responsive to such treatment. EZH2
plays a critical role at various stages in normal B-cell maturation, and a particularly important role during the stage
of B-cell development known as the germinal center reaction. Recent research has demonstrated that EZH2 acts as a
key gatekeeper for B-cell maturation and differentiation. Our own ongoing research suggests that it is a combination
of stem or progenitor cell of origin together with specific genetic lesions that confer sensitivity of cancer cells to
EZH2 inhibition. An analysis of patient samples with germinal center derived NHL has revealed a number of
genetic alterations that impact EZH2 function in ways that may confer sensitivity to EZH2 inhibition. While FL and
DLBCL remain the initial NHL target patient populations for tazemetostat, our clinical and preclinical data suggest
patients with other forms of B-cell NHL may also benefit from tazemetostat.
Background on FL: The population of patients with FL is large and growing. FL is considered to be incurable with
existing treatments and is characterized by cycles of relapse that become increasingly difficult to treat with each
disease progression. We estimate that the number of FL patients in the United States and five largest European
Union countries as measured by population, or EU5, that receive treatment in any year is approximately 40,000
patients. We estimate that approximately 20% of FL tumors carry an EZH2 activating mutation. Common treatments
for FL include multi-agent chemotherapy, usually combined with rituximab (Rituxan®), including R-CHOP and R-
Bendamustine. Upon clinical progression, salvage treatment regimens are typically other combinations of the cancer
agent rituximab and other chemotherapy drugs or idealisib or copanlisib. There are no approved treatments
specifically indicated for patients with FL with an EZH2 mutation.
Background on DLBCL: DLBCL is an aggressive form of NHL that, once diagnosed, typically requires immediate
treatment. We estimate that the number of DLBCL patients in the United States and EU5 that receive treatment in
any year are approximately 80,000 patients. DLBCL can be further subdivided into lymphoma originating from the
germinal center of the lymph node, known as GCB DLBCL, and lymphoma originating from B-Cells of a more
mature lineage, known as non-GCB DLBCL. We estimate that approximately 60% of DLBCL tumors are non-GCB
and approximately 40% are GCB. We estimate that approximately 20% of GCB DLBCL tumors carry an EZH2
activating mutation. While current therapies successfully treat more than 50% of DLBCL patients in the first line
setting, there remains an unmet medical need in patients who have relapsed or are not responding to treatment.
According to literature, 40-50% of patients will relapse on their first line treatment, which is most commonly the
chemotherapy regimen R-CHOP, and there are few treatment options for patients who relapse or become refractory
to chemotherapy.
Phase 2 Clinical Program: We are evaluating tazemetostat in a global Phase 2 trial in up to 340 patients with
relapsed or refractory NHL across six cohorts. Five of the cohorts are investigating tazemetostat as a monotherapy
and the sixth cohort, which we opened in March 2017, is investigating tazemetostat in combination with
prednisolone in patients with relapsed or refractory DLBCL. Patients are dosed with tazemetostat at 800 mg twice
daily with tablets taken orally. The cohorts enrolling patients with DLBCL are enrolling 60 patients each, the two
cohorts enrolling patients with FL are enrolling 45 patients each and the prednisolone combination cohort is
enrolling 70 patients. The monotherapy trial cohorts are as follows:
•
•
•
•
•
FL with EZH2 mutations;
FL with wild-type EZH2;
DLBCL with EZH2 mutations;
DLBCL with wild-type EZH2 with GCB subtype;
DLBCL with wild-type EZH2 with non-GCB subtype.
The prednisolone combination cohort has enrolled both GCB and non-GCB DLBCL patients with wild-type EZH2.
The primary endpoint of the trial is overall response rate. Secondary endpoints include duration of response, PFS,
overall survival, safety and population pharmacokinetics. We completed enrollment in the monotherapy cohorts
enrolling wild-type EZH2 FL and DLBCL patients in 2017 and expect to complete enrollment in the cohorts
enrolling patients with EZH2 mutations in 2018.
In June 2017, at the International Conference on Malignant Lymphoma, or ICML, we presented interim safety and
efficacy data from this trial. In addition, molecular analysis of tumor tissue revealed candidate predictors of
tazemetostat response in patients with various subtypes of NHL.
Follicular Lymphoma Cohorts: As of June 1, 2017, we had enrolled 19 FL patients with EZH2 activating mutations
in the Phase 2 trial, of which 13 were evaluable for efficacy. Enrollment of FL patients with wild-type EZH2 was
completed in late 2016 with a total of 54 patients, all of which were evaluable for efficacy as of June 1, 2017. More
than 75% of evaluable FL patients had three or more prior treatments, and approximately 50% of patients in each
group were refractory to their last therapy.
For FL patients with EZH2 activating mutations, 12 of 13 patients experienced a partial or complete response,
representing an objective response rate of 92%. One of the 12 experienced a complete response (8%), and 11
experienced a partial response (85%). Median time to first response was 11.9 weeks, with a range of 6.9 to 35.9
weeks. For FL patients with wild-type EZH2, 14 of 54 patients experienced a partial response or complete response,
representing an objective response rate of 26%. Three of the 14 experienced a complete response (6%) and 11
experienced a partial response (20%). An additional 12 patients (22%) experienced stable disease, and remained on
treatment as of the data cutoff date. Median time to first response was 15.2 weeks, with a range of 8.1 to 32.1 weeks.
We intend to complete enrollment of patients with FL with an EZH2 mutation in 2018, and present updated data
from both FL cohorts in the mid-to second half of 2018. Based on initial engagement with the FDA, we believe we
have the opportunity to submit for accelerated approval in FL. We plan to continue engaging with the FDA in 2018
to further refine our registration strategy for FL and, subject to the results of the FL cohorts, are targeting submission
of an NDA to the FDA for tazemetostat for FL in 2019. In addition, we are planning to commence in the second half
of 2018 a combination trial of tazemetostat in FL designed to support the potential registration in this indication.
Diffuse Large B-Cell Lymphoma Cohorts: As of June 1, 2017, we had enrolled 22 DLBCL patients with EZH2
activating mutations, of which 17 patients were evaluable for efficacy. Enrollment of DLBCL patients with wild-
type EZH2 (germinal center and non-germinal center) was completed in early 2017 with 120 patients, of which 119
were evaluable for efficacy as of June 1, 2017.
For DLBCL patients with EZH2 activating mutations, five of 17 patients experienced a confirmed objective
response (all partial), representing an objective response rate of 29%. Median time to first response was 8.3 weeks,
with a range of 4.6 to 48.1 weeks. For DLBCL patients with wild-type EZH2, 18 of 119 patients experienced a
partial response or complete response, representing an overall response rate of 15%. Ten of the 18 experienced a
complete response (8%) and eight experienced a partial response (7%). Median time to first response was 8.5 weeks,
with a range of 5.3 to 24.7 weeks.
We intend to complete enrollment of patients with DLBCL with an EZH2 mutation in 2018, and plan to present
updated data from the DLBCL cohorts and announce our next development steps in the mid-to second half of 2018.
Tazemetostat NHL Safety Data: Safety data from patients in the ongoing Phase 2 trial (n=210), as of June 1, 2017,
demonstrated favorable tolerability in the trial, consistent with the experience observed in a safety database
exceeding 700 patients from tazemetostat clinical trials to date. Across all cohorts of this trial, dose reductions and
discontinuations due to treatment-related adverse events were low, at only 3% and 2%, respectively. The majority of
treatment-emergent adverse events, or TEAEs, were grade 1 or 2, with only 18% of grade 3 or higher being
considered treatment-related. Treatment-related TEAEs, regardless of attribution and affecting more than five
percent of patients, included nausea (14%); thrombocytopenia (13%); anaemia (10%); neutropenia (9%); diarrhoea
and asthenia (8% each); and fatigue (7%).
Tazemetostat Combination Studies in NHL: In addition to evaluating tazemetostat as a monotherapy for NHL, we
are investigating the combination of tazemetostat with other cancer agents in both the relapsed or refractory and first
line settings. We expect to start reporting initial tazemetostat combination data in DLBCL in 2018.
•
•
•
•
Atezolizumab. Based on preclinical evidence showing that EZH2 inhibition may enhance the activity of
checkpoint inhibitors, we entered into a collaboration agreement with Genentech to conduct a global
Phase 1b trial combining tazemetostat with atezolizumab, a PD-L1 inhibitor. The global trial was
initiated in the fourth quarter of 2016 and is being conducted by Genentech. The trial will enroll
approximately 45 patients with relapsed or refractory DLBCL. Primary endpoints in the trial include
safety and combination tolerability with the objective of establishing a recommended Phase 2 dose.
Secondary and exploratory endpoints include overall response, objective response, duration of response,
pharmacokinetics and preliminary biomarker assessment.
R-CHOP. We are studying tazemetostat in combination with R-CHOP, in collaboration with the
Lymphoma Study Association (LYSA), a premier cooperative group in France dedicated to clinical and
translational research for lymphoma. We have generated preclinical data showing synergy between
tazemetostat and the chemotherapy and steroid components of R-CHOP. This multi-center Phase 1b/2
trial in first-line, elderly high-risk patients with DLBCL will enroll up to 133 patients. Primary
endpoints in the trial include complete response rate as well as safety and tolerability of the
combination. Secondary endpoints include overall response rate and PFS. The trial was initiated in the
fourth quarter of 2016.
Prednisolone. In March 2017, we opened an additional cohort of our ongoing global Phase 2 NHL trial
to investigate tazemetostat in combination with prednisolone for patients with relapsed or refractory
DLBCL. We determined to conduct this combination trial based on substantial preclinical synergy data
with prednisolone, a standard agent in a variety of NHL treatment regimens, including R-CHOP. The
objective of this cohort is to evaluate the clinical synergy of the agents and to explore the potential of
prednisolone to slow progression in patients with aggressive disease. The prednisolone combination
cohort has completed enrollment of 70 DLBCL patients with wild-type EZH2.
FL combination. We have seen extensive preclinical synergy of tazemetostat with a number of targeted
agents and chemotherapies used for, or in development for the treatment of FL. We are planning to
commence a combination trial of tazemetostat in patients with FL in the second half of 2018.
Preclinical Data in NHL: In preclinical development, tazemetostat demonstrated in vitro and in vivo activity in both
mutant and wild-type EZH2 NHL. EZH2 is the catalytic subunit of the PRC2 chromatin remodeling complex, and
activating mutations led to increased trimethylation of H3K27, a PRC2 substrate, and subsequent oncogenic
repression of gene transcription. Consistent with this mechanism, in vivo mouse studies demonstrated drug efficacy
and durability of response in EZH2-mutant NHL models treated with tazemetostat. Our preclinical studies with
wild-type EZH2 lymphoma cells suggest that EZH2 acts as a key regulator of B-cell maturation, and therefore
germinal center lymphomas are also likely to depend on EZH2 activity. We believe this hypothesis is supported by
cumulative preclinical data with EZH2 inhibitors, and preclinical models demonstrating synergy of tazemetostat
with B-cell signaling inhibitors, indicating that tazemetostat induces a cell fate decision.
Tazemetostat Clinical Program in Mesothelioma with BAP1 loss-of-function
Background on Mesothelioma: Mesothelioma is a rare form of cancer that typically occurs in the lining
surrounding the lungs but can also occur in the lining surrounding other organs. Relapsed or refractory
mesothelioma remains an unmet medical need. First line treatment typically includes the chemotherapy drugs
cisplatin and pemetrexed (Alimta). Mesothelioma is a very difficult to treat disease, with fewer than 10% of patients
alive five years following diagnosis. Median overall survival after standard of care treatment is approximately 13
months. We estimate the total annual incidence of mesothelioma is approximately 12,000 patients in the United
States, EU5, and Japan. Current literature estimates BAP1 loss-of-function to be associated with approximately 46%
to 66% of mesothelioma cases.
Phase 2 Clinical Program: We are conducting a global Phase 2 monotherapy trial of tazemetostat in relapsed or
refractory patients with mesothelioma characterized by BAP1 loss-of-function. The first stage of the trial evaluated
safety and pharmacokinetics in patients with relapsed or refractory mesothelioma, regardless of BAP1 status. The
second stage of the trial is evaluating disease control rate in patients with mesothelioma characterized by BAP1 loss-
of-function. The first patient in the trial was dosed in August 2016. We completed enrollment in this trial in the
second quarter of 2017 with 74 patients in total. Patients are dosed with tazemetostat 800 mg twice daily with tablets
taken orally. The primary endpoint of the trial is disease control rate, defined as complete response, partial response,
or stable disease, at 12 weeks. The trial has achieved the primary endpoint of a disease control rate of ≥35% at 12
weeks. We intend to present data from this trial at a medical meeting in mid-2018.
Tazemetostat Clinical Program in Non-Small Cell Lung Cancer
Background on NSCLC:
Lung cancer remains the leading cause of cancer deaths worldwide; it is the most common cancer in both men and
women with an estimated 221,200 new cases and 158,040 lung cancer deaths in the United States alone in 2015.
Non-small cell lung cancer, or NSCLC, is the predominant subtype of lung cancer, accounting for approximately
85% of all cases. The overall 5-year survival rate for advanced disease is reported to be 2%- 4%, depending on
geographic location. Poor prognostic factors for survival in patients with NSCLC include advanced-stage disease at
the time of initial diagnosis, poor performance status, and history of unintentional weight loss. More than half of
patients with NSCLC are diagnosed with distant disease, which directly contributes to poor survival prospects.
Therefore, there is a high unmet need for improved medical intervention.
Genetic changes that have prognostic and/or predictive significance in NSCLC include mutations in the EGFR gene,
rearrangements in the ALK gene, and mutations in the KRAS gene.
For patients without a mutation that confers sensitivity to a targeted agent, the globally recognized standard of care
for inoperable Stage IIIB or IV NSCLC is platinum-based chemotherapy followed by maintenance treatment until
progression. Agents that have been partnered with either cisplatin or carboplatin include taxanes (paclitaxel or
docetaxel), vinorelbine, gemcitabine, pemetrexed, and bevacizumab. Recently, however, a PD-1 blocking antibody
has emerged as a therapeutic option in first line treatment in NSCLC. Pembrolizumab is approved for this indication.
In the second line setting, PD-1/PD-L1 blocking antibodies are now the preferred treatment options for patients with
NSCLC and four have been approved: nivolumab (PD-1 inhibitor), pembrolizumab (PD-1 inhibitor), atezolizumab
(PD-L1 inhibitor) and durvalumab (PD-L1 inhibitor).
Phase 1b/2 Clinical Program: In June 2017, we announced an expansion of our clinical collaboration with
Genentech. Under the collaboration, tazemetostat administered in combination with atezolizumab will be evaluated
in a Phase 1b/2 clinical trial for the treatment of patients with relapsed or refractory metastatic NSCLC. The trial
will be part of MORPHEUS, Genentech’s open-label, multi-center, randomized umbrella trial evaluating the
efficacy and safety of multiple immunotherapy-based treatment combinations for metastatic NSCLC. Genentech is
sponsoring the Phase 1b/2 clinical trial. It is anticipated that the trial will enroll up to 40 patients who have
experienced disease progression during or following treatment with a platinum-containing chemotherapy regimen
and a PD-L1/PD-1 checkpoint inhibitor. This clinical trial was initiated at the end of 2017.
Tazemetostat in Other Solid Tumors
In October 2016, we announced a Cooperative Research and Development Agreement, or CRADA, with the NCI to
evaluate tazemetostat in clinical trials in a variety of hematologic malignancies and solid tumors. Under the same
CRADA, we plan to evaluate tazemetostat in a Phase 2 clinical trial in adult patients with ovarian cancer and in a
Phase 2 trial in pediatric patients with solid tumors and lymphoma. As part of the agreement, we may undertake
additional clinical trials. NCI will predominantly fund the studies and manage trial operations.
In July 2017, we announced that the NCI’s Pediatric MATCH trial will include a Phase 2 evaluation of tazemetostat
as one of its treatment cohorts. Conducted under our CRADA executed with NCI in 2016, this multi-institutional
trial will evaluate tazemetostat as a monotherapy for pediatric patients with advanced solid tumors, including CNS
tumors, NHL or histiocytic disorders that harbor EZH2 activating mutations, or loss of function mutations in the
SWI/SNF complex subunits SMARCB1 or SMARCA4. The Pediatric MATCH trial, which will be operationalized
by the Children’s Oncology Group, aims to match targeted agents, such as tazemetostat, with specific molecular
changes identified through genomic sequencing of refractory or recurrent tumors from children and adolescents with
cancer.
G9a Inhibitory Program for Sickle Cell Disease
Background on G9a: Elevation of fetal hemoglobin, which is normally silenced after birth, has disease-modifying
potential for patients with β-globinopathies, such as sickle cell disease, and β-thalassemia. Multiple academic groups
previously discovered that inhibition of G9a, a HMT, leads to increased levels of fetal hemoglobin in preclinical in
vitro studies.
Background on Sickle Cell Disease: Sickle cell disease, or SCD, is an inherited red blood cell disorder. People with
SCD have abnormal hemoglobin, called hemoglobin S or sickle hemoglobin, in their red blood cells. A monogenic
disease, SCD is most common in people with African ancestry. Approximately 300,000 people have SCD globally,
with an estimated 150,000 of those patients located in the United States and Europe. Potential complications include
stroke, vaso-occlusive crises, or VOC, associated with pain attacks, acute chest syndrome and anemia. Recurrent
acute pain crises and chronic long-term organ damage are the hallmarks for SCD. However, symptoms of SCD can
vary significantly in different patients, and better treatments for SCD patients are needed. Life expectancy of SCD
patients still lags the life expectancy of the general population.
EZM8266 Program: Building upon the industry’s findings on the G9a target, our scientists leveraged our expertise
in HMT drug discovery to generate potent, selective inhibitors of G9a with drug-like properties. We initially
developed a tool compound that induced on-target elevation of fetal hemoglobin in cell culture assays, and elicited
significant increases in mouse embryonic hemoglobin, which is the rodent developmental equivalent of human fetal
hemoglobin. We believe these findings represent the first in vivo study to demonstrate reactivation of developmental
hemoglobin with a G9a inhibitor. Following these efforts, we went on to identify the next product candidate in our
pipeline, EZM8266, a potent, selective and orally bioavailable G9a inhibitor. Throughout 2018, we plan to advance
EZM8266 toward clinical initiation, completing the necessary pre-IND work, including good laboratory practice, or
GLP, toxicology studies. We plan to initiate clinical development for EZM8266 for the treatment of sickle cell
disease in early 2019. We hold worldwide development and commercialization rights to EZM8266.
Pinometostat for DOT1L Cancers
Background on DOT1L Cancers. DOT1L is an HMT that can become oncogenic and cause certain subtypes of
acute leukemia, such as MLL-r.
Mixed-lineage leukemia-rearranged, or MLL-r, is an aggressive, genetically-defined subtype of two of the most
common forms of acute leukemia, acute lymphoblastic leukemia, or ALL, and acute myeloblastic leukemia, or
AML. In an article in the journal Blood in December 2002, the authors estimated that the five-year overall survival
rate for adult patients with the MLL-r subtype of AML ranges from approximately 5 to 24%. The disease
predominantly occurs in two different age ranges, an adult population and an infant/pediatric population. While they
share a common genetic alteration, the adult disease is frequently a secondary leukemia resulting from prior
chemotherapy for a different, unrelated cancer and the childhood disease is of unknown origin. MLL-r is caused by
a chromosomal translocation involving the MLL gene. The translocation results in DOT1L being recruited to a
specific place in the chromosome where it would not normally be present. As a result, DOT1L causes inappropriate
histone methylation at this location, which results in the increased expression of genes involved in causing leukemia.
There are no approved therapies specifically indicated for MLL-r. Physicians typically treat this hematological
cancer with therapies approved for other acute leukemia. Patients with AML and ALL typically are treated with
intensive multi-agent chemotherapy and high risk patients with ALL and AML who enter remission and have a
matched donor often receive an allogeneic stem cell transplant.
Pinometostat
We are developing pinometostat as an intravenously administered small molecule inhibitor of DOT1L for the
treatment of acute leukemias that harbor genetic alterations that we believe may lead to therapeutic benefit from
DOT1L inhibition such as specific chromosomal rearrangements or translocations of the mixed lineage leukemia, or
MLL, gene. We discovered pinometostat using our proprietary product platform.
Under the CRADA that we entered with the NCI in October 2016 for pinometostat, the NCI has agreed to evaluate
the safety and efficacy of pinometostat in patients with acute leukemias. Initial studies will evaluate the combination
of pinometostat with standard-of-care therapies or targeted agents in acute leukemia. As part of the agreement,
additional clinical trials will be considered. NCI will predominantly fund the studies and manage trial operations.
Through external collaborators, we are exploring in preclinical studies combinations of pinometostat with other anti-
cancer agents to enhance pinometostat’s efficacy in leukemia. We retain all U.S. rights to pinometostat and have
granted Celgene an exclusive license to pinometostat outside of the United States. Pinometostat has been granted
orphan drug designation by the FDA and the European Commission for the treatment of acute myeloid leukemia and
acute lymphoblastic leukemia.
Other Pipeline Programs
In addition to tazemetostat, pinometostat, EZM8266, and our partnered programs, we also have a pipeline of drug
discovery programs that target our other prioritized CMPs. These programs are directed to specific cancers,
including both hematological malignancies and solid tumors.
Under our collaboration with GSK, GSK is developing small molecule inhibitors against novel HMT targets, that
were discovered by us using our proprietary drug discovery platform. In September 2016, GSK advanced the first of
these programs into clinical testing. This drug candidate, GSK3326595, a PRMT5 inhibitor, is being tested in a
Phase 1 clinical trial in patients with solid tumors and NHL. In 2017, GSK initiated a GLP toxicology study for the
second target.
In March 2014, the Company and GSK amended certain terms of the agreement for the third licensed target,
revising the license terms with respect to candidate compounds and amending the corresponding financial terms,
including reallocating milestone payments and increasing royalty rates as to the third target. Subsequent to a GSK
strategic portfolio prioritization, the Company received notice in October 2017 that GSK terminated the agreement
with respect to the third target, effective December 31, 2017, which returned all rights to that target to the Company.
The two other targets continue to be subject to the agreement and are not impacted by the termination with respect to
the third target. GSK has worldwide rights to the inhibitors of the HMT targets included in the collaboration.
Under our collaboration with Celgene, we are developing small molecule inhibitors directed to three HMT targets,
in addition to pinometostat. Under the collaboration, we are responsible for all preclinical discovery work as well as
Phase 1 clinical development for all three targets. Celgene has the option to acquire worldwide rights to inhibitors
directed at two of the three targets, and the option to acquire ex-U.S. rights to inhibitors directed to the third target.
We retain rights to develop and commercialize inhibitors directed at the third target in the United States.
Our Epigenetic Approach
Epigenetics refers to a broad regulatory system that controls gene expression without altering the makeup of the
genes themselves. Genes are composed of DNA, and in nature, this DNA is wrapped around a core of proteins
known as histones. Together, the DNA and histone proteins form a complex known as chromatin that is the basic
structural component of chromosomes.
Gene regulation is determined by chromatin structure. The dynamics of chromatin structure are regulated through
multiple mechanisms by chromatin modifying proteins, or CMPs. Some CMPs place chemical groups onto specific
sites on histones or DNA, some remove these marks in site-specific ways, others recognize the uniquely marked
sites on histones and bind to these marked sites, and still other CMPs drive topological changes to histone-DNA
interactions within chromatin. Where, when and how such chromatin structure changes occur, determines which
genes in a cell are turned “on” or “off” at any particular time. When the function of these CMPs is altered, the
program of gene expression is changed in ways that can lead to disease.
We are discovering and developing inhibitors of CMPs as novel therapeutics for patients with cancer and other
diseases. Our focus is on the discovery, development and commercialization of small molecule inhibitors of CMPs
for applications in diseases that are uniquely dependent on the enzyme activity of a specific CMP. Among the CMP
target classes, we have had a particular emphasis on the HMTs, which have been shown to play pathogenic roles in a
number of human diseases. Today, we have programs in HMTs as well as new target classes, represented by histone
acetyltransferases, or HATs, and helicases. Beyond cancer, however, HMTs and other CMPs have been implicated
as pathogenic drivers of a number of diseases with significant unmet medical need. At the end of 2017 we
nominated our first development candidate, EZM8266, a HMT inhibitor targeting sickle cell disease. Targeting
pathogenic CMPs affords us multiple opportunities to create, develop and commercialize novel therapeutics.
Our Collaborations
We have entered into several key strategic collaborations. These therapeutic collaborations have provided us with
$217.8 million in non-equity funding through December 31, 2017. Our Celgene and GSK collaborations provide us
with the potential for significant research, development, regulatory and sales-based milestone payments as well as
royalties or profit sharing on net product sales. Our Celgene collaboration also provides for potential development
co-funding. In addition, we have entered into a collaboration to develop a companion diagnostic with Roche
Molecular. Key terms of these collaborations are summarized below.
Celgene
Overview. In July 2015, we entered into an amendment and restatement of our collaboration and license agreement
dated April 2012 with Celgene. Under the original agreement, we granted Celgene an exclusive license, for all
countries other than the United States, to small molecule HMT inhibitors targeting the DOT1L HMT, including
pinometostat, and an option, on a target-by-target basis, to exclusively license, for all countries other than the United
States, rights to small molecule HMT inhibitors targeting any HMT targets, other than EZH2 HMT, including
tazemetostat, and targets covered by our pre-existing collaboration and license agreement dated January 8, 2011
with GSK. Under the original agreement, Celgene’s option was exercisable during an option period that would have
expired in July 2015. Under the amended and restated collaboration and license agreement:
•
•
Celgene retained its exclusive license to small molecule HMT inhibitors targeting DOT1L, including
pinometostat,
Celgene’s option rights were narrowed to small molecule HMT inhibitors targeting three predefined
targets, which we refer to as Option Targets,
•
•
•
•
The exclusive licenses to HMT inhibitors targeting two of the Option Targets that Celgene may acquire
were expanded to include the United States, with the exclusive license to HMT inhibitors targeting the
third Option Target continuing to be for all countries other than the United States,
Celgene’s option period was extended for each of the Option Targets and Celgene’s option is
exercisable at the time of our investigational new drug, or IND, filing for an HMT inhibitor targeting the
applicable Option Target, upon the payment by Celgene at such time of a pre-specified development
milestone-based license payment,
Celgene’s license may be maintained beyond the end of Phase 1 clinical development for each of the
Option Targets, upon payment by Celgene at such time of a pre-specified development milestone-based
license payment, and
Our research and development obligations with respect to each Option Target under the amended
agreement were extended for at least an additional three years, subject to Celgene exercising its option
with respect to such Option Target at IND filing. Subject to our opt-out rights, our research and
development obligations were expanded to include the completion of a Phase 1 clinical trial as to each
Option Target following Celgene’s exercise of its option at IND filing.
Through December 31, 2017, we have recognized $74.3 million in total collaboration revenue. To date, we have
received $75.0 million of upfront payments (including $10.0 million as part of the amended and restated
agreement) and $25.0 million from the sale of our series C preferred stock to an affiliate of Celgene, of which $3.0
million was considered a premium and included as collaboration arrangement consideration for total upfront
payments of $78.0 million. In addition, we have received a $25.0 million clinical development milestone payment in
2014 and $7.0 million of global development co-funding through December 31, 2017. We are eligible to earn an
aggregate of up to $75.0 million in development milestones and license payments, up to $365.0 million in regulatory
milestone payments and up to $170.0 million in sales milestone payments related to the three Option Targets. We
are eligible to earn $35.0 million in an additional clinical development milestone payment and up to $100.0 million
in regulatory milestone payments related to DOT1L.
We are also eligible to receive royalties as follows:
•
•
•
As to DOT1L, we retain all product rights in the United States and are eligible to receive royalties at
defined percentages ranging from the mid-single digits to the mid-teens on annual net product sales
outside of the United States, subject to reductions in specified circumstances;
As to the Option Target for which Celgene’s option rights do not include the United States, if Celgene
exercises its option as to such Option Target, we will retain all product rights in the United States and
will be eligible to receive royalties, once an initial threshold of net product sales (for which we will not
receive royalties) is exceeded, at defined percentages ranging from the mid-single digits to the low-
double digits on net product sales outside of the United States, subject to reductions in specified
circumstances; and
As to the other two Option Targets, if Celgene exercises its option as to those Option Targets, we will
be eligible to receive royalties, once an initial threshold of net product sales (for which we will not
receive royalties) is exceeded, for each such Option Target at defined percentages ranging from the mid-
single digits to the low-double digits on net product sales on a worldwide basis, subject to reductions in
specified circumstances.
For DOT1L and, after Celgene’s payment of the specified IND filing license payment for each Option Target, for
each such Option Target, we are responsible for the conduct and funding of Phase 1 clinical trials, subject to our
right to opt-out of such responsibilities as described below. Celgene may obtain a license to small molecule HMT
inhibitors targeting each Option Target at the time of our IND filing for an HMT inhibitor for such target by
exercising its option and paying us a specified license payment. Celgene may maintain its license with respect to an
Option Target at the conclusion of the Phase 1 clinical trial of the Option Target by paying us a specified additional
license payment. If Celgene does not elect to obtain a license during the option exercise period applicable to an
Option Target, or to pay the specified IND license payment or end of Phase 1 license payment, we will retain
worldwide rights to HMT inhibitors directed to the Option Target, other than HMT inhibitors that may be provided
by Celgene if we were to agree to their introduction into the collaboration.
Research Obligations. We are primarily responsible for the research strategy under the collaboration. During each
applicable option period we are required to use commercially reasonable efforts to carry out an agreed research plan
for each Option Target, subject to our Opt-Out right described below. For the DOT1L target and each of the Option
Targets, we are required to conduct and solely fund development costs of the Phase 1 clinical trials for HMT
inhibitors directed to such targets, including for pinometostat. After completion of Phase 1 development, as to
DOT1L and the Option Target for which we retain U.S. rights, we and Celgene will equally co-fund global
development and each party will solely fund territory-specific development costs for its territory; and, as to the other
two Option Targets, after completion of Phase 1 development, Celgene will solely fund all development costs on a
worldwide basis.
Governance. Our collaboration with Celgene is guided by (a) a joint research committee, with authority over all
activities performed under the research plan with respect to the two Option Targets as to which we granted
worldwide rights; (b) a joint development committee, with authority over shared development activities with respect
to DOT1L and the Option Target for which we retain U.S. rights; and (c) a joint commercialization committee, with
authority over the commercialization of products developed under shared development programs with respect to
DOT1L and the Option Target for which we retain U.S. rights. Subject to limitations specified in the amended and
restated agreement, if the applicable governance committee is not able to make a decision by consensus and the
parties are not able to resolve the issue through escalation to specified senior executive officers of the parties, then
(a) prior to Celgene’s exercise of its option, we generally have final decision-making authority over research and
development matters with respect to the Option Targets; (b) with respect to DOT1L and any Option Targets for
which Celgene has exercised its option, Celgene generally has final decision-making authority over global
development matters, including over global activities and related expenses that we are obligated to co-fund, unless
we exercise our opt-out right as to such licensed program, and except that with respect to the Option Target for
which we retain U.S. rights, the parties have mutual decision-making authority even after Celgene exercises its
option as long as Celgene engages in a competitive development program with respect to such Option Target. Each
party has final decision-making authority over commercialization matters in its respective territory.
Opt-Out Right. On an Option Target-by-Option Target basis, we have the right, in our sole discretion, to opt-out of
further participation in any research and/or development activities after completion of the initial research plan and
prior to the filing of an IND for an HMT inhibitor directed to the applicable Option Target, or the Pre-IND Opt-Out.
Following exercise of a Pre-IND Opt-Out, if Celgene exercises its option as to the Option Target, Celgene will no
longer be required, to the extent not already paid, to make the specified IND license payment or end of Phase 1
license payment to us, specified sales milestone payments will no longer be payable and all royalties on net product
sales of applicable licensed products that become payable to us will be reduced by a specified percentage.
Additionally, if Celgene exercises its option as to such Option Target, we are obligated to grant Celgene an
exclusive worldwide license to HMT inhibitors directed to the applicable Option Target, even if we would otherwise
retain U.S. rights to HMT inhibitors directed to the applicable Option Target. Additionally, on a licensed program-
by-licensed program basis, we have the right, in our sole discretion, to opt-out of further participation in and co-
funding of development, other than specified costs necessary to complete development activities in process at the
time we exercise our opt-out right. We can exercise our licensed program opt-out right at specified times: (a) when
the clinical trial stopping rules set forth in a clinical trial protocol for DOT1L or the Option Target for which the we
retain U.S. rights dictate that such clinical trial be stopped, or the Post-EOP1 Clinical Opt-Out; or (b) for any or no
reason, in a licensed program for DOT1L or the Option Target for which we retain U.S. rights, during specified
periods before the scheduled initiation of the first pivotal clinical trial or before the estimated date of filing of the
first NDA for an HMT inhibitor directed to the licensed target or any time after regulatory approval of an HMT
inhibitor directed to the licensed target, or the Late Stage Opt-Out. In the event of a Post-EOP1 Clinical Opt-Out, the
royalties that become payable to us on net product sales of licensed products directed to DOT1L or the Option
Target for which we retain U.S. rights, as applicable, will be reduced by a specified percentage. Following a Post-
EOP1 Clinical Opt-Out or a Late Stage Opt-Out, we are no longer required to co-fund global development for the
applicable program other than specified costs necessary to complete development activities in process at the time we
exercise our opt-out right, and we are obligated to grant Celgene an exclusive license to HMT inhibitors directed to
the applicable target in the United States. Following our exercise of a Post-EOP1 Clinical Opt-Out or a Late Stage
Opt-Out, if any, we would be eligible to receive specified milestone payments and royalties based on net product
sales in the United States of HMT inhibitors directed to the licensed target in the event that Celgene develops and
commercializes a product in the United States.
Exclusivity Restrictions. Subject to exceptions specified in the amended agreement, during the option period, we
may not research, develop or commercialize HMT inhibitors directed to DOT1L and the three Option Targets.
Subject to exceptions specified in the amended agreement, following each applicable option period, we may not
research, develop or commercialize HMT inhibitors directed to DOT1L or any target licensed by Celgene.
Right of First Negotiation. The amended and restated agreement eliminated the right of first negotiation that we had
previously granted to Celgene under the original agreement with respect to business combination transactions that
we may desire to pursue with third parties.
Term and Termination. The amended and restated agreement with Celgene will expire on a product-by-product and
country-by-country basis on the date of the expiration of the applicable royalty term with respect to each licensed
product in each country and in its entirety upon the expiration of all applicable royalty terms for all licensed
products in all countries. The royalty term for each licensed product in each country is the period commencing with
first commercial sale of the applicable licensed product in the applicable country and ending on the latest of
expiration of specified patent coverage, specified regulatory exclusivity or 15 years following the first commercial
sale in the applicable country. Celgene has the right to terminate the amended agreement in its entirety, upon 60 or
120 days’ notice depending on the timing of such termination. The amended agreement may also be terminated in its
entirety during the option period, and on a licensed target-by-licensed target basis after the option period, by either
Celgene or us in the event of a material breach by the other party. The amended agreement may be terminated on a
licensed target-by-licensed target basis by either Celgene or us in the event the other party, or an affiliate or
sublicensee of the other party, participates or actively assists in a legal challenge to specified patents of the
terminating party or in its entirety in the event the other party becomes subject to specified bankruptcy, insolvency
or similar circumstances.
GlaxoSmithKline
Overview. In January 2011, we entered into a collaboration and license agreement with GSK to discover, develop
and commercialize novel small molecule HMT inhibitors directed to available targets from our product platform.
Under the terms of the agreement, we granted GSK the option to obtain exclusive worldwide license rights to HMT
inhibitors directed to three targets. In March 2014, we and GSK amended certain terms of this agreement for the
third target, revising the license terms with respect to candidate compounds and amending the corresponding
financial terms, including reallocating milestone payments and increasing royalty rates as to the third target.
Additionally, as part of the research collaboration provided for in the agreement, we agreed to provide research and
development services related to the licensed targets pursuant to agreed upon research plans during a research term
that ended January 8, 2015, or earlier if selection of a development candidate occurred.
Under the agreement, we have received and recognized as collaboration revenue a $20.0 million upfront payment, a
$3.0 million payment upon the execution of the March 2014 agreement amendment, $6.0 million of fixed research
funding, $9.0 million for research and development services and $31.0 million of preclinical research and
development milestone payments. These preclinical and research and development milestone payments includes a
$10.0 million milestone payment earned in May 2017 related to the second target in the collaboration, upon GSK’s
initiation of GLP toxicology studies, as well as a $6.0 million clinical milestone recognized in the third quarter of
2016 following GSK’s initiation of patient dosing in a Phase 1 clinical trial of a PRMT5 inhibitor that we discovered
and licensed to GSK.
Subsequent to a GSK strategic portfolio prioritization, we received notice in October 2017 that GSK terminated the
agreement with respect to the third target, effective December 31, 2017, which returns all rights to that target to us.
The two other targets continue to be subject to the agreement and are not impacted by the termination.
As of December 31, 2017, we are eligible to receive up to $70.0 million in clinical development milestone
payments, up to $197.0 million in regulatory milestone payments and up to $128.0 million in sales-based milestone
payments. As a result of the termination of the agreement as it relates to the third target, we will receive no
additional payments related to that target. In addition, GSK is required to pay us royalties, at percentages from the
mid-single digits to the low double-digits, on a licensed product-by-licensed product basis, on worldwide net
product sales, subject to reduction in specified circumstances. The Company determined the next milestone that
might be achieved under this agreement is for $8.0 million due at the first dosing of a patient for an undisclosed
target under a Phase 1 study. Due to the uncertainty of pharmaceutical development and the high historical failure
rates generally associated with drug development, the Company may not receive any additional milestone payments
or royalty payments from GSK.
For each selected target in the collaboration, we were primarily responsible for research until the earlier of selection
of a development candidate for the target or January 8, 2015, and GSK is solely responsible for subsequent
development and commercialization. GSK provided a fixed amount of research funding during the second and third
years of the research term and was obligated to provide research funding equal to 100.0% of mutually agreed
research and development costs, subject to specified limitations, for any research activities we conducted in the
fourth year of the research term. At this stage, GSK is solely responsible for subsequent development and
commercialization.
Exclusivity Provisions. Subject to exceptions specified in the agreement, during the term of the agreement, we may
not research, develop or commercialize HMT inhibitors directed to the two targets selected by GSK, other than
pursuant to the agreement.
Term and Termination. The agreement will expire in its entirety upon the expiration of all applicable royalty terms
for all licensed products in all countries. The royalty term for each licensed product in each country is the period
commencing with first commercial sale of the applicable licensed product in the applicable country and ending on
the later of expiration of specified patent coverage or ten years following the first commercial sale. GSK has the
right to terminate the agreement at any time with respect to one or more selected targets or in its entirety, upon 90
days’ prior written notice to us. The agreement may also be terminated with respect to one or more selected targets
or in its entirety by either GSK or us in the event of a material breach by the other party. The agreement may be
terminated with respect to selected targets by us in the event GSK participates or actively assists in a legal challenge
to one of the patents exclusively licensed to GSK under the agreement with respect to the applicable selected target.
Eisai
Overview. In March 2015, we entered into an amended and restated collaboration and license agreement with Eisai,
under which we reacquired worldwide rights, excluding Japan, to our EZH2 program, including tazemetostat. Under
the amended and restated collaboration and license agreement, we will be responsible for global development,
manufacturing and commercialization outside of Japan of tazemetostat and any other EZH2 product candidates, with
Eisai retaining development and commercialization rights in Japan, as well as a right to elect to manufacture
tazemetostat and any other EZH2 product candidates in Japan. Under the original collaboration and license
agreement, we had granted Eisai an exclusive worldwide license to our small molecule HMT inhibitors directed to
EZH2, including tazemetostat, while retaining an opt-in right to co-develop, co-commercialize and share profits with
Eisai as to licensed products in the United States.
Upon the execution of the amended and restated collaboration agreement in March 2015, we agreed to pay Eisai a
$40.0 million upfront payment. We also agreed to pay Eisai up to $20.0 million in clinical development milestone
payments, including a $10.0 million milestone payment upon the earlier of initiation of a first phase 3 clinical trial of
any EZH2 product or the first submission of an NDA or MAA, up to $50.0 million in regulatory milestone
payments, including a $25.0 million milestone payment upon regulatory approval of the first NDA or MAA, and
royalties at a percentage in the mid-teens on worldwide net sales of any EZH2 product, excluding net sales in Japan.
We are eligible to receive from Eisai royalties at a percentage in the mid-teens on net sales of any EZH2 product in
Japan.
Under the original agreement, Eisai was solely responsible for funding all research, development and
commercialization costs for licensed compounds. Under the amended agreement, we are solely responsible for
funding global development, manufacturing and commercialization costs for EZH2 compounds outside of Japan,
and Eisai is solely responsible for funding Japan-specific development and commercialization costs for EZH2
compounds. In connection with the amendment and restatement of our collaboration and license agreement with
Eisai, we and Eisai agreed to the transition to us of ongoing development and manufacturing activities that were
being conducted by or on behalf of Eisai. In January 2017, as part of Eisai’s obligations under the amended and
restated collaboration agreement, Eisai enrolled and dosed the first patient in a Phase 1 study of tazemetostat in
patients with relapsed or refractory B-cell NHL in Japan, and waived the right of first negotiation for the rest of
Asia.
In the event that we are awarded a priority review voucher from the FDA with respect to an EZH2 product, Eisai is
entitled to specified compensation if we use the voucher on a non-EZH2 program or sell the voucher to a third party.
Governance. Under the amended and restated collaboration and license agreement, development will be guided by a
joint steering committee, with Epizyme retaining final decision making authority with respect to global
development.
Exclusivity Restrictions. Subject to exceptions specified in the agreement, for an exclusivity period extending until
eight years after the first commercial sale of a product covered by the agreement, neither we nor Eisai may research,
develop or commercialize HMT inhibitors directed to EZH2, other than pursuant to the agreement.
Term and Termination. Our agreement with Eisai will remain in effect until the expiration of all payment
obligations under the agreement with respect to all licensed products. The royalty term for each licensed product in
each country commences on the first commercial sale of the applicable licensed product in the applicable country
and ends on the latest of expiration of specified patent coverage, expiration of specified regulatory exclusivity or ten
years following the first commercial sale. We or Eisai may terminate the agreement for convenience as to our
respective territories, upon 90 days’ prior written notice. The agreement will also terminate as to our territory if we
cease all development and commercialization activities for the United States and specified major countries in Europe
and as to Eisai’s territory if Eisai ceases all development and commercialization activities for Japan. The agreement
may also be terminated by either party in the event of an uncured material breach by the other party or by us in the
event Eisai, or an affiliate or sublicensee, participates or actively assists in an action or proceeding challenging or
denying the validity of one of our patents. If we terminate the agreement for our convenience, the agreement
terminates as a result of our cessation of development and commercialization activities or Eisai terminates the
agreement for our uncured material breach, Eisai may elect to have worldwide development and commercialization
rights revert to Eisai, and if Eisai so elects, Eisai will be required to pay us specified royalties on net sales of the
licensed products and reimburse certain development expenses incurred by us. If Eisai terminates the agreement for
its convenience, the agreement terminates as a result of Eisai’s cessation of development and commercialization
activities or we terminate the agreement for Eisai’s uncured material breach or Eisai’s, or its affiliate’s or
sublicensee’s, participation in, or assistance with, an action or proceeding challenging or denying the validity of one
of our patents, Japanese development and commercialization rights to the licensed products revert to us, and we will
be required to pay Eisai specified royalties on net sales of licensed products in Japan.
LYSA
In May 2016, we entered into a collaboration agreement with the Lymphoma Academic Research Organization, or
LYSARC, to conduct a combination trial of tazemetostat with R-CHOP. LYSARC is the operational arm of LYSA.
This multi-center Phase 1b/2 study is evaluating tazemetostat in combination with R-CHOP, as a first line treatment
in elderly, high-risk patients with DLBCL and is being sponsored by LYSARC. LYSA is managing the study
operations for the trial, and we are recognizing our share of the related expenses as those costs are incurred over the
duration of the trial. The study was initiated in December 2016.
Genentech
In June 2016, we entered into a collaboration agreement with Genentech, a member of the Roche Group, to conduct
a Phase 1b clinical trial to investigate the anti-cancer effects of tazemetostat and Genentech’s atezolizumab, when
used in combination. The trial will evaluate this combination regimen for the treatment of patients with relapsed or
refractory DLBCL. This trial was initiated in December 2016.
In June 2017, we announced an expansion of our clinical collaboration with Genentech to investigate the
combination of tazemetostat with atezolizumab in a Phase 1b/2 clinical trial for the treatment of patients with
relapsed or refractory metastatic NSCLC. The trial will be part of MORPHEUS, Genentech’s open-label, multi-
center, randomized umbrella trial evaluating the efficacy and safety of multiple immunotherapy-based treatment
combinations for metastatic NSCLC. This trial was initiated at the end of 2017.
Under the agreement, each company supplies its respective anti-cancer agent to support the trials and shares equally
in the trial costs. Genentech is managing the study operations for both trials, and we are recognizing our share of the
related expenses as those costs are incurred over the duration of each respective trial.
Companion Diagnostics
Roche Molecular
In December 2012, Eisai and we entered into an agreement with Roche Molecular under which Eisai and we
engaged Roche Molecular to develop a companion diagnostic to identify patients who possess certain point
mutations of EZH2. In October 2013, this agreement was amended to include additional point mutations in EZH2.
The $21.5 million of development costs due under the amended agreement with Roche Molecular were the
responsibility of Eisai until the execution of our amended and restated collaboration and license agreement with
Eisai in March 2015, at which time we assumed responsibility for the remaining development costs due under the
agreement. In December 2015, we entered into the second amendment to the companion diagnostic agreement with
Roche Molecular. As of December 31, 2017, we are responsible for the remaining development costs of $10.5
million due under the agreement. The agreement was further amended in March 2018. Under the amended
agreement, we are responsible for remaining development costs of $10.4 million due under the agreement and Eisai
has agreed to reimburse us for $0.9 million of this amount related to a regulatory milestone for Japan. We expect the
remaining development costs under the amended agreement to be incurred and paid through 2019.
Under our agreement with Roche Molecular, Roche Molecular is obligated to use commercially reasonable efforts to
develop and to make commercially available the companion diagnostic. Roche Molecular has exclusive rights to
commercialize the companion diagnostic.
Our agreement with Roche Molecular will expire when we are no longer developing or commercializing
tazemetostat. We may terminate the agreement by giving Roche Molecular 90 days’ written notice if we discontinue
development and commercialization of tazemetostat or determine, in conjunction with Roche Molecular, that the
companion diagnostic is not needed for use with tazemetostat. Either we or Roche Molecular may also terminate the
agreement in the event of a material breach by the other party, in the event of material changes in circumstances that
are contrary to key assumptions specified in the agreement or in the event of specified bankruptcy or similar
circumstances. Under specified termination circumstances, Roche Molecular may become entitled to specified
termination fees.
Intellectual Property
We strive to protect the proprietary compounds and technologies that we believe are important to our business,
including seeking and maintaining patent protection intended to cover the composition of matter of our product
candidates, their methods of use, related technologies, diagnostics and other inventions. Our patent portfolio is
currently composed of over 250 issued patents and allowed patent applications and over 500 pending patent
applications in the major pharmaceutical markets, that we own as well as license from other parties. In addition to
patent protection, we also rely on trade secrets and careful monitoring of our proprietary information to protect
aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.
Our success will depend significantly on our ability to obtain and maintain patent and other proprietary protection
for commercially important technology, inventions and know-how related to our business, defend and enforce our
patents, maintain our licenses to use intellectual property owned by third parties, preserve the confidentiality of our
trade secrets and operate without infringing the valid and enforceable patents and other proprietary rights of third
parties. We also rely on know-how, continuing technological innovation and in-licensing opportunities to develop,
strengthen, and maintain our proprietary position in the field of HMTs.
We plan to continue to expand our intellectual property estate by filing patent applications directed to dosage forms,
methods of treatment and additional CMP and HMT inhibitor compounds and their derivatives. Specifically, we
seek patent protection in the United States and internationally for novel compositions of matter covering the
compounds, the chemistries and processes for manufacturing these compounds and the use of these compounds in a
variety of therapies.
The patent portfolios for our most advanced programs are summarized below.
EZH2. Our EZH2 patent portfolio includes U.S. Patent No. 8,410,088 covering the composition of matter of
tazemetostat. This patent issued on April 2, 2013 and is expected to expire in 2032, not including extensions. Our
EZH2 portfolio also includes 28 additional U.S. patents and more than 170 foreign patents, expected to expire
between 2031 and 2034, not including extensions. The claims of these patents cover the composition of matter of
EZH2 inhibitor compounds and various methods of their making and use. Patent applications in the same families as
these patents are pending in a variety of worldwide jurisdictions, including the United States. The EZH2 program
portfolio encompasses more than 35 patent families with pending patent applications relating to compositions of
matter and methods of making and use of EZH2 inhibitors. The patent families in this portfolio are in various stages
of prosecution and include patent applications filed in a variety of worldwide jurisdictions, including the United
States; Patent Cooperation Treaty, or PCT, applications that are eligible for filing in most worldwide jurisdictions,
including the United States; and U.S. provisional applications that may be used to establish non-provisional U.S.
applications, PCT applications and other national filings worldwide. Our patent applications in the EZH2 portfolio,
if issued, would be expected to expire between 2031 and 2037.
DOT1L. Our DOT1L patent portfolio includes U.S. Patent No. 8,580,762 covering the composition of matter of
pinometostat. The patent issued on November 12, 2013 and is expected to expire in 2032, not including extensions.
Our DOT1L portfolio also includes nine additional U.S. patents and more than 40 foreign patents, expected to expire
between 2031 and 2034, not including extensions. The DOT1L program portfolio encompasses more than fifteen
patent families relating to compositions of matter of DOT1L inhibitor compounds and methods of their making and
use. The patent families in this portfolio are in various stages of prosecution and include patent families with
applications filed in a variety of worldwide jurisdictions including the United States; and PCT applications that are
eligible for filing in most worldwide jurisdictions, including the United States. These patents and patent applications
are wholly owned by us. Our patent applications in the DOT1L portfolio, if issued, would be expected to expire
between 2031 and 2037.
EHMT2. Our EHMT2 patent portfolio includes more than five patent families directed to various product
candidates and methods of use, with applications filed in the United States and internationally. The portfolio
includes PCT applications that are eligible for filing in most jurisdictions worldwide, and U.S. provisional
applications that may be used as the basis for non-provisional U.S. and international applications. For example, the
portfolio includes PCT application PCT/US2017/027918, published on October 19, 2017 under publication number
WO 2017/181177 A1, and U.S. non-provisional application 15/601,888, published on December 14, 2017, under
publication number US2017/0355712 A1. Patents, if issued from currently pending applications in the EHMT2
portfolio are expected to expire between 2037 and 2038.
Other Targets. We also have patent portfolios directed to targets other than EZH2 and DOT1L, including the HMT
targets PRMT1, PRMT3, CARM1 (also known as PRMT4), PRMT5, PRMT6, PRMT8, SMYD2, SMYD3, and
EHMT2. These patent portfolios have more than 40 patent families directed to various product candidates with
applications filed in the United States, PCT applications that are eligible for filing in most worldwide jurisdictions,
including the United States, and U.S. provisional applications that may be used to establish non-provisional U.S.
applications, PCT applications and other national filings worldwide. Patents, if issued in these portfolios are
expected to expire between 2033 and 2037. For example, we have eight U.S. and a foreign patent that cover PRMT5
inhibitors and methods of their making and use. These patents are expected to expire in 2033, not including
extensions.
The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained.
In most countries in which we file, the patent term is 20 years from the earliest date of filing a non-provisional
patent application.
In the United States, the patent term of a patent that covers an FDA-approved drug may also be eligible for patent
term extension, which permits patent term restoration as compensation for the patent term lost during the FDA
regulatory review process. The Hatch-Waxman Act permits a patent term extension of up to five years beyond the
expiration of the patent. The length of the patent term extension is related to the length of time the drug is under
regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the
date of product approval and only one patent applicable to an approved drug may be extended. Similar provisions
are available in Europe and other non-United States jurisdictions to extend the term of a patent that covers an
approved drug. In the future, if and when our pharmaceutical products receive FDA approval, we expect to apply for
patent term extensions on patents covering those products. We intend to seek patent term extensions to any of our
issued patents in any jurisdiction where these are available, however there is no guarantee that the applicable
authorities, including the FDA in the United States, will agree with our assessment of whether such extensions
should be granted, and even if granted, the length of such extensions.
We also rely on trade secret protection for our confidential and proprietary information. Although we take steps to
protect our proprietary information and trade secrets, including through contractual means with our employees and
consultants, third parties may independently develop substantially equivalent proprietary information and techniques
or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not be able to meaningfully
protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators,
sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of
employment or consulting relationships with us. These agreements provide that all confidential information
concerning our business or financial affairs developed or made known to the individual during the course of the
individual’s relationship with us is to be kept confidential and not disclosed to third parties except in specific
circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and
which are related to our current or planned business or research and development or made during normal working
hours, on our premises or using our equipment or proprietary information, are our exclusive property.
Manufacturing
We do not have any manufacturing facilities and currently rely, and expect to continue to rely, on third parties for
the manufacture of our product candidates for preclinical and clinical testing, as well as for commercial manufacture
if our product candidates receive marketing approval. Prior to the execution of the amended and restated
collaboration and license agreement with Eisai, Eisai manufactured tazemetostat for preclinical and clinical
development. Upon execution of the amended and restated collaboration and license agreement, as part of the
transition plan, Eisai agreed to sell us its existing inventories and manufacture additional tazemetostat clinical
supplies and the active pharmaceutical ingredient, or API. We took receipt of these API and clinical supplies from
Eisai during the year ended December 31, 2015. We have entered into clinical supply agreements with three contract
manufacturers, one to produce tazemetostat API and two to produce tazemetostat tablets. We intend to identify and
qualify additional manufacturers to provide API, tablets and a pediatric formulation as part of our ongoing
manufacturing efforts for tazemetostat. To date, we have obtained materials for pinometostat from multiple third
party manufacturers.
All of our product candidates are small molecules and are manufactured in reliable and reproducible synthetic
processes from readily available starting materials. The chemistry is amenable to scale up and does not require
unusual equipment in the manufacturing process. We expect to continue to develop product candidates that can be
produced cost-effectively at contract manufacturing facilities.
We generally expect to rely on third parties for the manufacture of any companion diagnostics. We are currently
collaborating with Roche Molecular for a diagnostic for use with tazemetostat, and we expect to rely on Roche
Molecular for the manufacture of the diagnostic it is developing. We may enter into similar agreements for the
manufacture of other companion diagnostics.
Commercialization
We have recently begun to establish a commercial infrastructure in preparation for a potential future launch of
tazemetostat and other product candidates that may receive marketing approval. We have retained commercial rights
in the United States to all of our product candidates for which we may receive marketing approvals, except for two
programs that are the subject of our collaboration with GSK and two of the preclinical programs that are the subject
of our collaboration with Celgene. We plan to retain commercialization rights in the United States and possibly in
select foreign jurisdictions in connection with any future collaborations. We intend to build a focused field presence
and marketing capabilities to commercialize any of our product candidates that receive regulatory approval in the
United States, as well as the capabilities to lead global commercial strategy.
Subject to receiving marketing approvals, we expect to commence commercialization activities by building an
organization in the United States to sell our products. We believe that such an organization will be able to address
the hematologists and oncologists who are the key specialists in treating the patient populations for which our
clinical stage product candidates are being developed. Outside the United States, we may choose to enter into
distribution and other marketing arrangements with third parties for any of our product candidates that obtain
marketing approval, or may choose to commercialize our products in certain markets, depending upon many factors,
including the target market size, availability of reimbursement, and our financial resources at the time.
We expect that our collaborators for any companion diagnostics we may develop in the future for use with our
therapeutic products will hold the commercial rights to these diagnostic products, as is the case for our collaboration
with Roche Molecular. We expect to coordinate closely with any diagnostic collaborators in connection with the
marketing and sale of any related therapeutic products.
Competition
The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense
competition and a strong emphasis on proprietary products. While we believe that our technology, knowledge,
experience and scientific resources provide us with competitive advantages, we face potential competition from
many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies,
academic institutions and governmental agencies and public and private research institutions. Any product
candidates that we successfully develop and commercialize will compete with existing therapies and new therapies
that may become available in the future.
There are a large number of companies developing or marketing treatments for cancer, including many major
pharmaceutical and biotechnology companies. Companies that are developing new epigenetic treatments for cancer
that target HMTs, and protein arginine methyltransferases, or PRMTs, include GSK, Johnson & Johnson, Novartis
AG, Pfizer, Inc., Merck & Co., Inc., Daiichi Sankyo Company Limited, Takeda Pharmaceutical Company Limited,
AbbVie Inc., AstraZeneca plc, Bayer Schering Pharma AG and Constellation Pharmaceuticals. Specifically,
companies which are known to have EZH2 inhibitor programs or related programs include: Constellation
Pharmaceuticals, developing an EZH2 inhibitor (CPI-1205, Phase 1/2 castration-resistant prostate cancer), Novartis
AG, developing an EED inhibitor which indirectly blocks EZH2 (MAK683, Phase 1/2, advanced malignancies),
Daiichi Sankyo, developing a EZH1/EZH2 dual inhibitor (DS-3201, Phase 1, relapsed or refractory non-Hodgkin
lymphomas), and Pfizer, which declared a development candidate (PF-06821497) in April 2017. In July 2017, GSK
discontinued their EZH2 inhibitor program, GSK2816126, which had been in Phase 1 development in solid tumors
and hematological malignancies. In addition, many companies are developing cancer therapeutics that work by
targeting epigenetic mechanisms other than HMTs, and some including Celgene, Merck & Co., Inc., Novartis AG,
Spectrum Pharmaceuticals, and Eisai, are now marketing cancer treatments that work by targeting epigenetic
mechanisms other than HMTs.
Many of the companies against which we are competing or against which we may compete in the future have
significantly greater financial resources and expertise in research and development, manufacturing, preclinical
testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do.
Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more
resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may
also prove to be significant competitors, particularly through collaborative arrangements with large and established
companies. These competitors also compete with us in recruiting and retaining qualified scientific and management
personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring
technologies complementary to, or necessary for, our programs.
The key competitive factors affecting the success of all of our therapeutic product candidates, if approved, are likely
to be their efficacy, safety, convenience, price, the effectiveness of companion diagnostics in guiding the use of
related therapeutics, the level of generic competition and the availability of reimbursement from government and
other third party payors.
Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products
that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than
any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their
products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a
strong market position before we are able to enter the market. In addition, our ability to compete may be affected in
many cases by insurers or other third party payors seeking to encourage the use of generic products. Generic
products that broadly address these indications are currently on the market for the indications that we are pursuing,
and additional products are expected to become available on a generic basis over the coming years. If our product
candidates achieve marketing approval, we expect that they will be priced at a significant premium over competitive
generic products.
The most common methods of treating patients with cancer are surgery, radiation and drug therapy. There are a
variety of available drug therapies marketed for cancer. In many cases, these drugs are administered in combination
to enhance efficacy. While our product candidates may compete with many existing drugs and other therapies, to the
extent they are ultimately used in combination with or as an adjunct to these therapies, our product candidates will
not be competitive with them. Some of the currently approved drug therapies are branded and subject to patent
protection, and others are available on a generic basis. Many of these approved drugs are well established therapies
and are widely accepted by physicians, patients and third party payors.
In addition to currently marketed therapies, there are also a number of products in late stage clinical development to
treat cancer. These products in development may provide efficacy, safety, convenience and other benefits that are
not provided by currently marketed therapies. As a result, they may provide significant competition for any of our
product candidates for which we obtain marketing approval.
If our lead product candidates are approved for the indications for which we are currently undertaking clinical trials,
they will compete with the therapies and currently marketed drugs discussed below.
Tazemetostat. The most common treatments for DLBCL and FL are chemotherapies, usually combined with the
monoclonal antibody Rituxan, or more recently, in the case of FL, Gazyva, which is a next-generation antibody that
acts against the same target as Rituxan, CD20. While Rituxan and a number of other widely used anti-cancer agents
are labeled either broadly for NHL or more narrowly for DLBCL or FL, no therapies are approved specifically for
the treatment of tumors associated with EZH2 activating mutations. Additionally, no therapies are approved
specifically for the treatment of INI1- and SMARCA4-negative tumors. Epithelioid sarcoma, an INI1-negative
tumor, is treated with surgical resection when it presents as localized disease. When epithelioid sarcoma recurs or
metastasizes, it may be treated with systemic chemotherapy or investigational agents since there are no approved
systemic therapies specifically indicated for this disease. Mesothelioma is typically treated with cisplatin and
pemetrexed chemotherapy in the first line setting. There are no established salvage treatments for patients with
epithelioid sarcoma or mesothelioma who relapse or who are refractory to first line treatment. Non-small cell lung
cancer patients without a mutation that confers sensitivity to a targeted agent, may receive first line treatment of
platinum-based chemotherapy, either cisplatin or carboplatin, potentially along with taxanes, either paclitaxel or
docetaxel, vinorelbine, gemcitabine, pemetrexed, and bevacizumab. Pembrolizumab, a PD-1 blocking antibody, is
approved as another therapeutic option in first line treatment in NSCLC. In the second line setting, PD-1/PD-L1
blocking antibodies are now the preferred treatment options for patients with NSCLC.
Research and Development Expenses
For the years ended December 31, 2017, 2016 and 2015, we incurred approximately $109.7 million, $91.5 million,
and $111.2 million, respectively, on research and development activities.
Government Regulation and Product Approval
Government authorities in the United States, at the federal, state and local level, and in other countries and foreign
jurisdictions, including the European Union, extensively regulate, among other things, the research, development,
testing, manufacture, quality control, packaging, storage, recordkeeping, labeling, advertising, promotion,
distribution, marketing, pricing, import and export of pharmaceutical products such as those we are developing. The
processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along
with subsequent compliance with applicable statutes and regulations, require the expenditure of substantial time and
financial resources.
United States Government Regulation
In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its
implementing regulations. The failure to comply with the applicable United States requirements at any time during
the product development process, approval process or after approval, may subject an applicant to a variety of
administrative or judicial sanctions, such as the FDA’s refusal to approve pending NDAs, withdrawal of an
approval, imposition of a clinical hold, issuance of warning or untitled letters, product recalls, product seizures, total
or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution,
disgorgement or civil or criminal penalties.
The process required by the FDA before a drug may be marketed in the United States generally involves the
following:
•
•
•
•
•
•
•
•
•
•
completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the
FDA’s GLP regulations;
submission to the FDA of an IND which must become effective before human clinical trials may begin;
approval by an independent institutional review board, or IRB, at each clinical site before each trial may
be initiated;
performance of human clinical trials, including adequate and well-controlled clinical trials, in
accordance with good clinical practices, or GCP, to establish the safety and efficacy of the proposed
drug product for each indication;
submission to the FDA of an NDA;
satisfactory completion of an FDA advisory committee review, if applicable;
satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the
product is produced to assess compliance with current good manufacturing practices, or cGMP, and to
assure that the facilities, methods and controls are adequate to preserve the drug’s identity, strength,
quality and purity, as well as satisfactory completion of an FDA inspection of selected clinical sites to
determine GCP compliance;
payment of user fees per published Prescription Drug User Fee Act, or PDUFA, guidelines for that year,
if applicable;
FDA review and approval of the NDA; and
compliance with any post-approval requirements, including the potential requirement to implement a
Risk Evaluation and Mitigation Strategy, or REMS, and the potential requirement to conduct post-
approval studies.
Preclinical Studies and an IND. Before an applicant begins testing a compound with potential therapeutic value in
humans, the product candidate enters the preclinical testing stage. Preclinical studies include laboratory evaluation
of product chemistry, toxicity and formulation, as well as animal studies to assess its potential safety and efficacy.
An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical
data and any available clinical data or literature, among other things, to the FDA as part of an IND. An IND is an
exemption from the FDCA that allows an unapproved product candidate to be shipped in interstate commerce for
use in an investigational clinical trial and a request for FDA authorization to administer such investigational product
to humans. Such authorization must be secured prior to interstate shipment and administration of any product
candidate that is not the subject of an approved NDA. An IND automatically becomes effective 30 days after
receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed
clinical trials and places the clinical trial on a clinical hold or partial hold. In such a case, the IND sponsor and the
FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND
may not result in the FDA allowing clinical trials to commence.
Clinical Trials. Clinical trials involve the administration of the investigational new drug to human subjects under the
supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all
research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials
are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in
monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent
protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution
participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that
institution, and the IRB must continue to oversee the clinical trial while it is being conducted. Additionally, some
trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data
safety monitoring board or committee, or DSMB.
Human clinical trials are typically conducted in four sequential phases, which may overlap or be combined. In Phase
1, the candidate drug is initially introduced into healthy human subjects or patients with the target disease or
condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to
gain an initial indication of its effectiveness. In Phase 2, the investigational drug typically is administered to a
limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy
of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. In Phase 3, the
candidate drug is administered to an expanded patient population, generally at geographically dispersed clinical trial
sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the
product for approval, to establish the overall risk-benefit profile of the product and to provide adequate information
for the labeling of the product. In Phase 4, post-approval studies may be conducted to gain additional experience
from the treatment of patients in the intended therapeutic indication.
Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more
frequently if serious adverse events occur. Clinical trials may not be completed successfully within any specified
period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on
various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk.
Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being
conducted in accordance with the IRB’s requirements or if the drug has been associated with unexpected serious
harm to patients.
In general, the FDA accepts foreign safety and efficacy studies that were not conducted under an IND provided that
they are well designed, well conducted, performed by qualified investigators, and conducted in accordance with
ethical principles acceptable to the world community. The conduct of these studies must meet at least minimum
standards for assuring human subject protection. Therefore, for studies submitted in support of an NDA that were
conducted outside the United States and not under an IND, the agency requires demonstration that such studies were
conducted in accordance with GCP.
Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of
Health, or NIH, for public dissemination on the ClinicalTrials.gov website.
Marketing Approval. Assuming successful completion of the required clinical testing, the results of the preclinical
and clinical studies, together with detailed information relating to the product’s chemistry, manufacture, controls and
proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market
the product for one or more indications. Under federal law, the submission of most applications are subject to an
application user fee, which for federal fiscal year 2018 is $2,421,495 for an application requiring clinical data. The
sponsor of an approved application is also subject to an annual program fee, which for fiscal year 2018 is $304,162.
Certain exceptions and waivers are available for some of these fees, such as an exception from the application fee
for products with orphan designation and a waiver for certain small businesses.
In addition, under the Pediatric Research Equity Act, or PREA, an NDA or supplement to an NDA must contain
data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant
pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the
product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals
for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial
waivers from the pediatric data requirements. Unless otherwise required by regulation, the pediatric data
requirements do not apply to products with orphan designation.
The FDCA requires that a sponsor who is planning to submit a marketing application for a drug or biological
product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of
administration submit an initial Pediatric Study Plan, or PSP, within sixty days of an end-of-phase 2 meeting or as
may be agreed between the sponsor and FDA. The initial PSP must include an outline of the pediatric study or
studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and
statistical approach, or a justification for not including such detailed information, and any request for a deferral of
pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with
supporting information. FDA and the sponsor must reach agreement on the PSP. A sponsor can submit amendments
to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data
collected from nonclinical studies, early phase clinical trials, or other clinical development programs.
The FDA also may require submission of a REMS plan to mitigate any identified or suspected serious risks. The
REMS plan could include medication guides, physician communication plans, assessment plans, and elements to
assure safe use, such as restricted distribution methods, patient registries or other risk minimization tools.
Under PDUFA guidelines that are currently in effect, the FDA has agreed to certain performance goals regarding the
timing of its review and disposition of an application. The FDA conducts a preliminary review of all NDAs within
the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently
complete to permit substantive review. The FDA may request additional information rather than accept an NDA for
filing. In this event, the application must be resubmitted with the additional information. The resubmitted
application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing,
the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things,
whether the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged or
held meets standards designed to assure the product’s continued safety, quality and purity.
The FDA has the option to refer questions regarding an application for a New Molecular Entity, or NME, to an
external advisory committee. An advisory committee is a panel of independent experts, including clinicians and
other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should
be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee,
but it considers such recommendations carefully when making decisions.
Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is
manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and
facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product
within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more
clinical trial sites to assure compliance with GCP and perform a sponsor-monitor audit if an audit has not been
completed in the previous two years.
The product development testing and approval process for an NDA requires substantial time, effort and financial
resources, and each may take several years to complete. Data obtained from preclinical and clinical testing are not
always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory
approval. The FDA may not grant approval of an NDA on a timely basis, or at all.
After evaluating the NDA and all related information, including the advisory committee recommendation, if any,
and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval
letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of
specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical
or preclinical testing in order for FDA to reconsider the application. Even with submission of this additional
information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.
If and when those conditions have been met to the FDA’s satisfaction, the FDA will typically issue an approval
letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for
specific indications.
Even if the FDA approves a product, it may limit the approved indications for use of the product, require that
contraindications, warnings or precautions be included in the product labeling, including a boxed warning, require
that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug’s safety after
approval, require testing and surveillance programs to monitor the product after commercialization, or impose other
conditions, including distribution restrictions or other risk management mechanisms under a REMS which can
materially affect the potential market and profitability of the product. The FDA may prevent or limit further
marketing of a product based on the results of post-marketing studies or surveillance programs. After approval,
some types of changes to the approved product, such as adding new indications, manufacturing changes, and
additional labeling claims, are subject to further testing requirements and FDA review and approval.
Orphan Drug Designation. Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug
(including a biologic) intended to treat a rare disease or condition, which is generally a disease or condition that
affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States
and for which there is no reasonable expectation that the cost of developing and making available in the United
States a drug for this type of disease or condition will be recovered from sales in the United States for that drug.
Orphan drug designation must be requested before submitting an NDA or BLA. After the FDA grants orphan drug
designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA.
Orphan designation qualifies the sponsor of the drug for various development incentives. For example, a marketing
application for a prescription drug product that has received orphan designation is not subject to a prescription drug
user fee unless the application includes an indication for other than the rare disease or condition for which the drug
was designated. Furthermore, federal law establishes certain tax credits designed to encourage the development of
orphan drugs. With passage of the Tax Cuts and Jobs Act of 2017, that tax credit was halved from 50% to 25%.
The granting of an orphan designation request does not alter the standard regulatory requirements and process for
obtaining marketing approval. Safety and effectiveness of a drug must be established through adequate and well-
controlled studies.
Breakthrough Drug Designation. FDA may grant breakthrough drug designation to a drug that is intended, alone or
in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and
preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing
therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in
clinical development. For drugs and biologics that have been designated as breakthrough therapies, interaction and
communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical
development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as
breakthrough therapies by the FDA are also eligible for accelerated approval.
Special FDA Expedited Review and Approval Programs. The FDA has various programs, including Fast Track
designation, Accelerated Approval, Priority Review and Breakthrough Designation, that are intended to expedite or
simplify the process for the development and FDA review of drugs that are intended for the treatment of serious or
life threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of
these programs is to provide important new drugs to patients earlier than under standard FDA review procedures.
To be eligible for a Fast Track designation, the FDA must determine, based on the request of a sponsor, that a
product is intended to treat a serious or life threatening disease or condition and demonstrates the potential to
address an unmet medical need. The FDA will determine that a product will fill an unmet medical need if it will
provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapy based
on efficacy or safety factors. For Fast Track products, sponsors may have greater interactions with the FDA
regarding drug development and may submit sections of a Fast Track product’s NDA on a rolling basis before the
entire application is complete.
The FDA may give a priority review designation to drugs that offer major advances in treatment, or provide a
treatment where no adequate therapy exists. A priority review means that the goal for the FDA to review an
application is six months, rather than the standard review of ten months under current PDUFA guidelines. These six-
and ten-month review periods are measured from the “filing” date rather than the receipt date for NDAs for new
molecular entities, which typically adds approximately two months to the timeline for review and decision from the
date of submission. Most products that are eligible for Fast Track designation are also likely to be considered
appropriate to receive a priority review.
In addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that
provide meaningful therapeutic benefit over existing treatments may receive accelerated approval and may be
approved on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect
on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be
measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible
morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition
and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA may require a
sponsor to perform post-marketing confirmatory study(ies) to verify and describe the predicted effect on irreversible
morbidity or mortality or other clinical endpoint, and the drug may be subject to accelerated withdrawal procedures.
Moreover, under the provisions of the new Food and Drug Administration Safety and Innovation Act, or FDASIA,
enacted in 2012, a sponsor can request designation of a product candidate as a “breakthrough therapy.” A
breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to
treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may
demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as
substantial treatment effects observed early in clinical development. Drugs designated as breakthrough therapies are
also eligible for accelerated approval. The FDA must take certain actions, such as holding timely meetings and
providing advice, intended to expedite the development and review of an application for approval of a breakthrough
therapy.
Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer
meets the conditions for qualification or decide that the time period for FDA review or approval will not be
shortened.
FDA Regulation of Companion Diagnostics. Our drug products may rely upon in vitro companion diagnostics for
use in selecting the patients that we believe will respond to our cancer therapeutics. FDA officials have issued
guidance that addresses issues critical to developing in vitro companion diagnostics, such as when the FDA will
require that the diagnostic and the drug be approved simultaneously. The guidance issued in August 2014 states that
if safe and effective use of a therapeutic product depends on an in vitro diagnostic, then the FDA generally will
require approval or clearance of the diagnostic at the same time that the FDA approves the therapeutic product.
The FDA previously has required in vitro companion diagnostics intended to select the patients who will respond to
the cancer treatment to obtain Pre-Market Approval, or PMA, simultaneously with approval of the drug. Based on
the guidance, and the FDA’s past treatment of companion diagnostics, we believe that the FDA will require PMA
approval of one or more in vitro companion diagnostics to identify patient populations suitable for our cancer
therapies. The review of these in vitro companion diagnostics in conjunction with the review of our cancer
treatments involves coordination of review by the FDA’s Center for Drug Evaluation and Research, or CDER, and
by the FDA’s Center for Devices and Radiological Health, or CDRH, Office of In Vitro Diagnostics Device
Evaluation and Safety.
The PMA process, including the gathering of clinical and preclinical data and the submission to and review by the
FDA, can take several years or longer. It involves a rigorous premarket review during which the applicant must
prepare and provide the FDA with reasonable assurance of the device’s safety and effectiveness and information
about the device and its components regarding, among other things, device design, manufacturing and labeling.
PMA applications are subject to an application fee: for federal fiscal year 2018, the standard fee for review of a
PMA is $310,764 and the small business fee is $77,691.
After a device is placed on the market, it remains subject to significant regulatory requirements. Medical devices
may be marketed only for the uses and indications for which they are cleared or approved. Device manufacturers
must also establish registration and device listings with the FDA. A medical device manufacturer’s manufacturing
processes and those of its suppliers are required to comply with the applicable portions of the Quality System
Regulation, or QSR, which cover the methods and documentation of the design, testing, production, processes,
controls, quality assurance, labeling, packaging and shipping of medical devices. Domestic facility records and
manufacturing processes are subject to periodic unscheduled inspections by the FDA. The FDA also may inspect
foreign facilities that export products to the U.S.
Post-Approval Commitments and Requirements. Drugs manufactured or distributed pursuant to FDA approvals are
subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to
recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of
adverse experiences with the product. After approval, most changes to the approved product, such as adding new
indications or other labeling claims are subject to prior FDA review and approval. There also are continuing, annual
user fee requirements for any marketed products and the establishments at which such products are manufactured, as
well as new application fees for supplemental applications with clinical data.
The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example,
the FDA may require post-marketing testing, including Phase 4 clinical trials and surveillance to further assess and
monitor the product’s safety and effectiveness after commercialization.
In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs
are required to register their establishments with the FDA and state agencies, and are subject to periodic
unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to
the manufacturing process are strictly regulated and often require prior FDA approval before being implemented.
FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and
documentation requirements upon the sponsor and any third party manufacturers that the sponsor may decide to use.
Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality
control to maintain cGMP compliance.
Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and
standards is not maintained or if problems occur after the product reaches the market.
Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity
or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in
mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or
clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program.
Other potential consequences include, among other things:
•
•
•
•
•
restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from
the market or product recalls;
fines, warning letters or holds on post-approval clinical trials;
refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or
revocation of product license approvals;
product seizure or detention, or refusal to permit the import or export of products; or
injunctions or the imposition of civil or criminal penalties.
The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market.
Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved
label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off label
uses, and a company that is found to have improperly promoted off label uses may be subject to significant liability.
If a company is found to have promoted off label uses, it may become subject to adverse public relations and
administrative and judicial enforcement by the FDA, the Department of Justice, or the Office of the Inspector
General of the Department of Health and Human Services, as well as state authorities. This could subject a company
to a range of penalties that could have a significant commercial impact, including civil and criminal fines and
agreements that materially restrict the manner in which a company promotes or distributes drug products.
In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing
Act, or PDMA, and its implementing regulations, as well as the Drug Supply Chain Security Act, or DSCA, which
regulate the distribution and tracing of prescription drugs and prescription drug samples at the federal level, and set
minimum standards for the regulation of drug distributors by the states. The PDMA, its implementing regulations
and state laws limit the distribution of prescription pharmaceutical product samples, and the DSCA imposes
requirements to ensure accountability in distribution and to identify and remove counterfeit and other illegitimate
products from the market.
Federal and State Fraud and Abuse and Data Privacy and Security Laws and Regulations. In addition to FDA
restrictions on marketing of pharmaceutical products, federal and state fraud and abuse laws restrict business
practices in the biopharmaceutical industry. These laws include anti-kickback and false claims laws and regulations
as well as data privacy and security laws and regulations.
The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying,
soliciting or receiving remuneration to induce or in return for purchasing, leasing, ordering, or arranging for or
recommending the purchase, lease, or order of any item or service reimbursable under Medicare, Medicaid or other
federal healthcare programs. The term “remuneration” has been broadly interpreted to include anything of value.
The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on
one hand and prescribers, purchasers, and formulary managers on the other. Although there are a number of
statutory exemptions and regulatory safe harbors protecting some common activities from prosecution, the
exemptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be
intended to induce prescribing, purchases, or recommendations may be subject to scrutiny if they do not qualify for
an exemption or safe harbor. Several courts have interpreted the statute’s intent requirement to mean that if any one
purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the
statute has been violated.
The reach of the Anti-Kickback Statute was also broadened by the Patient Protection and Affordable Care Act of
2010, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively PPACA, which,
among other things, amended the intent requirement of the federal Anti-Kickback Statute such that a person or entity
no longer needs to have actual knowledge of this statute or specific intent to violate it in order to have committed a
violation. In addition, PPACA provides that the government may assert that a claim including items or services
resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of
the civil False Claims Act or the civil monetary penalties statute, which imposes penalties against any person who is
determined to have presented or caused to be presented a claim to a federal health program that the person knows or
should know is for an item or service that was not provided as claimed or is false or fraudulent. PPACA also created
new federal requirements for reporting, by applicable manufacturers of covered drugs, payments and other transfers
of value to physicians and teaching hospitals.
The federal False Claims Act prohibits any person from knowingly presenting, or causing to be presented, a false
claim for payment to the federal government or knowingly making, using, or causing to be made or used a false
record or statement material to a false or fraudulent claim to the federal government. A claim includes “any request
or demand” for money or property presented to the U.S. government. Several pharmaceutical and other healthcare
companies have been prosecuted under these laws for allegedly providing free product to customers with the
expectation that the customers would bill federal programs for the product. Other companies have been prosecuted
for causing false claims to be submitted because of the companies’ marketing of products for unapproved, and thus
non-reimbursable, uses. The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA,
created new federal criminal statutes that prohibit knowingly and willfully executing a scheme to defraud any
healthcare benefit program, including private third party payors and knowingly and willfully falsifying, concealing
or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with
the delivery of or payment for healthcare benefits, items or services. Also, many states have similar fraud and abuse
statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in
several states, apply regardless of the payor.
We may also be subject to data privacy and security regulation by both the federal government and the states in
which we conduct our business. HIPAA, as amended by the Health Information Technology and Clinical Health
Act, or HITECH, and its implementing regulations, imposes specified requirements relating to the privacy, security
and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA’s
privacy and security standards directly applicable to “business associates,” defined as independent contractors or
agents of covered entities that receive or obtain protected health information in connection with providing a service
on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against
covered entities, business associates and possibly other persons, and gave state attorneys general new authority to
file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney’s
fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security
of health information in certain circumstances, many of which differ from each other in significant ways and may
not have the same effect, thus complicating compliance efforts.
In addition, federal transparency requirements known as the federal Physician Payments Sunshine Act, under the
Patient Protection and Affordable Care Act, as amended by the Health Care Education Reconciliation Act, or the
Affordable Care Act, require certain manufacturers of drugs, devices, biologics and medical supplies to report
annually to the Centers for Medicare & Medicaid Services, within the United States Department of Health and
Human Services, information related to payments and other transfers of value made by that entity to physicians and
teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family
members. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry’s
voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in
addition to requiring drug manufacturers to report information related to payments to physicians and other health
care providers or marketing expenditures
To the extent that any of our products are sold in a foreign country, we may be subject to similar foreign laws and
regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance,
anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or
transfers of value to healthcare professionals.
Coverage and Reimbursement. The commercial success of our product candidates and our ability to commercialize
any approved product candidates successfully will depend in part on the extent to which governmental authorities,
private health insurers and other third party payors provide coverage for and establish adequate reimbursement
levels for our therapeutic product candidates and related companion diagnostics. Government health administration
authorities, private health insurers and other organizations generally decide which drugs they will pay for and
establish reimbursement levels for healthcare. In particular, in the United States, private health insurers and other
third party payors often provide reimbursement for products and services based on the level at which the
government (through the Medicare or Medicaid programs) provides reimbursement for such treatments. In the
United States, the European Union and other potentially significant markets for our product candidates, government
authorities and third party payors are increasingly attempting to limit or regulate the price of medical products and
services, particularly for new and innovative products and therapies, which often has resulted in average selling
prices lower than they would otherwise be. Further, the increased emphasis on managed healthcare in the United
States and on country and regional pricing and reimbursement controls in the European Union will put additional
pressure on product pricing, reimbursement and usage, which may adversely affect our future product sales and
results of operations. These pressures can arise from rules and practices of managed care groups, judicial decisions
and governmental laws and regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical
reimbursement policies and pricing in general.
Third party payors are increasingly imposing additional requirements and restrictions on coverage and limiting
reimbursement levels for medical products. For example, federal and state governments reimburse covered
prescription drugs at varying rates generally below average wholesale price. These restrictions and limitations
influence the purchase of healthcare services and products. Legislative proposals to reform healthcare or reduce
costs under government insurance programs may result in lower reimbursement for our products and product
candidates or exclusion of our products and product candidates from coverage. The cost containment measures that
healthcare payors and providers are instituting and any healthcare reform could significantly reduce our revenues
from the sale of any approved product candidates. We cannot provide any assurances that we will be able to obtain
and maintain third party coverage or adequate reimbursement for our product candidates in whole or in part.
Impact of Healthcare Reform on Coverage, Reimbursement, and Pricing. The Medicare Prescription Drug,
Improvement, and Modernization Act of 2003, or the MMA, imposed new requirements for the distribution and
pricing of prescription drugs for Medicare beneficiaries. Under Part D, Medicare beneficiaries may enroll in
prescription drug plans offered by private entities that provide coverage of outpatient prescription drugs. Part D
plans include both standalone prescription drug benefit plans and prescription drug coverage as a supplement to
Medicare Advantage plans. Unlike Medicare Part A and B, Part D coverage is not standardized. Part D prescription
drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug
formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription drug
formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not
necessarily all the drugs in each category or class. Any formulary used by a Part D prescription drug plan must be
developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of
prescription drugs may increase demand for any products for which we receive marketing approval. However, any
negotiated prices for our future products covered by a Part D prescription drug plan will likely be lower than the
prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare
beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own
payment rates. Any reduction in payment that results from Medicare Part D may result in a similar reduction in
payments from non-governmental payors.
The American Recovery and Reinvestment Act of 2009 provides funding for the federal government to compare the
effectiveness of different treatments for the same illness. A plan for the research will be developed by the
Department of Health and Human Services, the Agency for Healthcare Research and Quality and the National
Institutes for Health, and periodic reports on the status of the research and related expenditures will be made to
Congress. Although the results of the comparative effectiveness studies are not intended to mandate coverage
policies for public or private payors, it is not clear what effect, if any, the research will have on the sales of any
product, if any such product or the condition that it is intended to treat is the subject of a study. It is also possible
that comparative effectiveness research demonstrating benefits in a competitor’s product could adversely affect the
sales of our product candidates. If third party payors do not consider our product candidates to be cost-effective
compared to other available therapies, they may not cover our product candidates, once approved, as a benefit under
their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products on a profitable
basis.
The United States and some foreign jurisdictions are considering enacting or have enacted a number of additional
legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our
products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest
in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality
and expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts
and has been significantly affected by major legislative initiatives, including, most recently, PPACA, which became
law in March 2010 and substantially changed the way healthcare is financed by both governmental and private
insurers. Among the provisions of the Affordable Care Act of importance to potential product candidates are:
•
•
•
•
an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription
drugs and biologic agents, apportioned among these entities according to their market share in certain
government healthcare programs, although this fee would not apply to sales of certain products
approved exclusively for orphan indications;
expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer
Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level,
thereby potentially increasing a manufacturer’s Medicaid rebate liability;
expanded manufacturers’ rebate liability under the Medicaid Drug Rebate Program by increasing the
minimum rebate for both branded and generic drugs and revising the definition of “average
manufacturer price,” or AMP, for calculating and reporting Medicaid drug rebates on outpatient
prescription drug prices and extending rebate liability to prescriptions for individuals enrolled in
Medicare Advantage plans;
addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug
Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;
•
•
•
•
•
expanded the types of entities eligible for the 340B drug discount program;
established the Medicare Part D coverage gap discount program by requiring manufacturers to provide a
50% point-of-sale-discount off the negotiated price of applicable brand drugs to eligible beneficiaries
during their coverage gap period as a condition for the manufacturers’ outpatient drugs to be covered
under Medicare Part D;
a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct
comparative clinical effectiveness research, along with funding for such research;
the Independent Payment Advisory Board, or IPAB, which has authority to recommend certain changes
to the Medicare program to reduce expenditures by the program that could result in reduced payments
for prescription drugs. However, the IPAB implementation has been not been clearly defined. PPACA
provided that under certain circumstances, IPAB recommendations will become law unless Congress
enacts legislation that will achieve the same or greater Medicare cost savings; and
established the Center for Medicare and Medicaid Innovation within CMS to test innovative payment
and service delivery models to lower Medicare and Medicaid spending, potentially including
prescription drug spending. Funding has been allocated to support the mission of the Center for
Medicare and Medicaid Innovation from 2011 to 2019.
Other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was
enacted. For example, in August 2011, the Budget Control Act of 2011, among other things, created measures for
spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a
targeted deficit reduction of at least $1.2 trillion for the years 2012 through 2021, was unable to reach required
goals, thereby triggering the legislation’s automatic reduction to several government programs. This includes
aggregate reductions of Medicare payments to providers of up to 2% per fiscal year, which went into effect in April
2013 and will remain in effect through 2024 unless additional Congressional action is taken. In January 2013, the
American Taxpayer Relief Act of 2012 became law, which, among other things, further reduced Medicare payments
to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of
limitations period for the government to recover overpayments to providers from three to five years.
These healthcare reforms, as well as other healthcare reform measures that may be adopted in the future, may result
in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment
methodologies and additional downward pressure on the price for any approved product and/or the level of
reimbursement physicians receive for administering any approved product. Reductions in reimbursement levels may
negatively impact the prices or the frequency with which products are prescribed or administered. Any reduction in
reimbursement from Medicare or other government programs may result in a similar reduction in payments from
private payors. Since enactment of the PPACA, there have been numerous legal challenges and Congressional
actions to repeal and replace provisions of the law.
With enactment of the Tax Cuts and Jobs Act of 2017, which was signed by the President on December 22, 2017,
Congress repealed the “individual mandate.” The repeal of this provision, which requires most Americans to carry a
minimal level of health insurance, will become effective in 2019. According to the Congressional Budget Office,
the repeal of the individual mandate will cause 13 million fewer Americans to be insured in 2027 and premiums in
insurance markets may rise. Additionally, on January 22, 2018, President Trump signed a continuing resolution on
appropriations for fiscal year 2018 that delayed the implementation of certain ACA-mandated fees, including the so-
called “Cadillac” tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain
health insurance providers based on market share, and the medical device excise tax on non-exempt medical
devices. The Congress will likely consider other legislation to replace elements of the ACA during the next
Congressional session.
Further, there have been several recent U.S. congressional inquiries and proposed federal and proposed and enacted
state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship
between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform
government program reimbursement methodologies for drug products. At the federal level, Congress and the Trump
administration have each indicated that it will continue to seek new legislative and/or administrative measures to
control drug costs. At the state level, individual states are increasingly aggressive in passing legislation and
implementing regulations designed to control pharmaceutical and biological product pricing, including price or
patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure
and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk
purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding
procedures to determine what pharmaceutical products and which suppliers will be included in their prescription
drug and other health care programs. These measures could reduce the ultimate demand for our products, once
approved, or put pressure on our product pricing.
Exclusivity and Approval of Competing Products
Patent Term Restoration and Extension. A patent claiming a new drug product may be eligible for a limited patent
term extension under the Hatch-Waxman Act, which permits a patent restoration of up to five years for patent term
lost during product development and the FDA regulatory review. The restoration period granted is typically one-half
the time between the effective date of an IND and the submission date of an NDA, plus the time between the
submission date of an NDA and the ultimate approval date. Patent term restoration cannot be used to extend the
remaining term of a patent past a total of 14 years from the product’s approval date. Only one patent applicable to an
approved drug product is eligible for the extension, and the application for the extension must be submitted prior to
the expiration of the patent in question. A patent that covers multiple drugs for which approval is sought can only be
extended in connection with one of the approvals. The USPTO reviews and approves the application for any patent
term extension or restoration in consultation with the FDA.
Hatch-Waxman Patent Exclusivity. In seeking approval for a drug through an NDA, applicants are required to list
with the FDA each patent with claims that cover the applicant’s product or a method of using the product. Upon
approval of a drug, each of the patents listed in the application for the drug is then published in the FDA’s Approved
Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the
Orange Book can, in turn, be cited by potential competitors in support of approval of an abbreviated new drug
application, or ANDA, or 505(b)(2) NDA.
Generally, an ANDA provides for marketing of a drug product that has the same active ingredients in the same
strengths, dosage form and route of administration as the listed drug and has been shown to be bioequivalent through
in vitro or in vivo testing or otherwise to the listed drug. ANDA applicants are not required to conduct or submit
results of preclinical or clinical tests to prove the safety or effectiveness of their drug product, other than the
requirement for bioequivalence testing. Drugs approved in this way are commonly referred to as “generic
equivalents” to the listed drug, and can often be substituted by pharmacists under prescriptions written for the
original listed drug.
A 505(b)(2) application applies to a drug for which the investigations made to show whether or not the drug is safe
for use and effective in use and relied upon by the applicant for approval of the application “were not conducted by
or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for
whom the investigations were conducted.” As with an ANDA, Section 505(b)(2) authorizes the FDA to approve an
NDA based on safety and effectiveness data that were not developed by the applicant. 505(b)(2) NDAs generally are
submitted for changes to a previously approved drug product, such as a new dosage form or indication.
The ANDA or 505(b)(2) NDA applicant is required to certify to the FDA concerning any patents listed for the
approved product in the FDA’s Orange Book, except for patents covering methods of use for which the ANDA
applicant is not seeking approval. Specifically, the applicant must certify with respect to each patent that:
•
•
•
•
the required patent information has not been filed;
the listed patent has expired;
the listed patent has not expired, but will expire on a particular date and approval is sought after patent
expiration; or
the listed patent is invalid, unenforceable, or will not be infringed by the new product.
Generally, the ANDA or 505(b)(2) NDA cannot be approved until all listed patents have expired, except when the
ANDA or 505(b)(2) NDA applicant challenges a listed drug. A certification that the proposed product will not
infringe the already approved product’s listed patents or that such patents are invalid or unenforceable is called a
Paragraph IV certification. If the applicant does not challenge the listed patents or indicate that it is not seeking
approval of a patented method of use, the ANDA or 505(b)(2) NDA application will not be approved until all the
listed patents claiming the referenced product have expired.
If the ANDA or 505(b)(2) NDA applicant has provided a Paragraph IV certification to the FDA, the applicant must
also send notice of the Paragraph IV certification to the NDA and patent holders once the application has been
accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in
response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days
after the receipt of notice of the Paragraph IV certification automatically prevents the FDA from approving the
ANDA or 505(b)(2) NDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit or a
decision in the infringement case that is favorable to the ANDA applicant.
Hatch—Waxman Non-Patent Exclusivity. Market and data exclusivity provisions under the FDCA also can delay
the submission or the approval of ANDAs and 505(b)(2) NDAs for competing products. The FDCA provides a five-
year period of non-patent data exclusivity within the United States to the first applicant to gain approval of an NDA
for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new
drug containing the same active moiety, which is the molecule or ion responsible for the activity of the drug
substance. During the exclusivity period, the FDA may not accept for review an ANDA or a 505(b)(2) NDA
submitted by another company that contains the previously approved active moiety. However, an ANDA or
505(b)(2) NDA may be submitted after four years if it contains a certification of patent invalidity or non-
infringement.
The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA, or supplement to an
existing NDA or 505(b)(2) NDA if new clinical investigations, other than bioavailability studies, that were
conducted or sponsored by the applicant, are deemed by the FDA to be essential to the approval of the application or
supplement. Three-year exclusivity may be awarded for changes to a previously approved drug product, such as new
indications, dosages, strengths or dosage forms of an existing drug. This three-year exclusivity covers only the
conditions of use associated with the new clinical investigations and, as a general matter, does not prohibit the FDA
from approving ANDAs or 505(b)(2) NDAs for generic versions of the original, unmodified drug product. Five-year
and three-year exclusivity will not delay the submission or approval of a full NDA; however, an applicant
submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and
adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.
The FDA must establish a priority review track for certain generic drugs, requiring the FDA to review a drug
application within eight months for a drug that has three or fewer approved drugs listed in the Orange Book and is
no longer protected by any patent or regulatory exclusivities, or is on the FDA’s drug shortage list. The new
legislation also authorizes FDA to expedite review of ‘‘competitor generic therapies’’ or drugs with inadequate
generic competition, including holding meetings with or providing advice to the drug sponsor prior to submission of
the application.
Orphan Drug Exclusivity. Under the Orphan Drug Act, a drug that is approved for the orphan drug designated
indication is granted seven years of orphan drug exclusivity. Orphan drug exclusivity means that the FDA may not
approve another sponsor’s marketing application for the same drug for the same indication for seven years, except in
certain limited circumstances. Orphan exclusivity does not block the approval of a different product for the same
rare disease or condition, nor does it block the approval of the same product for different indications. If a drug or
biologic designated as an orphan drug ultimately receives marketing approval for an indication broader than what
was designated in its orphan drug application, it may not be entitled to exclusivity.
Orphan drug exclusivity will also not bar approval of another product under certain circumstances, including if a
subsequent product with the same drug or biologic for the same indication is shown to be clinically superior to the
approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care, or if the
company with orphan drug exclusivity is not able to meet market demand. This is the case despite an earlier court
opinion holding that the Orphan Drug Act unambiguously required the FDA to recognize orphan exclusivity
regardless of a showing of clinical superiority.
We intend to seek orphan drug designation and exclusivity for our products whenever it is available. We have been
granted orphan drug designation in the United States and the European Union for pinometostat, and orphan drug
designation in the United States for tazemetostat for the treatment of patients with FL, MRT, soft tissue sarcoma and
mesothelioma.
Pediatric Exclusivity. Pediatric exclusivity is another type of non-patent marketing exclusivity in the United States
and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any
existing regulatory exclusivity, including the non-patent and orphan drug exclusivity periods described above, and
any listed patent. This six-month exclusivity may be granted if an NDA sponsor submits pediatric data that fairly
respond to a written request from the FDA for such data. The data do not need to show the product to be effective in
the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA’s request, the
additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA
within the statutory time limits, whatever statutory or regulatory periods of exclusivity or Orange Book listed patent
protection cover the drug are extended by six months. This is not a patent term extension, but it effectively extends
the regulatory period during which the FDA cannot approve an ANDA or 505(b)(2) application owing to regulatory
exclusivity or listed patents. When any of our products is approved, we anticipate seeking pediatric exclusivity when
it is appropriate.
The 21st Century Cures Act. On December 13, 2016, President Obama signed the Cures Act into law. The Cures
Act is designed to modernize and personalize healthcare, spur innovation and research, and streamline the discovery
and development of new therapies through increased federal funding of particular programs. It authorizes increased
funding for the FDA to spend on innovation projects. The new law also amends the Public Health Service Act to
reauthorize and expand funding for the National Institutes of Health. The Act establishes the NIH Innovation Fund
to pay for the cost of development and implementation of a strategic plan, early stage investigators and research. It
also charges NIH with leading and coordinating expanded pediatric research. Further, the Cures Act directs the
Centers for Disease Control and Prevention to expand surveillance of neurological diseases.
With amendments to the FDCA and the Public Health Service Act, or PHSA, Title III of the Cures Act seeks to
accelerate the discovery, development, and delivery of new medicines and medical technologies. To that end, and
among other provisions, the Cures Act reauthorizes the existing priority review voucher program for certain drugs
intended to treat rare pediatric diseases until 2020; creates a new priority review voucher program for drug
applications determined to be material national security threat medical countermeasure applications; revises the
FDCA to streamline review of combination product applications; requires the FDA to evaluate the potential use of
“real world evidence” to help support approval of new indications for approved drugs; provides a new “limited
population” approval pathway for antibiotic and antifungal drugs intended to treat serious or life-threatening
infections; and authorizes the FDA to designate a drug as a “regenerative advanced therapy,” thereby making it
eligible for certain expedited review and approval designations.
European Union Drug Approval Process
In order to market any product outside of the United States, we would need to comply with numerous and varying
regulatory requirements of other countries regarding safety and efficacy and governing, among other things, clinical
trials, marketing authorization, commercial sales and distribution of our products. Whether or not we obtain FDA
approval for a product, we would need to obtain the necessary approvals by the comparable regulatory authorities of
foreign countries before we can commence clinical trials or marketing of the product in those countries. The
approval process varies from country to country and can involve additional product testing and additional
administrative review periods. The time required to obtain approval in other countries might differ from and be
longer than that required to obtain FDA approval. Regulatory approval in one country does not ensure regulatory
approval in another, but a failure or delay in obtaining regulatory approval in one country may negatively impact the
regulatory process in others.
Clinical Trial Approval in the EU. Pursuant to the currently applicable Clinical Trials Directives, an applicant must
obtain approval from the competent national authority of the EU Member State in which the clinical trial is to be
conducted. If the clinical trial is conducted in different EU Member States, the competent authorities in each of these
EU Member States must provide their approval for the conduct of the clinical trial. Furthermore, the applicant may
only start a clinical trial at a specific study site after the competent ethics committee has issued a favorable opinion.
In April 2014, the EU adopted a new Clinical Trials Regulation, which is set to replace the current Clinical Trials
Directive. The new Clinical Trials Regulation will be directly applicable to and binding in all 28 EU Member States
without the need for any national implementing legislation, and will become applicable no earlier than 2019. Under
the new coordinated procedure for the approval of clinical trials, the sponsor of a clinical trial will be required to
submit a single application for approval of a clinical trial to a reporting EU Member State (RMS) through an EU
Portal. The submission procedure will be the same irrespective of whether the clinical trial is to be conducted in a
single EU Member State or in more than one EU Member State. The Clinical Trials Regulation also aims to
streamline and simplify the rules on safety reporting for clinical trials.
Marketing Authorization. To obtain marketing approval of a drug under European Union regulatory systems, we
may submit marketing authorization applications, or MAAs, either under a centralized or decentralized procedure.
The centralized procedure provides for the grant of a single marketing authorization that is valid for all EU member
states. The centralized procedure is compulsory for medicines produced by specified biotechnological processes,
products designated as orphan medicinal products, and products with a new active substance indicated for the
treatment of specified diseases, and optional for those products that are highly innovative or for which a centralized
process is in the interest of patients. Under the centralized procedure in the European Union, the maximum
timeframe for the evaluation of an MAA is 210 days, excluding clock stops, when additional written or oral
information is to be provided by the applicant in response to questions asked by the Scientific Advice Working Party
of the Committee of Medicinal Products for Human Use, or the CHMP. Accelerated evaluation might be granted by
the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest,
defined by three cumulative criteria: the seriousness of the disease, such as heavy disabling or life-threatening
diseases, to be treated; the absence or insufficiency of an appropriate alternative therapeutic approach; and
anticipation of high therapeutic benefit. In this circumstance, the European Medicines Agency, or EMA, ensures that
the opinion of the CHMP is given within 150 days.
The decentralized procedure provides for approval by one or more other, or concerned, member states of an
assessment of an application performed by one member state, known as the reference member state. Under this
procedure, an applicant submits an application, or dossier, and related materials, including a draft summary of
product characteristics, and draft labeling and package leaflet, to the reference member state and concerned member
states. The reference member state prepares a draft assessment and drafts of the related materials within 120 days
after receipt of a valid application. Within 90 days of receiving the reference member state’s assessment report, each
concerned member state must decide whether to approve the assessment report and related materials. If a member
state cannot approve the assessment report and related materials on the grounds of potential serious risk to public
health, the disputed points may eventually be referred to the European Commission, whose decision is binding on all
member states. For the EMA, a Pediatric Investigation Plan, or a request for waiver or deferral, is required for
submission prior to submitting an MAA for use for drugs in pediatric populations.
Data and Market Exclusivity. In the European Union, new chemical entities qualify for eight years of data
exclusivity upon marketing authorization and an additional two years of market exclusivity. This data exclusivity, if
granted, prevents regulatory authorities in the European Union from assessing a generic (abbreviated) application for
eight years, after which generic marketing authorization can be submitted but not approved for two years. The
overall ten-year period will be extended to a maximum of eleven years if, during the first eight years of those ten
years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications
which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in
comparison with existing therapies. Even if a compound is considered to be a new chemical entity and the sponsor is
able to gain the prescribed period of data exclusivity, another company nevertheless could also market another
version of the drug if such company can complete a full MAA with a complete human clinical trial database and
obtain marketing approval of its product.
Orphan Drug Exclusivity. The EMA grants orphan drug designation to promote the development of products that
may offer therapeutic benefits for life-threatening or chronically debilitating conditions affecting not more than five
in 10,000 people in the European Union. In addition, orphan drug designation can be granted if the drug is intended
for a life threatening, seriously debilitating or serious and chronic condition in the European Union and without
incentives it is unlikely that sales of the drug in the European Union would be sufficient to justify developing the
drug. Orphan drug designation is only available if there is no other satisfactory method approved in the European
Union of diagnosing, preventing or treating the condition, or if such a method exists, the proposed orphan drug will
be of significant benefit to patients. Orphan drug designation provides opportunities for free protocol assistance, fee
reductions for access to the centralized regulatory procedures before and during the first year after marketing
authorization and 10 years of market exclusivity following drug approval. Fee reductions are not limited to the first
year after authorization for small and medium enterprises. The exclusivity period may be reduced to six years if the
designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to
justify maintenance of market exclusivity.
Priority Medicines, or PRIME, Drug Designation. EMA may grant prime drug designation to medicine developers
to treat an unmet medical need upon selection. Medicines eligible for PRIME must address an unmet medical need,
have data available showing the potential to address this need and bring a major therapeutic advantage to patients,
and provide early and enhanced support to optimize the development of eligible medicines speed up their evaluation
and contribute to timely patients’ access. Once a candidate is selected for PRIME designation the EMA will provide
scientific advice at key development milestones and confirm potential for accelerated assessment at the time of an
application for marketing authorization. These medicines are considered priority medicines by EMA.
Brexit and the Regulatory Framework in the United Kingdom. On June 23, 2016, the electorate in the United
Kingdom voted in favor of leaving the European Union (commonly referred to as “Brexit”). Thereafter, on March
29, 2017, the country formally notified the European Union of its intention to withdraw pursuant to Article 50 of the
Lisbon Treaty. The withdrawal of the United Kingdom from the European Union will take effect either on the
effective date of the withdrawal agreement or, in the absence of agreement, two years after the United Kingdom
provides a notice of withdrawal pursuant to the EU Treaty. Since the regulatory framework for pharmaceutical
products in the United Kingdom covering quality, safety and efficacy of pharmaceutical products, clinical trials,
marketing authorization, commercial sales and distribution of pharmaceutical products is derived from European
Union directives and regulations, Brexit could materially impact the future regulatory regime which applies to
products and the approval of product candidates in the United Kingdom. It remains to be seen how, if at all, Brexit
will impact regulatory requirements for product candidates and products in the United Kingdom.
Employees
As of March 1, 2018, we had 131 full-time employees, 89 of whom were primarily engaged in research and
development activities.
Executive Officers of the Company
The following table sets forth the name, age and position of each of our executive officers as of March 1, 2018.
Name
Robert B. Bazemore
Susan E. Graf
Matthew E. Ros
Age
50 President, Chief Executive Officer and Director
45 Chief Business Officer
51 Chief Operating Officer
Position
Robert B. Bazemore has served as a director and our President and Chief Executive Officer since joining us in
September 2015. Prior to joining us, from September 2014 to July 2015, Mr. Bazemore served as the Chief
Operating Officer of Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for
rare disorders. Prior to joining Synageva, Mr. Bazemore served in increasing levels of responsibility at Johnson &
Johnson, a healthcare company, including Vice President, Centocor Ortho Biotech Sales & Marketing from 2008 to
2010, President of Janssen Biotech from March 2010 to October 2013 and Vice President of Global Surgery at
Ethicon from October 2013 to September 2014. Prior to Johnson & Johnson, Mr. Bazemore worked at Merck & Co.,
Inc. for eleven years, where he served in a variety of roles in medical affairs, sales and marketing. Mr. Bazemore is a
director of Ardelyx, Inc., a biopharmaceutical company. He received a B.S. in biochemistry from the University of
Georgia.
Susan E. Graf has served as our Chief Business Officer since April 2016. Prior to joining us, from May 2013 to
March 2015, Ms. Graf served as the Vice President, Corporate Development and Strategy for NPS Pharma before it
was acquired by Shire in 2015. Prior to joining NPS Pharma, Ms. Graf spent nearly18 years at Roche in a number of
leadership and executive positions, including Global Head, Commercial Assessment and Due Diligence for Roche
Partnering. Ms. Graf is a director of Vitrisa Therapeutics, Inc., a private biopharmaceutical company. Ms. Graf
received a Bachelor of Pharmacy degree from Purdue University and an M.B.A. from the Stern School of Business
at New York University.
Matthew E. Ros has served as our Chief Operating Officer since May 2016. Prior to joining us, from September
2010 to May 2016, Mr. Ros served in increasing levels of responsibility at Sanofi, a multinational pharmaceutical
company, most recently as Chief Operating Officer/Global Head of the Oncology Business unit from December
2014 to May 2016. Prior to that role, Mr. Ros served in the rare disease business of Genzyme, a Sanofi company,
where he served as Vice President and Franchise Head of its Pompe disease unit from September 2012 to December
2014. From October 2007 to June 2010, Mr. Ros served at ARIAD Pharmaceuticals, Inc., a global oncology
company, most recently as Senior Vice President, Commercial Operations. He started his pharmaceutical career in
Bristol-Myers Squibb’s Oncology Division, serving in roles with increasing responsibility from 1990-2007. He
received a B.S. from the State University of New York, College at Plattsburgh and completed the Executive
Education Program in Finance and Accounting for the Non-Financial Manager at Wharton School of the University
of Pennsylvania.
Our Corporate Information
We were incorporated under the laws of the state of Delaware on November 1, 2007 under the name Epizyme, Inc.
Our principal executive offices are located at 400 Technology Square, Cambridge, Massachusetts 02139. Our
telephone number is (617) 229-5872, and our website is located at www.epizyme.com. References to our website
are inactive textual references only and the content of our website should not be deemed incorporated by reference
into this Annual Report on Form 10-K.
Available Information
Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and any
amendments to these reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of
1934, are available free of charge on our website located at www.epizyme.com as soon as reasonably practicable
after they are electronically filed with or furnished to the SEC. These reports are also available at the SEC’s Internet
website at www.sec.gov. The public may also read and copy any materials filed with the SEC at the SEC’s Public
Reference Room at 100 F Street, N.E., Washington D.C. 20549. Information on the operation of the Public
Reference Room may be obtained by calling the SEC at 1-800-SEC-0330.
A copy of our Corporate Governance Guidelines, Code of Business Conduct and Ethics and the charters of the Audit
Committee, Compensation Committee and Nominating and Corporate Governance Committee are posted on our
website, www.epizyme.com, under “Investor Center” and are available in print to any person who requests copies
by contacting Epizyme by calling (617) 229-5872 or by writing to Epizyme, Inc., 400 Technology Square,
Cambridge, Massachusetts 02139.
Item 1A. Risk Factors
Careful consideration should be given to the following risk factors, in addition to the other information set forth in
this Annual Report on Form 10-K and in other documents that we file with the SEC, in evaluating our company and
our business. Investing in our common stock involves a high degree of risk. If any of the following risks and
uncertainties actually occurs, our business, prospects, financial condition and results of operations could be
materially and adversely affected. The risks described below are not intended to be exhaustive and are not the only
risks facing our company. New risk factors can emerge from time to time, and it is not possible to predict the impact
that any factor or combination of factors may have on our business, prospects, financial condition and results of
operations.
Risks Related to the Discovery and Development of Our Product Candidates
We are dependent on the successful development and commercialization of our lead product candidate,
tazemetostat. If we are unable to develop, obtain marketing approval for or successfully commercialize this
product candidate, either alone or through a collaboration, or if we experience significant delays in doing so, our
business could be harmed.
We currently have no products approved for sale and are investing a significant portion of our efforts and financial
resources to fund the development of our lead product candidate, tazemetostat. We have another product candidate
in clinical trials that we are developing pinometostat, and GSK has initiated a Phase 1 clinical trial for a PRMT5
inhibitor that it has licensed from us. However, these development programs are early stage, and all of our other
product candidates are still in preclinical development. As a result, our prospects are substantially dependent on our
ability, or the ability of any future collaborator, to develop, obtain marketing approval for and successfully
commercialize tazemetostat in one or more disease indications. The success of tazemetostat and any other product
candidate will depend on several factors, including the following:
•
•
•
•
•
•
•
•
•
•
•
•
successful enrollment in, and completion of, clinical trials;
safety, tolerability and efficacy profiles that are satisfactory to the U.S. Food and Drug Administration,
or FDA, the European Medicines Agency, or EMA, or any comparable foreign regulatory authority for
marketing approval;
timely receipt of marketing approvals from applicable regulatory authorities;
the extent of any required post-marketing approval commitments to applicable regulatory authorities;
making arrangements with third party manufacturers for, or establishing, clinical and commercial
manufacturing capabilities;
launching commercial sales of the products, if and when approved, whether alone or in collaboration
with others;
acceptance of the products, if and when approved, by patients, the medical community and third party
payors;
effectively competing with other therapies;
obtaining and maintaining healthcare coverage and adequate reimbursement;
obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product
candidates;
protecting our rights in our intellectual property portfolio; and
maintaining a continued acceptable safety profile of the products following approval.
Many of these factors are beyond our control, including clinical development, the regulatory review process,
potential threats to our intellectual property rights and the manufacturing, marketing and sales efforts of any
collaborator. If we or any collaborators do not achieve one or more of these factors in a timely manner or at all, we
could experience significant delays or an inability to successfully commercialize our product candidates, which
would materially harm our business.
Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur
additional costs or experience delays in completing, or ultimately be unable to complete, the development and
commercialization of our product candidates.
We are conducting multiple clinical trials of tazemetostat and pinometostat, and GSK’s PRMT5 inhibitor is in
clinical development. The risk of failure for each of these product candidates is high. It is impossible to predict when
or if any of our product candidates will prove effective or safe in humans or will receive regulatory approval. Before
obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete
preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our
product candidates in humans.
Product candidates are subject to preclinical safety studies, which may be conducted concurrently with our clinical
testing. The outcomes of these safety studies may delay the launch of or enrollment in future clinical studies. For
example, in the course of our preclinical safety studies of tazemetostat, we observed the development of lymphoma
in Sprague Dawley rats. As a result of these findings, coupled with our limited clinical experience in FL at the time
of the IND submission in December 2015, we were unable to conduct our Phase 2 trial of tazemetostat in FL
patients in the United States until the beginning of 2017. If we are unable to adequately address matters such as this
when they arise, we may be unable to conduct clinical trials of our product candidates in the United States or in
other countries, our trials may be limited to certain patient populations or our ability to conduct other trials in the
United States or in other countries may be delayed.
Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as
to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical
testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a
clinical trial do not necessarily predict final results. For example, the complete responses that were observed in
two patients with MLL-r in the fourth dose cohort of the dose escalation portion of our Phase 1 clinical trial of
pinometostat in adults were not achieved by any other patient treated with pinometostat in the Phase 1 clinical trial.
Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many
companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical
trials have nonetheless failed to obtain marketing approval of their products.
We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent
our ability to receive marketing approval or commercialize our product candidates, including:
•
•
•
•
•
•
regulators or institutional review boards may not authorize us or our investigators to commence a
clinical trial or conduct a clinical trial at a prospective trial site;
we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts
or clinical trial protocols with prospective trial sites;
clinical trials of our product candidates may produce negative or inconclusive results, and we may
decide, or regulators may require us, to conduct additional clinical trials or abandon product
development programs;
preclinical testing may produce results based on which we may decide, or regulators may require us, to
conduct additional preclinical studies before we proceed with certain clinical trials, limit the scope of
our clinical trials, halt ongoing clinical trials or abandon product development programs;
the number of patients required for clinical trials of our product candidates may be larger than we
anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop
out of these clinical trials at a higher rate than we anticipate;
our third party contractors may fail to comply with regulatory requirements or meet their contractual
obligations to us in a timely manner, or at all;
•
•
•
•
•
we may have to suspend or terminate clinical trials of our product candidates for various reasons,
including a finding that the participants are being exposed to unacceptable health risks;
regulators or institutional review boards may require that we or our investigators suspend or terminate
clinical research for various reasons, including noncompliance with regulatory requirements or a finding
that the participants are being exposed to unacceptable health risks;
the cost of clinical trials of our product candidates may be greater than we anticipate;
the supply or quality of our product candidates or other materials necessary to conduct clinical trials of
our product candidates may be insufficient or inadequate; and
our product candidates may have undesirable side effects or other unexpected characteristics, causing us
or our investigators, regulators or institutional review boards to suspend or terminate the trials.
If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we
currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other
testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety
concerns, we may:
•
•
•
•
•
•
be delayed in obtaining marketing approval for our product candidates;
not obtain marketing approval at all;
obtain approval for indications or patient populations that are not as broad as intended or desired;
obtain approval with labeling or a risk evaluation mitigation strategy that includes significant use or
distribution restrictions or safety warnings;
be subject to additional post-marketing testing requirements; or
have the product removed from the market after obtaining marketing approval.
Our product development costs may also increase if we experience delays in clinical testing or in obtaining
marketing approvals. We do not know whether any of our preclinical studies or clinical trials will continue or begin
as planned, will need to be restructured or will be completed on schedule, or at all. Significant preclinical or clinical
trial delays also could shorten any periods during which we may have the exclusive right to commercialize our
product candidates or allow our competitors to bring products to market before we do and impair our ability to
successfully commercialize our product candidates and may harm our business and results of operations.
If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary
regulatory approvals could be delayed or prevented.
We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and
enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar
regulatory authorities outside of the United States. In particular, because certain of our product candidates may be
focused on specific patient populations, our ability to enroll eligible patients may be limited or may result in slower
enrollment than we anticipate. In addition, some of our competitors have ongoing clinical trials for product
candidates that may treat the broader patient populations within which our product candidates are being developed
for the treatment of a subset of identifiable patients with cancer and other diseases, and patients who would
otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors’ product
candidates. For instance, our ongoing clinical trials of tazemetostat in adult and pediatric patients with INI1-negative
tumors are targeting rare patient populations. In addition, our Phase 2 clinical trial of tazemetostat in patients with
NHL has two arms targeting patients with EZH2 activating mutations in their tumors, one in diffuse large B-cell
lymphoma, or DLBCL, originating from the germinal center of the lymph node, or GCB DLBCL, and one in
follicular lymphoma, or FL. Based on the aggregate scientific literature, we believe that patients with these
mutations represent approximately 20% of the total GCB DLBCL and FL population in the United States and other
major reimbursable markets. In any clinical study, the actual percentage of patients enrolled with these EZH2
mutations may vary from the range suggested by the literature. As a result, these arms of the Phase 2 NHL clinical
trial have been, and are likely to continue to be, slower to enroll than the other arms of the Phase 2 NHL clinical
trial.
Patient enrollment is affected by other factors including:
•
•
•
•
•
•
•
•
the severity of the disease under investigation;
the eligibility criteria for the trial in question;
the perceived risks and benefits of the product candidate under trial;
the efforts to facilitate timely enrollment in clinical trials;
the patient referral practices of physicians;
the ability to monitor patients adequately during and after treatment;
the proximity and availability of clinical trial sites for prospective patients; and
the ability to identify specific patient population for molecularly defined study cohort(s).
Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays and
could require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result
in increased development costs for our product candidates, which may cause the value of our company to decline
and limit our ability to obtain additional financing.
If serious adverse or unacceptable side effects are identified during the development of our product candidates,
we may need to abandon or limit our development of some of our product candidates.
If our product candidates are associated with undesirable side effects in clinical trials or have characteristics that are
unexpected in clinical trials or preclinical testing, we may need to abandon their development or limit development
to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less
prevalent, less severe or more acceptable from a risk-benefit perspective. In pharmaceutical development, many
compounds that initially show promise in early-stage testing for treating cancer are later found to cause side effects
that prevent further development of the compound.
Our research and development is focused on the creation of novel epigenetic therapies for patients with cancer
and other diseases, which is a rapidly evolving area of science, and the approach we are taking to discover and
develop drugs is novel and may never lead to marketable products.
The discovery of novel epigenetic therapies for patients with cancer and other serious diseases is an emerging field,
and the scientific discoveries that form the basis for our efforts to discover and develop product candidates are
relatively new. Although epigenetic regulation of gene expression plays an essential role in biological function, few
drugs premised on epigenetics have been discovered. Moreover, those drugs based on an epigenetic mechanism that
have received marketing approval are in different target classes than the CMPs where our research and development
is principally focused. Although preclinical studies suggest that genetic alterations can result in changes to the
activity of CMPs making them oncogenic, to date no company has translated these biological observations into
systematic drug discovery that has yielded a drug that has received marketing approval. We believe that our first
three HMT inhibitors in the clinic are all the first molecules against these targets to enter clinical development.
Therefore, we do not know if our approach of inhibiting HMTs or other CMPs to treat patients with cancer and other
serious diseases will be successful.
We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize
on product candidates or indications that may be more profitable or for which there is a greater likelihood of
success.
Because we have limited financial and managerial resources, we focus on research programs and product candidates
that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other
product candidates or for other indications that later prove to have greater commercial potential. Our resource
allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market
opportunities. Our spending on current and future research and development programs and product candidates for
specific indications may not yield any commercially viable products. If we do not accurately evaluate the
commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that
product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have
been more advantageous for us to retain sole development and commercialization rights to such product candidate.
If we or our collaborators are unable to successfully develop companion diagnostics for our therapeutic product
candidates when needed, or experience significant delays in doing so, we may not achieve marketing approval or
realize the full commercial potential of our therapeutic product candidates.
We may develop, or we may work with collaborators, to develop companion diagnostics for our therapeutic product
candidates to identify patients for our clinical trials who have the specific cancers that we are seeking to treat as
appropriate and when existing, available technology may not be sufficient to identify those patients. We do not have
experience or capabilities in developing or commercializing diagnostics and plan to rely in large part on third parties
to perform these functions. For example, we have entered into an agreement with Roche Molecular to develop and
commercialize a companion diagnostic for use with tazemetostat for NHL patients with EZH2 activating mutations.
Companion diagnostics are subject to regulation by the FDA and similar regulatory authorities outside of the United
States as medical devices and require separate regulatory approval prior to commercialization. If any third parties
that we engage to assist us are unable to successfully develop companion diagnostics that are needed for our
therapeutic product candidates, or experience delays in doing so:
•
•
•
the development of our therapeutic product candidates may be adversely affected if we are unable to
appropriately select patients for enrollment in our clinical trials;
our therapeutic product candidates may not receive marketing approval if their safe and effective use
depends on a companion diagnostic; and
we may not realize the full commercial potential of any therapeutic product candidates that receive
marketing approval if, among other reasons, we are unable to appropriately identify patients with the
specific genetic alterations targeted by our therapeutic product candidates.
If any of these events were to occur, our business would be harmed, possibly materially.
We may not be successful in our efforts to use and expand our proprietary drug discovery platform to build a
pipeline of product candidates.
A key element of our strategy is to use and expand our proprietary drug discovery platform to build a pipeline of
small molecule inhibitors of HMT and other CMP targets and progress these product candidates through clinical
development for the treatment of a variety of different types of cancer and other diseases. Although our research and
development efforts to date have resulted in a pipeline of programs directed to specific HMT and other CMP targets,
we may not be able to develop product candidates that are safe and effective CMP inhibitors. Even if we are
successful in continuing to build our pipeline, the potential product candidates that we identify may not be suitable
for clinical development, including as a result of being shown to have harmful side effects or other characteristics
that indicate that they are unlikely to be products that will receive marketing approval and achieve market
acceptance. If we do not successfully develop and commercialize product candidates based upon our technological
approach, we will not be able to obtain product revenues in future periods, which likely would result in significant
harm to our financial position and adversely affect our stock price.
Risks Related to Our Financial Position and Need For Additional Capital
We have incurred significant losses since our inception. We expect to incur losses over the next several years and
may never achieve or maintain profitability.
Since inception, we have incurred significant operating losses. Our net loss was $134.3 million for the year ended
December 31, 2017, $110.2 million for the year ended December 31, 2016, and $132.4 million for the year ended
December 31, 2015. As of December 31, 2017, we had an accumulated deficit of $488.1 million. To date, we have
financed our operations primarily through our collaborations, our public offerings, and private placements of our
preferred stock. All of our revenue to date has been collaboration revenue. We have devoted substantially all of our
financial resources and efforts to research and development, including clinical and preclinical studies. We are still in
the early to middle stages of development of our product candidates, and we have not completed development of any
product candidates. We expect to continue to incur significant expenses and operating losses over the next several
years. Our net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our
expenses will continue to increase over the next several years as we:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
continue our Phase 2 clinical trial of tazemetostat for the treatment of patients with NHL;
continue our Phase 2 clinical trial of tazemetostat for the treatment of adult patients with certain
molecularly defined solid tumors;
continue our Phase 1 clinical trial of tazemetostat for the treatment of pediatric patients with certain
molecularly-defined solid tumors;
continue our Phase 2 clinical trial of tazemetostat in relapsed or refractory patients with mesothelioma
characterized by BAP1 loss-of-function;
continue our clinical trials of tazemetostat in combination with R-CHOP in first line elderly patients
with DLBCL and in combination with Genentech Inc.’s anti-PD-L1 cancer immunotherapy,
atezolizumab, in patients with relapsed or refractory DLBCL being conducted by our collaborators;
continue our clinical trial of tazemetostat in combination with Genentech’s anti-PD-L1 cancer
immunotherapy, atezolizumab, in patients with relapsed or refractory NSCLC being conducted by our
collaborator, Genentech;
design and conduct a new combination trial of tazemetostat in FL;
pay any milestone payments provided for and achieved under the amended and restated collaboration
and license agreement with Eisai;
complete IND-enabling studies for EZM8266, a G9a inhibitor designed to treat patients with sickle cell
disease, and prepare for a Phase 1 study;
conduct research and development for Celgene under our amended and restated collaboration and
license agreement;
continue the research and development of our other product candidates;
seek to discover and develop additional product candidates;
seek regulatory approvals for any product candidates that successfully complete clinical trials;
ultimately establish a sales, marketing and distribution infrastructure and scale up external
manufacturing capabilities to commercialize any products for which we may obtain regulatory approval;
maintain, expand and protect our intellectual property portfolio;
hire additional clinical, quality control and scientific personnel; and
add operational, financial and management information systems and personnel, including personnel to
support our product development and planned future commercialization efforts.
To become and remain profitable, we must succeed in developing, and eventually commercializing, a product or
products that generate significant revenue. The ability to achieve this success will require us to be effective in a
range of challenging activities, including completing preclinical testing and clinical trials of our product candidates,
discovering additional product candidates, obtaining regulatory approval for these product candidates and
manufacturing, marketing and selling any products for which we may obtain regulatory approval. We are only in the
preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may
never generate revenues that are significant enough to achieve profitability. Because of the numerous risks and
uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or
amount of increased expenses or when, or if, we will be able to achieve profitability. If we are required by the FDA,
the European Medicines Agency, or EMA, or other regulatory authorities to perform studies in addition to those
currently expected, or if there are any delays in completing our clinical trials or the development of any of our
product candidates, our expenses could increase.
Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual
basis. Our failure to become and remain profitable would depress the value of our company and could impair our
ability to raise capital, expand our business, maintain our research and development efforts, diversify our product
offerings or even continue our operations. A decline in the value of our company could cause our stockholders to
lose all or part of their investment in our company.
We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to
delay, reduce or eliminate our product development programs or commercialization efforts.
We expect our expenses to increase in connection with our ongoing activities, particularly to fund our tazemetostat
development program; make any milestone payments provided for and achieved under the amended and restated
collaboration and license agreement with Eisai; continue research for Celgene under our amended and restated
collaboration and license agreement; and continue research and development and initiate clinical trials of, and seek
regulatory approval for, any future product candidates. In addition, if we obtain regulatory approval for any of our
product candidates, we expect to incur significant commercialization expenses related to product manufacturing,
marketing, sales and distribution. Accordingly, we will need to obtain substantial additional funding in connection
with our continuing operations. If we are unable to raise capital when needed or on acceptable terms, we could be
forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.
Based on our research and development plans and our timing expectations related to the progress of our programs,
we expect that our existing cash, cash equivalents and marketable securities as of December 31, 2017, will be
sufficient to fund our planned operating expenses and capital expenditure requirements into the third quarter of
2019. We have based these expectations on assumptions that may prove to be wrong, and we could use our capital
resources sooner than we expect. Our future capital requirements will depend on many factors, including:
•
•
•
•
•
•
•
•
•
the progress and results of our ongoing and planned clinical trials of tazemetostat;
the number and development requirements of additional indications for tazemetostat and other product
candidates that we may pursue, including the scope, progress, results and costs of discovery research,
preclinical development, laboratory testing and clinical trials for such product candidates;
our ongoing research for Celgene under our amended and restated collaboration and license agreement;
the costs, timing and outcome of regulatory review of our product candidates;
milestones, option exercise fees, license fees, and other collaboration-based revenues, if any;
the costs and timing of future commercialization activities, including product manufacturing, marketing,
sales and distribution for any of our product candidates for which we receive marketing approval;
the revenue, if any, received from commercial sales of our product candidates for which we receive
marketing approval;
the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing
our intellectual property rights and defending any intellectual property-related claims; and
the extent to which we acquire or in-license other products and technologies.
Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming,
expensive and uncertain process that takes years to complete, and we may never generate the necessary data or
results required to obtain regulatory approval and achieve product sales. In addition, our product candidates, if
approved, may not achieve commercial success. Commercial revenues, if any, will not be derived until and unless
we can achieve sales of commercially available products. Accordingly, we will need to continue to rely on
additional financing to achieve our business objectives. Adequate additional financing may not be available to us on
acceptable terms, or at all. In addition, we may seek additional capital due to favorable market conditions or
strategic considerations, even if we believe we have sufficient funds for our current or future operating plans.
Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to
relinquish rights to our technologies or product candidates.
Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs
through a combination of equity offerings, debt financings and license and development agreements with
collaboration partners. To the extent that we raise additional capital through the sale of equity or convertible debt
securities, the ownership interest of our existing stockholders will be diluted and the terms of these securities may
include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing
and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting
our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring
dividends.
If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing
arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue
streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we
are unable to raise additional funds through equity or debt financings when needed, we may be required to delay,
limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and
market product candidates that we would otherwise prefer to develop and market ourselves.
Our limited operating history may make it difficult to evaluate the success of our business to date and to assess
our future viability.
We commenced active operations in early 2008, and our operations to date have been limited to organizing and
staffing our company, business planning, raising capital, developing our technology, identifying potential product
candidates, undertaking preclinical studies and, beginning in 2012, conducting clinical trials. All but three of the
product candidates discovered by us are still in preclinical development. We have not yet demonstrated our ability to
obtain regulatory approvals, manufacture a commercial scale product, or arrange for a third party to do so on our
behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently,
any predictions about our future success or viability may not be as accurate as they could be if we had a longer
operating history.
In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and
unknown factors. We will need to transition at some point from a company with a research and development focus
to a company capable of supporting commercial activities. We may not be successful in such a transition.
We expect our financial condition and operating results to continue to fluctuate significantly from quarter-to-quarter
and year-to-year due to a variety of factors, many of which are beyond our control. Accordingly, the results of any
quarterly or annual periods should not be relied upon as indications of future operating performance.
Risks Related to the Commercialization of Our Product Candidates
We may be unable to obtain, or may be delayed in obtaining, marketing approval for our product candidates.
Based on interactions with the FDA, we have identified a potential path for accelerated approval in epithelioid
sarcoma and we are targeting submission of our first NDA to the FDA for tazemetostat for this indication in the
fourth quarter of 2018. In addition, based on initial engagement with the FDA, we believe we have the opportunity
to submit for accelerated approval for tazemetostat as a monotherapy in FL. We plan to continue engaging with the
FDA in 2018 to further refine our registration strategy for FL and, subject to the results of the FL cohorts in our
ongoing Phase 2 study, are targeting submission of an NDA to the FDA for tazemetostat for FL in 2019. It is
possible that the FDA or any other regulatory authority may refuse to accept our applications for substantive review,
or that the FDA or other regulatory authority may conclude after review of our data that our application is
insufficient to obtain marketing approval of tazemetostat on an accelerated basis or at all. If the FDA does not agree
that we have sufficient data to seek accelerated approval or does not accept or approve one or more of our planned
NDAs for tazemetostat, we may be required to study tazemetostat in additional patients or conduct additional
clinical trials, preclinical studies or manufacturing validation studies and submit that data to regulators before our
application can be resubmitted or will be reconsidered. Depending on the extent of these or any other required trials
or studies, submission of our planned NDAs or acceptance or approval of these NDAs for tazemetostat may be
delayed by several years, or may require us to expend more resources than we have available. It is also possible that
additional trials or studies, if performed and completed, may not be considered sufficient by the FDA to accept or
approve the planned NDAs for tazemetostat. Any delay in obtaining, or an inability to obtain, marketing approvals
would prevent us from commercializing tazemetostat in the United States and/or abroad, generating revenue and
achieving and sustaining profitability. If any of these outcomes occurs, either to tazemetostat or to any future
product candidate for which we may seek marketing approval, we may be forced to abandon our development
efforts for tazemetostat or such future product candidates, which could significantly harm our business.
Even if any of our product candidates receives marketing approval, it may fail to achieve the degree of market
acceptance by physicians, patients, third party payors and others in the medical community necessary for
commercial success.
If any of our product candidates receives marketing approval, it may nonetheless fail to gain sufficient market
acceptance by physicians, patients, third party payors and others in the medical community. If our product
candidates do not achieve an adequate level of acceptance, we may not generate significant product revenues and we
may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial
sale, will depend on a number of factors, including:
•
•
•
•
•
•
•
•
the efficacy and potential advantages compared to alternative treatments;
our ability to offer our products for sale at competitive prices;
the convenience and ease of administration compared to alternative treatments;
the willingness of the patient population to try new therapies and of physicians to prescribe these
therapies;
the strength of marketing and distribution support;
the availability of third party coverage and adequate reimbursement;
the prevalence and severity of any side effects; and
any restrictions on the use of our products together with other medications.
If we are unable to establish sales, marketing and distribution capabilities, we may not be successful in
commercializing our product candidates if and when they are approved.
We do not have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of
pharmaceutical products. To achieve commercial success for any product for which we have obtained marketing
approval, we will need to establish a sales and marketing organization.
We have recently begun building the infrastructure necessary to support the successful commercial launch and
marketing of tazemetostat and other product candidates that may receive marketing approval. There are risks
involved with establishing our own sales, marketing and distribution capabilities. For example, recruiting and
training a sales force is expensive and time consuming and could delay any product launch. If the commercial
launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or
does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization
expenses. These efforts may be costly, and our investment would be lost if we cannot retain or reposition our sales
and marketing personnel.
Factors that may inhibit our efforts to commercialize our products on our own include:
•
•
•
•
our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;
the inability of sales personnel to obtain access to physicians or persuade adequate numbers of
physicians to prescribe any future products;
the lack of complementary products to be offered by sales personnel, which may put us at a competitive
disadvantage relative to companies with more extensive product lines; and
unforeseen costs and expenses associated with creating an independent sales and marketing
organization.
If we are unable to establish our own sales, marketing and distribution capabilities and enter into arrangements with
third parties to perform these services, our product revenues and our profitability, if any, are likely to be lower than
if we were to market, sell and distribute any products that we develop ourselves. In addition, we may not be
successful in entering into arrangements with third parties to sell, market and distribute our product candidates or
may be unable to do so on terms that are acceptable to us. We likely will have little control over such third parties,
and any of them may fail to devote the necessary resources and attention to sell and market our products effectively.
If we do not establish sales, marketing and distribution capabilities successfully, either on our own or in
collaboration with third parties, we will not be successful in commercializing our product candidates.
We face substantial competition, which may result in others discovering, developing or commercializing products
before or more successfully than we do.
The development and commercialization of new drug products is highly competitive. We face competition with
respect to our current product candidates, and will likely face competition with respect to any product candidates
that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty
pharmaceutical companies and biotechnology companies worldwide. There are a number of large pharmaceutical
and biotechnology companies that currently market and sell products or are pursuing the development of products
for the treatment of many of the disease indications for which we are developing our product candidates. Some of
these competitive products and therapies are based on scientific approaches that are the same as or similar to our
approach, and others are based on entirely different approaches. Potential competitors also include academic
institutions, government agencies and other public and private research organizations that conduct research, seek
patent protection and establish collaborative arrangements for research, development, manufacturing and
commercialization.
Specifically, there are a large number of companies developing or marketing treatments for cancer, including many
major pharmaceutical and biotechnology companies. Companies that are developing new epigenetic treatments for
cancer that target HMTs include GSK, Johnson & Johnson, Novartis AG, Pfizer, Inc., Merck & Co., Inc., Daiichi
Sankyo Company Limited, Takeda Pharmaceutical Company Limited, AbbVie Inc., AstraZeneca Plc, Bayer
Schering Pharma AG and Constellation Pharmaceuticals. Specifically, companies which are known to have EZH2
inhibitor programs or related programs include: Constellation Pharmaceuticals, developing an EZH2 inhibitor (CPI-
1205, Phase 1/2 castration-resistant prostate cancer), Novartis AG, developing an EED inhibitor which indirectly
blocks EZH2 (MAK683, Phase 1/2, advanced malignancies), Daiichi Sankyo, developing a EZH1/EZH2 dual
inhibitor (DS-3201, Phase 1, relapsed or refractory non-Hodgkin lymphomas), and Pfizer, which declared a
development candidate (PF-06821497) in April 2017. In July 2017, GSK discontinued their EZH2 inhibitor
program, GSK2816126, which had been in Phase 1 development in solid tumors and hematological malignancies. In
addition, many companies are developing cancer therapeutics that work by targeting epigenetic mechanisms other
than HMTs, and some including Celgene, Merck & Co., Inc., Novartis AG, Spectrum Pharmaceuticals, and Eisai,
are now marketing cancer treatments that work by targeting epigenetic mechanisms other than HMTs.
Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products
that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than
any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their
products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a
strong market position before we are able to enter the market. In addition, our ability to compete may be affected in
many cases by insurers or other third party payors seeking to encourage the use of generic products. Generic
products are currently on the market for many of the indications that we are pursuing, and additional products are
expected to become available on a generic basis over the coming years. If our product candidates achieve marketing
approval, we expect that they will be priced at a significant premium over competitive generic products.
Many of the companies against which we are competing or against which we may compete in the future have
significantly greater financial resources and expertise in research and development, manufacturing, preclinical
testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do.
Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources
being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also
prove to be significant competitors, particularly through collaborative arrangements with large and established
companies. These third parties compete with us in recruiting and retaining qualified scientific and management
personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring
technologies complementary to, or necessary for, our programs.
Even if we are able to commercialize any product candidates, the products may become subject to unfavorable
pricing regulations, third party reimbursement practices or healthcare reform initiatives, which could harm our
business.
The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary
widely from country to country. Current and future legislation may significantly change the approval requirements
in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval
of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after
marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing
remains subject to continuing governmental control even after initial approval is granted. As a result, we might
obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay
our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are
able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to
recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval.
Our ability to commercialize any product candidates successfully also will depend in part on the extent to which
coverage and adequate reimbursement for these products and related treatments will be available from government
health administration authorities, private health insurers and other organizations. Government authorities and third
party payors, such as private health insurers and health maintenance organizations, decide which medications they
will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is
cost containment. Government authorities and third party payors have attempted to control costs by limiting
coverage and the amount of reimbursement for particular medications. Increasingly, third party payors are requiring
that drug companies provide them with predetermined discounts from list prices and are challenging the prices
charged for medical products. Coverage and reimbursement may not be available for any product that we
commercialize and, even if these are available, the level of reimbursement may not be satisfactory. Reimbursement
may affect the demand for, or the price of, any product candidate for which we obtain marketing approval.
Obtaining and maintaining adequate reimbursement for our products may be difficult. We may be required to
conduct expensive pharmacoeconomic studies to justify coverage and reimbursement or the level of reimbursement
relative to other therapies. If coverage and adequate reimbursement are not available or reimbursement is available
only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain
marketing approval.
There may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more
limited than the purposes for which the drug is approved by the FDA or similar regulatory authorities outside of the
United States. Moreover, eligibility for reimbursement does not imply that a drug will be paid for in all cases or at a
rate that covers our costs, including research, development, manufacture, sale and distribution. Interim
reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be
made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it
is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into
existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates
required by government healthcare programs or private payors and by any future relaxation of laws that presently
restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third party
payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement
policies. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded
and private payors for any approved products that we develop could have a material adverse effect on our operating
results, our ability to raise capital needed to commercialize products and our overall financial condition.
Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization
of any products that we may develop.
We face an inherent risk of product liability exposure related to the testing of our product candidates in human
clinical trials and will face an even greater risk if we commercially sell any products that we may develop. If we
cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will
incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:
•
•
•
•
•
•
•
•
decreased demand for any product candidates or products that we may develop;
injury to our reputation and significant negative media attention;
withdrawal of clinical trial participants;
significant costs to defend any related litigation;
substantial monetary awards to trial participants or patients;
loss of revenue;
reduced resources of our management to pursue our business strategy; and
the inability to commercialize any products that we may develop.
We currently hold $20.0 million in product liability insurance coverage in the aggregate, with a per incident limit of
$20.0 million, which may not be adequate to cover all liabilities that we may incur. We may need to increase our
insurance coverage as we expand our clinical trials or if we commence commercialization of our product candidates.
Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable
cost or in an amount adequate to satisfy any liability that may arise.
Risks Related to Our Dependence on Third Parties
Our existing therapeutic collaborations are important to our business, and future collaborations may also be
important to us. If we are unable to maintain any of these collaborations, or if these collaborations are not
successful, our business could be adversely affected.
Our resources for drug development are limited and we do not yet have any capability for sales, marketing or
distribution. Accordingly, we have entered into therapeutic collaborations with other companies that we believe can
provide such capabilities, including our collaboration and license agreements with Celgene and GSK. We also rely
on Genentech to manage our combination trial of tazemetostat and atezolizumab in relapsed or refractory DLBCL
and relapsed or refractory non-small cell lung cancer, and on the Lymphoma Study Association to manage our
combination study of tazemetostat and R-CHOP in newly diagnosed, elderly, high risk patients with DLBCL. With
our reacquisition of tazemetostat rights under our amended and restated collaboration and license agreement with
Eisai, we don’t have access to Eisai’s capabilities for tazemetostat except with Eisai in Japan. Our collaborations
have provided us with important funding for our development programs and product platform and we expect to
receive additional funding under these collaborations in the future. Our existing therapeutic collaborations, and any
future collaborations we enter into, may pose a number of risks, including the following:
•
•
•
•
•
•
•
•
•
•
•
•
collaborators have significant discretion in determining the efforts and resources that they will apply to
these collaborations;
collaborators may not have the ability or the development capabilities to perform their obligations as
expected;
collaborators may not pursue commercialization of any product candidates that achieve regulatory
approval or may elect not to continue or renew development or commercialization programs based on
clinical trial results, changes in the collaborators’ strategic focus or available funding, or external
factors, such as an acquisition, that may divert resources or create competing priorities;
collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a
clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new
formulation of a product candidate for clinical testing;
collaborators could independently develop, or develop with third parties, products that compete directly
or indirectly with our products and product candidates if the collaborators believe that the competitive
products are more likely to be successfully developed or can be commercialized under terms that are
more economically attractive than ours;
product candidates discovered in collaboration with us may be viewed by our collaborators as
competitive with their own product candidates or products, which may cause collaborators to cease to
devote resources to the commercialization of our product candidates;
a collaborator may fail to comply with applicable regulatory requirements regarding the development,
manufacture, distribution or marketing of a product candidate or product;
a collaborator with marketing and distribution rights to one or more of our product candidates that
achieve regulatory approval may not commit sufficient resources to the marketing and distribution of
such product or products;
disagreements with collaborators, including disagreements over proprietary rights, contract
interpretation or the preferred course of development, might cause delays or terminations of the
research, development or commercialization of product candidates, might lead to additional
responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any
of which would be time-consuming and expensive;
collaborators may not properly maintain or defend our intellectual property rights or may use our
proprietary information in such a way as to invite litigation that could jeopardize or invalidate our
intellectual property or proprietary information or expose us to potential litigation;
collaborators may infringe the intellectual property rights of third parties, which may expose us to
litigation and potential liability; and
collaborations may be terminated for the convenience of the collaborator, and, if terminated, we could
be required to raise additional capital to pursue further development or commercialization of the
applicable product candidates.
If our therapeutic collaborations do not result in the successful development and commercialization of products or if
one of our collaborators terminates its agreement with us, we may not receive any future research funding or
milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these
agreements, our development of our product platform and product candidates could be delayed and we may need
additional resources to develop product candidates and our product platform. All of the risks relating to product
development, regulatory approval and commercialization described in this Annual Report on Form 10-K also apply
to the activities of our therapeutic collaborators.
Our existing therapeutic collaborations contain restrictions on our engaging in activities that are the subject of the
collaboration with third parties for specified periods of time. For example, under our collaboration agreement with
Celgene, subject to specified exceptions, we may not, during the option period, research, develop or commercialize
inhibitors directed to DOT1L and the three option targets covered by the agreement outside of the collaboration.
These restrictions may have the effect of preventing us from undertaking development and other efforts that may
appear to be attractive to us.
Additionally, subject to its contractual obligations to us, if a collaborator of ours is involved in a business
combination, the collaborator might deemphasize or terminate the development or commercialization of any product
candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more
difficult to attract new collaborators and our perception in the business and financial communities could be
adversely affected.
For some of our product candidates or for some CMP targets, we may in the future collaborate with pharmaceutical
and biotechnology companies for development and potential commercialization of therapeutic products. We face
significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for a
collaboration will depend, among other things, upon our assessment of the collaborator’s resources and expertise,
the terms and conditions of the proposed collaboration and the proposed collaborator’s evaluation of a number of
factors. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at
all, we may have to curtail the development of a product candidate, reduce or delay its development program or one
or more of our other development programs, delay its potential commercialization or reduce the scope of any sales
or marketing activities, or increase our expenditures and undertake development or commercialization activities at
our own expense. If we elect to fund and undertake development or commercialization activities on our own, we
may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms
or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the
necessary development and commercialization activities, we may not be able to further develop our product
candidates or bring them to market or continue to develop our product platform and our business may be materially
and adversely affected.
Failure of our third party collaborators to successfully commercialize companion diagnostics, developed for use
with our therapeutic product candidates, if and when needed, could harm our ability to commercialize these
product candidates.
We do not plan to develop companion diagnostics internally and, as a result, we are dependent on the efforts of our
third party collaborators to successfully commercialize companion diagnostics when existing, available technology
may not be sufficient to identify patients for treatment with our therapeutic product candidates. For example, we
may rely on Roche Molecular to develop a companion diagnostic for detecting activating mutations in EZH2 in the
tazemetostat in NHL program. Our collaborators:
•
•
•
•
•
•
•
•
may not perform their obligations as expected or have difficulty responding to accelerated approval time
lines alongside the therapeutic product development;
may encounter production difficulties that could constrain the supply of the diagnostics;
may encounter delays or have difficulty obtaining regulatory approval for the diagnostic in target
markets;
may have difficulties gaining acceptance of the use of the diagnostics in the clinical community;
may not pursue commercialization of any diagnostics that achieve regulatory approval;
may elect not to continue or renew commercialization programs based on changes in the collaborators’
strategic focus or available funding, or external factors such as an acquisition, that divert resources or
create competing priorities;
may not commit sufficient resources to the marketing and distribution of such product or products; and
may terminate their relationship with us.
If complementary or companion diagnostics for use with our therapeutic product candidates fail to gain market
acceptance, our ability to derive revenues from sales of our therapeutic product candidates could be harmed. If our
collaborators fail to commercialize these companion diagnostics, we may not be able to enter into arrangements with
another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with our
therapeutic product candidates or do so on commercially reasonable terms, which could adversely affect and delay
the development or commercialization of our therapeutic product candidates.
We rely, and expect to continue to rely, on third parties to conduct our clinical trials, and those third parties may
not perform satisfactorily, including failing to meet deadlines for the completion of such trials.
We currently rely on third party clinical research organizations to conduct our ongoing clinical trials and plan to rely
on third party clinical research organizations or third party research collaborative groups to conduct our planned
clinical trials. We do not plan to independently conduct clinical trials of any future product candidates. We expect to
continue to rely on third parties, such as clinical research organizations, research collaborative groups, clinical data
management organizations, medical institutions and clinical investigators, to conduct our clinical trials. These
agreements might terminate for a variety of reasons, including a failure to perform by the third parties. If we need to
enter into alternative arrangements, our product development activities might be delayed.
Our reliance on these third parties for research and development activities will reduce our control over these
activities but will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that
each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial.
Moreover, the FDA requires us to comply with standards, commonly referred to as good clinical practices, or GCPs,
for conducting, recording and reporting the results of clinical trials to assure that data and reported results are
credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. We also are
required to register ongoing clinical trials and post the results of completed clinical trials on a government-
sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in fines, adverse
publicity and civil and criminal sanctions.
Furthermore, these third parties may also have relationships with other entities, some of which may be our
competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or
conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to
obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or
may be delayed in our efforts to, successfully commercialize our product candidates.
We also expect to rely on other third parties to store and distribute drug supplies for our clinical trials. Any
performance failure on the part of our distributors could delay clinical development or marketing approval of our
product candidates or commercialization of our products, producing additional losses and depriving us of potential
product revenue.
We contract with third parties for the manufacture of our product candidates for preclinical and clinical testing
and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we
will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost
or quality, which could delay, prevent or impair our development or commercialization efforts.
We do not have any manufacturing facilities and rely, and expect to continue to rely, on third parties for the
manufacture of our product candidates for preclinical and clinical testing, as well as for commercial manufacture if
any of our product candidates receive marketing approval. This reliance on third parties increases the risk that we
will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or
quality, which could delay, prevent or impair our development or commercialization efforts.
We also expect to rely on third party manufacturers or third party collaborators for the manufacture of commercial
supply of any other product candidates for which our collaborators or we obtain marketing approval. We may be
unable to establish any agreements with third party manufacturers or to do so on acceptable terms. Even if we are
able to establish agreements with third party manufacturers, reliance on third party manufacturers entails additional
risks, including:
•
•
reliance on the third party for regulatory compliance and quality assurance;
the possible breach of the manufacturing agreement by the third party;
•
•
the possible misappropriation of our proprietary information, including our trade secrets and know-how;
and
the possible termination or nonrenewal of the agreement by the third party at a time that is costly or
inconvenient for us.
Third party manufacturers may not be able to comply with current good manufacturing practices, or cGMP,
regulations or similar regulatory requirements outside of the United States. Our failure, or the failure of our
third party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us,
including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license
revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions,
any of which could significantly and adversely affect supplies of our products.
Our product candidates and any products that we may develop may compete with other product candidates and
products for access to manufacturing facilities. There are a limited number of manufacturers that operate under
cGMP regulations and that might be capable of manufacturing for us.
Any performance failure on the part of our existing or future manufacturers could delay clinical development or
marketing approval. We do not currently have arrangements in place for redundant supply or a second source for
bulk drug substance. If our current contract manufacturers cannot perform as agreed, we may be required to replace
such manufacturers. Although we believe that there are several potential alternative manufacturers who could
manufacture our product candidates, we may incur added costs and delays in identifying and qualifying any such
replacement.
Our current and anticipated future dependence upon others for the manufacture of our product candidates or
products may adversely affect our future profit margins and our ability to commercialize any products that receive
marketing approval on a timely and competitive basis.
Risks Related to Our Intellectual Property
If we are unable to obtain and maintain patent protection for our technology and products or if the scope of the
patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology
and products similar or identical to ours, and our ability to successfully commercialize our technology and
products may be impaired.
Our success depends in large part on our ability to obtain and maintain patent protection in the United States and
other countries with respect to our proprietary technology and products. We seek to protect our proprietary position
by filing patent applications in the United States and abroad related to our novel technologies and product
candidates.
The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all
necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will
fail to identify patentable aspects of our research and development output before it is too late to obtain patent
protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and
prosecution of patent applications, or to maintain the patents, covering technology that we license from third parties.
Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best
interests of our business.
The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex
legal and factual questions and has in recent years been the subject of much litigation. In addition, the laws of
foreign countries may not protect our rights to the same extent as the laws of the United States. For example,
European patent law restricts the patentability of methods of treatment of the human body more than United States
law does. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent
applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in
some cases at all. Therefore, we cannot know with certainty whether we were the first to make the inventions
claimed in our owned or licensed patents or pending patent applications, or that we were the first to file for patent
protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our
patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued
which protect our technology or products, in whole or in part, or which effectively prevent others from
commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the
patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our
patent protection.
In the United States, the patent term of a patent that covers an FDA-approved drug may also be eligible for patent
term extension, which permits patent term restoration as compensation for the patent term lost during the FDA
regulatory review process. The Hatch-Waxman Act permits a patent term extension of up to five years beyond the
expiration of the patent. The length of the patent term extension is related to the length of time the drug is under
regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the
date of product approval and only one patent applicable to an approved drug may be extended. Similar provisions
are available in Europe and other non-United States jurisdictions to extend the term of a patent that covers an
approved drug. In the future, if and when our product candidates receive FDA approval, we expect to apply for
patent term extensions on patents covering those product candidates. We intend to seek patent term extensions for
any of our issued patents in any jurisdiction where they are available, however there is no guarantee that the
applicable authorities will agree with our assessment of whether such extensions should be granted, and even if
granted, the length of such extensions.
Patent reform legislation such as the Leahy-Smith America Invents Act, or the Leahy-Smith Act, could increase the
uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our
issued patents. The Leahy-Smith Act includes a number of significant changes to United States patent law. These
changes include provisions that affect the way patent applications are prosecuted, redefine prior art, provide more
efficient and cost-effective avenues for competitors to challenge the validity of patents, and enable third-party
submission of prior art to the U.S. Patent and Trademark Office during patent prosecution and additional procedures
to attack the validity of a patent at U.S. Patent and Trademark Office administered post-grant proceedings, including
post-grant review, inter partes review, and derivation proceedings. In addition, under the Leahy-Smith Act, the
United States transitioned to a first inventor to file system in which, assuming that the other statutory requirements
are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of
whether a third party was the first to invent the claimed invention. As such, the Leahy-Smith Act and its
implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and
the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business
and financial condition.
Moreover, we may be subject to a third party preissuance submission of prior art to the U.S. Patent and Trademark
Office, or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or
interference proceedings challenging our patent rights or the patent rights of others. For example, we are involved in
an opposition proceeding against one of our European patents, the claims of which cover a method for determining
whether a cancer patient is a candidate for treatment with an EZH2 inhibitor based on their EZH2 mutation status.
An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate,
our patent rights, allow third parties to commercialize our technology or products and compete directly with us,
without payment to us, or result in our inability to manufacture or commercialize products without infringing third
party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent
applications is threatened, it could dissuade companies from collaborating with us to license, develop or
commercialize current or future product candidates.
Even if our owned and licensed patent applications issue as patents, they may not issue in a form that will provide us
with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any
competitive advantage.
Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative
technologies or products in a non-infringing manner.
The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and
licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges
may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held
unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing
similar or identical technology and products, or limit the duration of the patent protection of our technology and
products. Given the amount of time required for the development, testing and regulatory review of new product
candidates, patents protecting such candidates might expire before or shortly after such candidates are
commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to
exclude others from commercializing products similar or identical to ours.
We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could
be expensive, time consuming and unsuccessful.
Competitors may infringe our issued patents or other intellectual property. To counter infringement or unauthorized
use, we may be required to file infringement claims, which can be expensive and time consuming. Any claims we
assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we
infringe their patents. In addition, in a patent infringement proceeding, a court may decide that a patent of ours is
invalid or unenforceable, in whole or in part, construe the patent’s claims narrowly or refuse to stop the other party
from using the technology at issue on the grounds that our patents do not cover the technology in question. An
adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or
interpreted narrowly.
We may need to license certain intellectual property from third parties, and such licenses may not be available or
may not be available on commercially reasonable terms.
A third party may hold intellectual property, including patent rights, that are important or necessary to the
development of our products. It may be necessary for us to use the patented or proprietary technology of third
parties to commercialize our products, in which case we may be required to obtain a license from these third parties
on commercially reasonable terms, or our business could be harmed, possibly materially.
Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the
outcome of which would be uncertain and could have a material adverse effect on the success of our business.
Our commercial success depends upon our ability, and the ability of our collaborators, to develop, manufacture,
market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights
of third parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical
industries. We may become party to, or threatened with, future adversarial proceedings or litigation regarding
intellectual property rights with respect to our products and technology, including interference or derivation
proceedings before the U.S. Patent and Trademark Office. Third parties may assert infringement claims against us
based on existing patents or patents that may be granted in the future.
If we are found to infringe a third party’s intellectual property rights, we could be required to obtain a license from
such third party to continue developing and marketing our products and technology. However, we may not be able
to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it
could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be
forced, including by court order, to cease commercializing the infringing technology or product. In addition, we
could be found liable for monetary damages, including treble damages and attorneys’ fees if we are found to have
willfully infringed a patent. A finding of infringement could prevent us from commercializing our product
candidates or force us to cease some of our business operations, which could materially harm our business. Claims
that we have misappropriated the confidential information or trade secrets of third parties could have a similar
negative impact on our business.
If we fail to comply with our obligations in our intellectual property licenses and funding arrangements with
third parties, we could lose rights that are important to our business.
We are party to license and research agreements that impose, and we may enter into additional licensing and funding
arrangements with third parties that may impose, diligence, development and commercialization timelines,
milestone payment, royalty, insurance and other obligations on us. Under our existing licensing and funding
agreements, we are obligated to pay royalties on net product sales of product candidates or related technologies to
the extent they are covered by the agreements. We also had diligence and development obligations under those
agreements that we have satisfied. If we fail to comply with our obligations under current or future license and
funding agreements, our counterparties may have the right to terminate these agreements, in which event we might
not be able to develop, manufacture or market any product that is covered by these agreements or may face other
penalties under the agreements. Such an occurrence could materially adversely affect the value of the product
candidate being developed under any such agreement. Termination of these agreements or reduction or elimination
of our rights under these agreements may result in our having to negotiate new or reinstated agreements with less
favorable terms, or cause us to lose our rights under these agreements, including our rights to important intellectual
property or technology.
We may be subject to claims by third parties asserting that our employees or we have misappropriated their
intellectual property, or claiming ownership of what we regard as our own intellectual property.
Many of our employees were previously employed at universities or other biotechnology or pharmaceutical
companies, including our competitors or potential competitors. Although we try to ensure that our employees do not
use the proprietary information or know-how of others in their work for us, we may be subject to claims that these
employees or we have used or disclosed intellectual property, including trade secrets or other proprietary
information, of any such employee’s former employer. Litigation may be necessary to defend against these claims.
In addition, while it is our policy to require our employees and contractors who may be involved in the development
of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in
executing such an agreement with each party who in fact develops intellectual property that we regard as our own.
Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring
claims against third parties, or defend claims they may bring against us, to determine the ownership of what we
regard as our intellectual property.
If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose
valuable intellectual property rights or personnel. Even if we are successful in prosecuting or defending against such
claims, litigation could result in substantial costs and be a distraction to management.
Intellectual property litigation could cause us to spend substantial resources and distract our personnel from
their normal responsibilities.
Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause
us to incur significant expenses, and could distract our technical and management personnel from their normal
responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim
proceedings or developments and if securities analysts or investors perceive these results to be negative, it could
have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could
substantially increase our operating losses and reduce the resources available for development activities or any
future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct
such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation
or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting
from the initiation and continuation of patent litigation or other proceedings could compromise our ability to
compete in the marketplace.
If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be
harmed.
In addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets,
including unpatented know-how, technology and other proprietary information, to maintain our competitive
position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality
agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific
collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality
and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of
these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and
we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed
or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In
addition, some courts inside and outside of the United States are less willing or unwilling to protect trade secrets. If
any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no
right to prevent them, or those to whom they communicate it, from using that technology or information to compete
with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our
competitive position would be harmed.
Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters
Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is
expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the
commercialization of some or all of our product candidates. If we are not able to obtain, or if there are delays in
obtaining, required regulatory approvals, we will not be able to commercialize our product candidates, and our
ability to generate revenue will be materially impaired.
Our product candidates and the activities associated with their development and commercialization, including their
design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion,
sale and distribution, export and import are subject to comprehensive regulation by the FDA and other regulatory
agencies in the United States and by the EMA and similar regulatory authorities outside of the United States. We
have not submitted an application for or received marketing approval for any of our product candidates in the United
States or in any other jurisdiction.
However, we plan to submit an NDA to the FDA for tazemetostat for the treatment of epithelioid sarcoma in the
fourth quarter of 2018 and to submit an NDA to the FDA for tazemetostat for the treatment of FL in 2019. Failure
to obtain marketing approval for tazemeotstat or any other product candidate will prevent us from commercializing
the product candidate. We have only limited experience in filing and supporting the applications necessary to gain
marketing approvals and expect to rely on third party clinical research organizations to assist us in this process.
Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting
information to regulatory authorities for each therapeutic indication to establish the product candidate’s safety and
efficacy. Securing marketing approval also requires the submission of information about the product manufacturing
process to, and inspection of manufacturing facilities by, the regulatory authorities. Our product candidates may not
be effective, may be only moderately effective or may prove to have undesirable or unintended side effects,
toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial
use. New cancer drugs frequently are indicated only for patient populations that have not responded to an existing
therapy or have relapsed.
The process of obtaining marketing approvals, both in the United States and abroad, is expensive, may take many
years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a
variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in
marketing approval policies during the development period, changes in or the enactment of additional statutes or
regulations, or changes in regulatory review for each submitted product application, may cause delays in the
approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and
may refuse to accept any application or may decide that our data is insufficient for approval and require additional
preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and
clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we
ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved
product not commercially viable.
If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the
commercial prospects for our product candidates may be harmed and our ability to generate revenues will be
materially impaired.
We may not be able to obtain orphan drug exclusivity for our product candidates and, even if we do, that
exclusivity may not prevent the FDA or the EMA from approving other competing products.
Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for
relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product
as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient
population of fewer than 200,000 individuals annually in the United States. We have obtained orphan drug
designations for tazemetostat for the treatment of patients with FL, MRT, soft tissue sarcoma and mesothelioma.
The orphan drug designation for the treatment of MRT applies to INI1-negative MRT as well as SMARCA4-
negative malignant rhabdoid tumor of ovary. We have also obtained orphan drug designations for pinometostat for
the treatment of acute lymphoblastic leukemia and acute myeloid leukemia in the United States and Europe. We
may not receive orphan drug designation for these product candidates for other indications, or for any other future
clinical candidates we may develop.
Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the
indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which
precludes the EMA or the FDA from approving another marketing application for the same drug for the same
indication for that time period. The applicable period is seven years in the United States and ten years in Europe.
The exclusivity period in Europe can be reduced to six years if a drug no longer meets the criteria for orphan drug
designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug
exclusivity may be lost if the FDA or EMA determines that the request for designation was materially defective or if
the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease
or condition.
Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product
from competition because different drugs can be approved for the same condition. In addition, even after an orphan
drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes
that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution
to patient care.
On August 3, 2017, the Congress passed the FDA Reauthorization Act of 2017 (FDARA). FDARA, among other
things, codified the FDA’s pre-existing regulatory interpretation, to require that a drug sponsor demonstrate the
clinical superiority of an orphan drug that is otherwise the same as a previously approved drug for the same rare
disease in order to receive orphan drug exclusivity. The new legislation reverses prior precedent holding that the
Orphan Drug Act unambiguously requires that the FDA recognize the orphan exclusivity period regardless of a
showing of clinical superiority. The FDA may further reevaluate the Orphan Drug Act and its regulations and
policies. We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the
future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may
make to its orphan drug regulations and policies, our business could be adversely impacted.
A Fast Track designation by the FDA, such as the Fast Track designation we received for tazemetostat, may not
lead to a faster development or regulatory review or approval process.
We have announced that we have received Fast Track designation from the FDA for tazemetostat for patients with
relapsed or refractory FL, with or without activating EZH2 mutations, and relapsed or refractory DLBCL with
EZH2 activating mutations. We intend to seek Fast Track designation for tazemetostat for other indications and for
our other product candidates as appropriate. If a drug is intended for the treatment of a serious or life-threatening
condition and the drug demonstrates the potential to address unmet medical needs for this condition, the drug
sponsor may apply for FDA Fast Track designation. Drugs that have received Fast Track designation from the FDA
are eligible for expedited development and priority review, and the opportunity for a rolling review, under certain
circumstances. The FDA has broad discretion whether or not to grant this designation, so even if we believe a
particular product candidate is eligible for this designation, we cannot assure that the FDA would decide to grant it.
Even if we do receive Fast Track designation, as we have for tazemetostat, we may not experience a faster
development process, review or approval compared to conventional FDA procedures. We or the FDA may withdraw
Fast Track designation if it believes that the designation is no longer supported by data from our clinical
development program.
A breakthrough therapy designation by the FDA for our product candidates may not lead to a faster development
or regulatory review or approval process, and it does not increase the likelihood that our product candidates will
receive marketing approval.
A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs,
to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug
may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints,
such as substantial treatment effects observed early in clinical development. For drugs and biologics that have been
designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial
can help to identify the most efficient path for clinical development while minimizing the number of patients placed
in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA are also eligible for
accelerated approval.
Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of
our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and
instead determine not to make such designation. Even if we receive breakthrough therapy designation, the receipt of
such designation for a product candidate may not result in a faster development process, review or approval
compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate
approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies,
the FDA may later decide that the products no longer meet the conditions for qualification or decide that the time
period for FDA review or approval will not be shortened.
Failure to obtain marketing approval in foreign jurisdictions would prevent our product candidates from being
marketed in that jurisdiction.
In order to market and sell our products in the European Union and many other foreign jurisdictions, we or our third
party collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory
requirements. The approval procedure varies among countries and can involve additional testing. The time required
to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval
process outside of the United States generally includes all of the risks associated with obtaining FDA approval. In
addition, in many countries outside of the United States, a product must be approved for reimbursement before the
product can be approved for sale in that country. We or our third party collaborators may not obtain approvals from
regulatory authorities outside of the United States on a timely basis, if at all. Approval by the FDA does not ensure
approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority
outside of the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or
by the FDA. We may not be able to file for marketing approvals and may not receive necessary approvals to
commercialize our products in any market.
Additionally, on June 23, 2016, the electorate in the United Kingdom voted in favor of leaving the European Union,
commonly referred to as Brexit. On March 29, 2017, the country formally notified the European Union of its
intention to withdraw pursuant to Article 50 of the Lisbon Treaty. Since a significant proportion of the regulatory
framework in the United Kingdom is derived from European Union directives and regulations, the referendum could
materially impact the regulatory regime with respect to the approval of our product candidates in the United
Kingdom or the European Union. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a
result of Brexit or otherwise, would prevent us from commercializing our product candidates in the United Kingdom
and/or the European Union and restrict our ability to generate revenue and achieve and sustain profitability. If any of
these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United
Kingdom and/or European Union for our product candidates, which could significantly and materially harm our
business.
If we are required by the FDA to obtain approval of a companion diagnostic in connection with approval of a
candidate therapeutic product, and we do not obtain or there are delays in obtaining FDA approval of a
diagnostic device, we will not be able to commercialize the product candidate and our ability to generate revenue
will be materially impaired.
According to FDA guidance, if the FDA determines that a companion diagnostic device is essential to the safe and
effective use of a novel therapeutic product or indication, the FDA generally will not approve the therapeutic
product or new therapeutic product indication if the companion diagnostic is not also approved or cleared for that
indication. Under the Federal Food, Drug, and Cosmetic Act, companion diagnostics are regulated as medical
devices, and the FDA has generally required companion diagnostics intended to select the patients who will respond
to cancer treatment to obtain Premarket Approval, or a PMA, for the diagnostic. The PMA process, including the
gathering of clinical and preclinical data and the submission to and review by the FDA, involves a rigorous
premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the
device’s safety and effectiveness and information about the device and its components regarding, among other
things, device design, manufacturing and labeling. A PMA is not guaranteed and may take considerable time, and
the FDA may ultimately respond to a PMA submission with a “not approvable” determination based on deficiencies
in the application and require additional clinical trial or other data that may be expensive and time-consuming to
generate and that can substantially delay approval. As a result, if we are required by the FDA to obtain approval of a
companion diagnostic for a candidate therapeutic product, and we do not obtain or there are delays in obtaining FDA
approval of a diagnostic device, we may not be able to commercialize the product candidate on a timely basis or at
all and our ability to generate revenue will be materially impaired.
Any product candidate for which we obtain marketing approval could be subject to post-marketing restrictions or
withdrawal from the market and we may be subject to substantial penalties if we fail to comply with regulatory
requirements or if we experience unanticipated problems with our products, when and if any of them are
approved.
Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-
approval clinical data, labeling, advertising and promotional activities for such product, will be subject to continual
requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of
safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements
relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and
documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing
approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for
which the product may be marketed or to the conditions of approval, including the requirement to implement a risk
evaluation and mitigation strategy. New cancer drugs frequently are indicated only for patient populations that have
not responded to an existing therapy or have relapsed. If any of our product candidates receives marketing approval,
the accompanying label may limit the approved use of our drug in this way, which could limit sales of the product.
The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to
monitor the safety or efficacy of the product. The FDA and other agencies, including the Department of Justice, or
the DOJ, closely regulate and monitor the post-approval marketing and promotion of drugs to ensure they are
marketed and distributed only for the approved indications and in accordance with the provisions of the approved
labeling. The FDA and DOJ impose stringent restrictions on manufacturers’ communications regarding off-label
use, and if we do not market our products for their approved indications, we may be subject to enforcement action
for off-label marketing. Violations of the Federal Food, Drug, and Cosmetic Act and other statutes, including the
False Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations and
enforcement actions alleging violations of federal and state health care fraud and abuse laws, as well as state
consumer protection laws.
In addition, later discovery of previously unknown adverse events or other problems with our products,
manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various
results, including:
•
•
restrictions on such products, manufacturers or manufacturing processes;
restrictions on the labeling or marketing of a product;
•
•
•
•
•
•
•
•
•
•
•
•
•
•
restrictions on product distribution or use;
requirements to conduct post-marketing studies or clinical trials;
warning letters or untitled letters;
withdrawal of the products from the market;
refusal to approve pending applications or supplements to approved applications that we submit;
recall of products;
fines, restitution or disgorgement of profits or revenues;
suspension or withdrawal of marketing approvals;
damage to relationships with any potential collaborators;
unfavorable press coverage and damage to our reputation;
refusal to permit the import or export of our products;
product seizure;
injunctions or the imposition of civil or criminal penalties; or
litigation involving patients using our products.
Non-compliance with European Union requirements regarding safety monitoring or pharmacovigilance, and with
requirements related to the development of products for the pediatric population, can also result in significant
financial penalties. Similarly, failure to comply with the European Union’s requirements regarding the protection of
personal information can also lead to significant penalties and sanctions.
Our relationships with healthcare providers, physicians and third party payors will be subject to applicable anti-
kickback, fraud and abuse and other healthcare laws and regulations, which, in the event of a violation, could
expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits
and future earnings.
Healthcare providers, physicians and third party payors will play a primary role in the recommendation and
prescription of any product candidates for which we obtain marketing approval. Our future arrangements with
healthcare providers, physicians and third party payors may expose us to broadly applicable fraud and abuse and
other healthcare laws and regulations that may constrain the business or financial arrangements and relationships
through which we market, sell and distribute any products for which we obtain marketing approval. Restrictions
under applicable federal and state healthcare laws and regulations include the following:
•
•
•
the federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully
soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to
induce or reward, or in return for, either the referral of an individual for, or the purchase, order or
recommendation or arranging of, any good or service, for which payment may be made under a federal
healthcare program such as Medicare and Medicaid;
the federal False Claims Act imposes criminal and civil penalties, including through civil whistleblower
or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or
causing to be presented, false or fraudulent claims for payment by a federal healthcare program or
making a false statement or record material to payment of a false claim or avoiding, decreasing or
concealing an obligation to pay money to the federal government, with potential liability including
mandatory treble damages and significant per-claim penalties, currently set at $5,500 to $11,000 per
false claim;
the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal
and civil liability for executing a scheme to defraud any healthcare benefit program or making false
statements relating to healthcare matters;
•
•
•
HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and
its implementing regulations, also imposes obligations, including mandatory contractual terms, with
respect to safeguarding the privacy, security and transmission of individually identifiable health
information;
the federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs to
report payments and other transfers of value to physicians and teaching hospitals; and
analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws and
transparency statutes, may apply to sales or marketing arrangements and claims involving healthcare
items or services reimbursed by non-governmental third party payors, including private insurers.
Some state laws require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary
compliance guidelines and the relevant compliance guidance promulgated by the federal government and may
require drug manufacturers to report information related to payments and other transfers of value to physicians and
other healthcare providers or marketing expenditures. State and foreign laws also govern the privacy and security of
health information in some circumstances, many of which differ from each other in significant ways and often are
not preempted by HIPAA, thus complicating compliance efforts.
Efforts to ensure that our business with third parties will comply with applicable healthcare laws and regulations will
involve substantial costs. We do not have a fully developed compliance program and will need to establish a more
robust compliance infrastructure to address our needs in this area. We may fail to establish appropriate compliance
measures, and even with a stronger program in place, it is possible that governmental authorities will conclude that
our business practices may not comply with current or future statutes, regulations or case law involving applicable
fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of
these laws or any other governmental regulations that may apply to us, we may be subject to significant civil,
criminal and administrative penalties, damages, fines, imprisonment, exclusion of products from government funded
healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any
of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in
compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including
exclusions from government funded healthcare programs.
Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval
of and commercialize our product candidates and affect the prices we may obtain.
In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes
and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product
candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates
for which we obtain marketing approval. In the United States, the Medicare Prescription Drug, Improvement, and
Modernization Act of 2003, or the MMA, changed the way Medicare covers and pays for pharmaceutical products.
The legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new reimbursement
methodology based on average sales prices for physician-administered drugs. In addition, this legislation provided
authority for limiting the number of drugs that will be covered in any therapeutic class. Cost reduction initiatives and
other provisions of this legislation could decrease the coverage and price that we receive for any approved products.
While the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare
coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in
reimbursement that results from the MMA may result in a similar reduction in payments from private payors.
In March 2010, the U.S. Congress enacted the Patient Protection and Affordable Care Act, as amended by the
Health Care and Education Affordability Reconciliation Act, or collectively, the PPACA, a sweeping law which
included changes to the coverage and reimbursement of drug products under government healthcare programs.
Among the provisions of the PPACA of importance to our potential product candidates are the following:
•
an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription
drugs and biologic agents;
•
•
•
•
•
•
•
•
•
an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate
Program;
expansion of healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback
Statute, new government investigative powers, and enhanced penalties for noncompliance;
a Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50%
point-of-sale discounts off negotiated prices;
extension of manufacturers’ Medicaid rebate liability;
expansion of eligibility criteria for Medicaid programs;
expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing
program;
requirements to report financial arrangements with physicians and teaching hospitals;
a requirement to annually report drug samples that manufacturers and distributors provide to physicians;
and
a Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct
comparative clinical effectiveness research, along with funding for such research.
Further, other legislative changes have been proposed and adopted since the PPACA was enacted. These changes
include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, starting in 2013. In
January 2013, the American Taxpayer Relief Act of 2012 became law, which, among other things, reduced
Medicare payments to several providers, and increased the statute of limitations period for the government to
recover overpayments to providers from three to five years. These new laws may result in additional reductions in
Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product
candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is
prescribed or used.
We expect that these healthcare reforms, as well as other healthcare reform measures that may be adopted in the
future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage
criteria, new payment methodologies and additional downward pressure on the price that we receive for any
approved product and/or the level of reimbursement physicians receive for administering any approved product we
might bring to market. Reductions in reimbursement levels may negatively impact the prices we receive or the
frequency with which our products are prescribed or administered. Any reduction in reimbursement from Medicare
or other government programs may result in a similar reduction in payments from private payors.
With enactment of the Tax Cuts and Jobs Act of 2017, which was signed by President Trump on December 22,
2017, Congress repealed the “individual mandate.” The repeal of this provision, which requires most Americans to
carry a minimal level of health insurance, will become effective in 2019. According to the Congressional Budget
Office, the repeal of the individual mandate will cause 13 million fewer Americans to be insured in 2027 and
premiums in insurance markets may rise. Further, each chamber of the Congress has put forth multiple bills
designed to repeal or repeal and replace portions of the PPACA. Although none of these measures has been enacted
by Congress to date, Congress may consider other legislation to repeal and replace elements of the ACA. The
Congress will likely consider other legislation to replace elements of the PPACA, during the next Congressional
session.
The Trump administration has also taken executive actions to undermine or delay implementation of the PPACA. In
January 2017, President Trump signed an Executive Order directing federal agencies with authorities and
responsibilities under the PPACA to waive, defer, grant exemptions from, or delay the implementation of any
provision of the PPACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers,
health insurers, or manufacturers of pharmaceuticals or medical devices. In October 2017, President Trump signed a
second Executive Order allowing for the use of association health plans and short-term health insurance, which may
provide fewer health benefits than the plans sold through the PPACA exchanges. At the same time, the Trump
administration announced that it will discontinue the payment of cost-sharing reduction (CSR) payments to
insurance companies until Congress approves the appropriation of funds for such CSR payments. The loss of the
CSR payments is expected to increase premiums on certain policies issued by qualified health plans under the
PPACA. A bipartisan bill to appropriate funds for CSR payments was introduced in the Senate, but the future of
that bill is uncertain.
The costs of prescription pharmaceuticals in the United States has also been the subject of considerable discussion in
the United States, and members of Congress and the Trump administration have stated that they will address such
costs through new legislative and administrative measures. To date, there have been several recent U.S.
congressional inquiries and proposed state and federal legislation designed to, among other things, bring more
transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the
costs of drugs under Medicare and reform government program reimbursement methodologies for drug products.
The pricing of prescription pharmaceuticals is also subject to governmental control outside the United States. In
these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of
marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be
required to conduct a clinical trial that compares the cost effectiveness of our product candidates to other available
therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at
unsatisfactory levels, our ability to generate revenues and become profitable could be impaired.
Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and
promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be
enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such
changes on the marketing approvals of our product candidates, if any, may be. Increased scrutiny by the U.S.
Congress of the FDA’s approval process may significantly delay or prevent marketing approval, as well as subject
us to more stringent product labeling and post-marketing testing and other requirements.
Governments outside of the United States tend to impose strict price controls, which may adversely affect our
revenues, if any.
In some countries, particularly the countries of the European Union, the pricing of prescription pharmaceuticals is
subject to governmental control. In these countries, pricing negotiations with governmental authorities can take
considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval
in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product
candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount,
or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially.
If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines
or penalties or incur costs that could harm our business.
We are subject to numerous environmental, health and safety laws and regulations, including those governing
laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our
operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our
operations also produce hazardous waste products. We generally contract with third parties for the disposal of these
materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of
contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting
damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or
criminal fines and penalties for failure to comply with such laws and regulations.
Although we maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to
injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate
coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims
that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive
materials.
In addition, we may incur substantial costs in order to comply with current or future environmental, health and
safety laws and regulations. These current or future laws and regulations may impair our research, development or
production efforts. Our failure to comply with these laws and regulations also may result in substantial fines,
penalties or other sanctions.
Our employees may engage in misconduct or other improper activities, including non-compliance with regulatory
standards and requirements, which could cause significant liability for us and harm our reputation.
We are exposed to the risk of employee fraud or other misconduct, including intentional failures to comply with
FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to
the FDA or comparable foreign regulatory authorities, comply with manufacturing standards we have established,
comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations
established and enforced by comparable foreign regulatory authorities, report financial information or data
accurately or disclose unauthorized activities to us. Employee misconduct could also involve the improper use of
information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to
our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to
detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in
protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in
compliance with such laws, standards or regulations. If any such actions are instituted against us, and we are not
successful in defending ourselves or asserting our rights, those actions could have a significant impact on our
business and results of operations, including the imposition of significant fines or other sanctions.
Our internal computer systems, or those of any collaborators or contractors or consultants, may fail or suffer
security breaches, which could result in a material disruption of our product development programs.
Our internal computer systems and those of any collaborators, contractors or consultants are vulnerable to damage
from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical
failures. While we have not experienced any such material system failure, accident or security breach to date, if such
an event were to occur and cause interruptions in our operations, it could result in a material disruption of our
development programs and our business operations, whether due to a loss of our trade secrets or other proprietary
information or other similar disruptions. For example, the loss of clinical trial data from completed or future clinical
trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or
reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our
data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability,
our competitive position could be harmed and the further development and commercialization of our product
candidates could be delayed.
Risks Related to Employee Matters and Managing Growth
Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified
personnel.
We are highly dependent on the research and development, clinical and business expertise of our executive officers
as well as the other principal members of our management, scientific and clinical teams. Although we have entered
into employment letter agreements with our executive officers, each of them may terminate their employment with
us at any time. For instance, since January 1, 2017, our former Executive Vice President and Chief Financial
Officer, our former President of Research and Chief Scientific Officer, and our former Executive Vice President and
Chief Medical Officer have terminated their employment with us. We do not maintain “key person” insurance for
any of our executives or other employees.
Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be
critical to our success. The loss of the services of our executive officers or other key employees could impede the
achievement of our research, development and commercialization objectives and seriously harm our ability to
successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be
difficult and may take an extended period of time because of the limited number of individuals in our industry with
the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize
products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or
motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and
biotechnology companies, universities and research institutions for similar personnel. In addition, we rely on
consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and
development and commercialization strategy. Our consultants and advisors may be employed by employers other
than us and may have commitments under consulting or advisory contracts with other entities that may limit their
availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our
growth strategy will be limited.
We expect to expand our development and regulatory capabilities and potentially implement sales, marketing and
distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could
disrupt our operations.
We expect to experience significant growth in the number of our employees and the scope of our operations,
particularly in the areas of drug development, regulatory affairs and, if any of our product candidates receives
marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue
to implement and improve our managerial, operational and financial systems, expand our facilities and continue to
recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of
our management team in managing a company with such anticipated growth, we may not be able to effectively
manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our
operations may lead to significant costs and may divert our management and business development resources. Any
inability to manage growth could delay the execution of our business plans or disrupt our operations.
Risks Related to Our Common Stock
Provisions in our corporate charter documents, under Delaware law and in our collaboration agreements could
make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may
prevent attempts by our stockholders to replace or remove our current management.
Provisions in our certificate of incorporation and our bylaws may discourage, delay or prevent a merger, acquisition
or other change in control of our company that stockholders may consider favorable, including transactions in which
stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that
investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price
of our common stock. In addition, because our board of directors is responsible for appointing the members of our
management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove
our current management by making it more difficult for stockholders to replace members of our board of directors.
Among other things, these provisions:
•
•
•
•
•
•
•
•
establish a classified board of directors such that only one of three classes of directors is elected each
year;
allow the authorized number of our directors to be changed only by resolution of our board of directors;
limit the manner in which stockholders can remove directors from our board of directors;
establish advance notice requirements for stockholder proposals that can be acted on at stockholder
meetings and nominations to our board of directors;
require that stockholder actions must be effected at a duly called stockholder meeting and prohibit
actions by our stockholders by written consent;
limit who may call stockholder meetings;
authorize our board of directors to issue preferred stock without stockholder approval, which could be
used to institute a “poison pill” that would work to dilute the stock ownership of a potential hostile
acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and
require the approval of the holders of at least 75% of the votes that all our stockholders would be
entitled to cast to amend or repeal specified provisions of our certificate of incorporation or bylaws.
Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the
Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting
stock from merging or combining with us for a period of three years after the date of the transaction in which the
person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a
prescribed manner.
An active trading market for our common stock may not be sustained.
Although our common stock is listed on The NASDAQ Global Market, an active trading market for our shares may
not be sustained. If an active market for our common stock does not continue, it may be difficult for our
stockholders to sell their shares without depressing the market price for the shares or sell their shares at all. Any
inactive trading market for our common stock may also impair our ability to raise capital to continue to fund our
operations by selling shares and may impair our ability to acquire other companies or technologies by using our
shares as consideration.
The price of our common stock has been and may in the future be volatile and fluctuate substantially.
Our stock price has been and may in the future be volatile. The stock market in general and the market for smaller
biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the
operating performance of particular companies. From January 1, 2015 until March 1, 2018, the sale price of our
common stock as reported on the NASDAQ Global Market ranged from a high of $28.48 to a low of $7.02. The
market price for our common stock may be influenced by many factors, including:
•
•
•
•
•
•
•
•
•
•
•
•
•
the success of competitive products or technologies;
results of clinical trials of our product candidates or those of our competitors;
regulatory or legal developments in the United States and other countries;
developments or disputes concerning patent applications, issued patents or other proprietary rights;
the recruitment or departure of key personnel;
the level of expenses related to any of our product candidates or clinical development programs;
the results of our efforts to discover, develop, acquire or in-license additional product candidates or
products;
actual or anticipated changes in estimates as to financial results, development timelines or
recommendations by securities analysts;
variations in our financial results or the financial results of companies that are perceived to be similar to
us;
changes in the structure of healthcare payment systems;
market conditions in the pharmaceutical and biotechnology sectors;
general economic, industry and market conditions; and
the other factors described in this Risk Factors section.
We have broad discretion over the use of our cash and cash equivalents and may not use them effectively.
Our management has broad discretion to use our cash and cash equivalents to fund our operations and could spend
these funds in ways that do not improve our results of operations or enhance the value of our common stock. The
failure by our management to apply these funds effectively could result in financial losses that could have a material
adverse effect on our business, cause the price of our common stock to decline and delay the development of our
product candidates. Pending their use to fund operations, we may invest our cash and cash equivalents in a manner
that does not produce income or that loses value.
We are an “emerging growth company,” and the reduced disclosure requirements applicable to emerging growth
companies may make our common stock less attractive to investors.
We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS
Act, and will remain an emerging growth company through 2018. For so long as we remain an emerging growth
company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable
to other public companies that are not emerging growth companies. These exemptions include:
•
•
•
•
not being required to comply with the auditor attestation requirements in the assessment of our internal
control over financial reporting;
not being required to comply with any requirement that may be adopted by the Public Company
Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s
report providing additional information about the audit and the financial statements;
reduced disclosure obligations regarding executive compensation; and
exemptions from the requirements of holding a nonbinding advisory vote on executive compensation
and stockholder approval of any golden parachute payments not previously approved.
We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If
some investors find our common stock less attractive, as a result, there may be a less active trading market for our
common stock and our stock price may be more volatile. In addition, the JOBS Act provides that an emerging
growth company can take advantage of an extended transition period for complying with new or revised accounting
standards. This provision allows an emerging growth company to delay the adoption of these accounting standards
until they would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this
exemption and, therefore, we will be subject to the same new or revised accounting standards as other public
companies that are not emerging growth companies.
The recently passed comprehensive tax reform bill could adversely affect our business and financial condition.
On December 22, 2017, President Trump signed into law new legislation that significantly revised the Internal
Revenue Code of 1986, as amended. The newly enacted federal income tax law, among other things, contains
significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of
35% to a flat rate of 21%, limitation of the tax deduction for interest expense to 30% of adjusted earnings (except for
certain small businesses), limitation of the deduction for net operating losses to 80% of current year taxable income
and elimination of net operating loss carrybacks, one time taxation of offshore earnings at reduced rates regardless
of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions),
immediate deductions for certain new investments instead of deductions for depreciation expense over time, and
modifying or repealing many business deductions and credits. Notwithstanding the reduction in the corporate
income tax rate, the overall impact of the new federal tax law is uncertain and our business and financial condition
could be adversely affected. In addition, it is uncertain how various states will respond to the newly enacted federal
tax law. The impact of this tax reform on holders of our common stock is also uncertain and could be adverse. We
urge our stockholders to consult with their legal and tax advisors with respect to this legislation and the potential tax
consequences of investing in or holding our common stock.
We will continue to incur increased costs as a result of operating as a public company, and our management will
be required to devote substantial time to compliance initiatives and corporate governance practices.
As a public company, and particularly after we are no longer an emerging growth company, we will continue to
incur significant legal, accounting and other expenses. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall
Street Reform and Consumer Protection Act, the listing requirements of The NASDAQ Global Market and other
applicable securities rules and regulations impose various requirements on public companies, including
establishment and maintenance of effective disclosure and financial controls and corporate governance practices.
Our management and other personnel will need to continue to devote a substantial amount of time to these
compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs
and make some activities more time-consuming and costly.
We cannot predict or estimate the amount of additional costs we may incur to continue to operate as a public
company, nor can we predict the timing of such costs. These rules and regulations are often subject to varying
interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may
evolve over time as new guidance is provided by regulatory and governing bodies which could result in continuing
uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and
governance practices.
Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404, we are required to furnish a report by
our management on our internal control over financial reporting. However, while we remain an emerging growth
company, we are not required to include an attestation report on internal control over financial reporting issued by
our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed
period, we are engaged in a process to document and evaluate our internal control over financial reporting, which is
both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially
engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control
over financial reporting, continue steps to improve control processes as appropriate, validate through testing that
controls are functioning as documented and implement a continuous reporting and improvement process for internal
control over financial reporting. If we identify one or more material weaknesses, it could result in an adverse
reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.
Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital
appreciation, if any, will be the sole source of gain for our stockholders.
We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future
earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt
agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock
will be the sole source of gain for our stockholders for the foreseeable future.
If securities or industry analysts do not continue to publish research or publish inaccurate or unfavorable
research about our business, our share price and trading volume could decline.
The trading market for our common stock may be impacted, in part, by the research and reports that securities or
industry analysts publish about us or our business. There can be no assurance that analysts will cover us, continue to
cover us or provide favorable coverage. If one or more analysts downgrade our stock or change their opinion of our
stock, our share price may decline. In addition, if one or more analysts cease coverage of our company or fail to
regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price
or trading volume to decline.
Item 1B. Unresolved Staff Comments
None.
Item 2.
Properties
Our headquarters are located in Cambridge, Massachusetts, where we occupy approximately 43,066 square feet of
office and laboratory space. The term of the Cambridge lease expires November 30, 2022. In addition, we occupy
approximately 6,830 square feet of office space in Durham, North Carolina. The term of the Durham lease expires
on November 30, 2020.
Item 3.
Legal Proceedings
We are not currently a party to any material legal proceedings.
Item 4.
Mine Safety Disclosures
Not applicable.
PART II
Item 5.
Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases
of Equity Securities
Our common stock is traded on the NASDAQ Global Market under the symbol “EPZM.” Trading of our common
stock commenced on May 31, 2013, following the completion of our initial public offering. The following table sets
forth the high and low sale prices per share of our common stock, as reported on the NASDAQ Global Market, for
the periods indicated:
Year ended December 31, 2017:
Fourth quarter
Third quarter
Second quarter
First quarter
Year ended December 31, 2016:
Fourth quarter
Third quarter
Second quarter
First quarter
Market Price
High
Low
$20.45
$20.00
$18.50
$17.80
$12.35
$10.55
$13.20
$15.28
$11.35
$11.15
$ 9.30
$ 9.45
$ 8.55
$ 7.12
$ 8.96
$ 8.79
As of March 1, 2018, the number of holders of record of our common stock was 18. This number does not include
beneficial owners whose shares are held in street name.
Dividends
We have never declared or paid cash dividends on our capital stock. We intend to retain all of our future earnings, if
any, to finance the growth and development of our business. We do not intend to pay cash dividends to our
stockholders in the foreseeable future.
Stock Performance Graph
The following graph shows a comparison from May 31, 2013, the first date that shares of our common stock were
publicly traded, through December 31, 2017 of the cumulative total return on an assumed investment of $100.00 in
cash in our common stock, the NASDAQ Composite Index and the NASDAQ Biotechnology Index. Such returns
are based on historical results and are not intended to suggest future performance. Data for the NASDAQ Composite
Index and NASDAQ Biotechnology Index assume reinvestment of dividends.
COMPARISON OF 55 MONTH CUMULATIVE TOTAL RETURN*
Among Epizyme, Inc., the NASDAQ Composite Index
and the NASDAQ Biotechnology Index
$250
$200
$150
$100
$50
$0
5/13 6/13 9/13 12/13 3/14 6/14 9/14 12/14 3/15 6/15 9/15 12/15 3/16 6/16 9/16 12/16 3/17 6/17 9/17 12/17
Epizyme, Inc.
NASDAQ Composite
NASDAQ Biotechnology
*$100 invested on 5/31/13 in stock or index, including reinvestment of dividends.
Fiscal year ending December 31.
The performance graph in this Item 5 is not deemed to be “soliciting material” or to be “filed” with the SEC for
purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the
liabilities under that Section, and shall not be deemed incorporated by reference into any of our filings under the
Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent we specifically incorporate it by
reference into such a filing.
Item 6.
Selected Financial Data
The following selected financial data has been derived from our consolidated financial statements. The information
set forth below should be read in conjunction with Item 7. Management’s Discussion and Analysis of Financial
Condition and Results of Operations and with our consolidated financial statements and notes thereto included
elsewhere in this document.
Year Ended December 31,
2017
2016
2014
(In thousands, except per share data)
2015
2013
Consolidated Statements of Operations Data:
Collaboration revenue
Operating expenses:
Research and development
General and administrative
Total operating expenses
Operating loss
Other income (expense), net
Income tax benefit (expense)
Net loss
Accretion of redeemable convertible preferred stock to
redemption value
Loss allocable to common stockholders
Basic and diluted loss per share allocable to common
stockholders
Basic and diluted weighted average shares outstanding
Consolidated Balance Sheets Data:
Cash and cash equivalents
Marketable securities
Total assets
Deferred revenue
Total stockholders’ equity
$ 10,000 $
8,007 $
2,560 $ 41,411 $68,482
109,661
37,181
91,461 111,209 75,595 57,567
23,900 20,866 14,042
28,372
146,842 119,833 135,109 96,461 71,609
(136,842) (111,826) (132,549) (55,050) (3,127)
(7)
(349)
$(134,309) $(110,212) $(132,376) $(55,005) $ (3,483)
1,614
—
2,197
336
154
(109)
173
—
—
264
$(134,309) $(110,212) $(132,376) $(55,005) $ (3,747)
—
—
—
$
(2.18) $
61,471
(1.93) $
57,126
(3.32) $
(1.67) $ (0.22)
39,839 33,027 17,049
2017
2016
As of December 31,
2015
(In thousands)
2014
2013
$226,664 $ 77,895 $208,323 $190,095 $123,564
—
49,775 164,297
289,359 252,441 217,903 199,203 162,988
28,809 28,809 30,709 23,151 46,872
235,371 201,700 169,532 160,282 104,313
—
—
Item 7.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
Our management’s discussion and analysis of our financial condition and results of operations are based upon our
consolidated financial statements included in this Annual Report on Form 10-K, which have been prepared by us in
accordance with accounting principles generally accepted in the United States, or GAAP, and with Regulation S-X
promulgated under the Securities Exchange Act of 1934, as amended. This discussion and analysis should be read in
conjunction with these consolidated financial statements and the notes thereto included elsewhere in this Annual
Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in
this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business,
includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those
factors set forth in Part I, Item 1A. Risk Factors of this Annual Report on Form 10-K, our actual results could differ
materially from the results described in or implied by the forward-looking statements contained in the following
discussion and analysis.
Overview
We are a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other
serious diseases through discovering, developing, and commercializing novel epigenetic medicines. By focusing on
the genetic drivers of disease, our science seeks to match targeted medicines with the patients who need them. We
are broadly developing our lead product candidate, tazemetostat, an oral, first-in-class selective inhibitor of the
EZH2 histone methyltransferase, or HMT, in a range of cancer types and settings, and developing the lead
development candidate in our novel G9a program, EZM8266, for the treatment of sickle cell disease, or SCD.
We have taken a “pipeline in a product” approach to developing tazemetostat with a broad clinical development
program through company-sponsored studies and collaborations that are evaluating tazemetostat as both a
monotherapy and combination treatment in both hematological malignancies and solid tumors. Tazemetostat has
shown meaningful clinical activity as a monotherapy in indications in both disease areas and has been well tolerated
across clinical trials to date.
In our hematological program, we are conducting global Phase 2 studies evaluating tazemetostat’s treatment
potential in patients with relapsed or refractory follicular lymphoma, or FL, or diffuse large B-cell lymphoma, or
DLBCL, the two most prevalent forms of non-Hodgkin lymphoma, or NHL, both with and without EZH2 activating
mutations. We are continuing to enroll FL and DLBCL patients with EZH2 mutations in our ongoing global Phase 2
monotherapy relapsed or refractory FL and DLBCL study. Based on initial engagement with the U.S. Food and
Drug Administration, or FDA, we believe we have the opportunity to submit for accelerated approval for
tazemetostat as a monotherapy in FL. We plan to continue to engage with the FDA in 2018 to further refine our
registration strategy for FL, and subject to the results of our FL study, are targeting a planned submission to the
FDA of a New Drug Application, or NDA, for tazemetostat for FL in 2019. We also have multiple combination
studies underway through collaborators with both targeted agents and chemotherapy in DLBCL, in both relapsed or
refractory and first-line treatment settings, and plan to commence a combination study of tazemetostat in FL in the
second half of 2018.
In our solid tumor program, we are evaluating tazemetostat’s treatment potential in adults and children with
molecularly defined solid tumors, including INI1- and SMARCA4-negative tumors, which we collectively refer to
as INI1-negative tumors. We are conducting a global Phase 2 trial of tazemetostat in adults with INI1-negative
tumors, including epithelioid sarcoma, malignant rhabdoid tumors, or MRT, other INI1-negative tumors, and
chordoma. Based on positive data that we observed in the epithelioid sarcoma cohort in the ongoing study, we
engaged with the FDA in May 2017. Based on this FDA interaction, we have identified a potential path to
submission for accelerated approval in this indication and we are targeting submission of our first NDA to the FDA
for tazemetostat for epithelioid sarcoma in the fourth quarter of 2018. In connection with this submission, we plan to
commence a clinical trial of tazemetostat for epithelioid sarcoma that could serve as the confirmatory trial required
in connection with any accelerated approval. We are also evaluating tazemetostat in the dose-expansion portion of a
Phase 1 study in pediatric patients with INI1-negative tumors and in a Phase 2 study in adults with mesothelioma
characterized by BAP1 loss-of-function. In addition, as part of a study conducted by our collaborator Genentech,
Inc., or Genentech, tazemetostat is being evaluated in combination with atezolizumab (TECENTRIQ®), a PD-L1
inhibitor, in patients with non-small cell lung cancer, or NSCLC. In 2018, we expect to execute on the following
relating to tazemetostat:
•
•
•
•
•
•
•
•
•
•
continue dosing patients in our Phase 2 monotherapy trial of tazemetostat in adults with molecularly
defined solid tumors and present updated epithelioid sarcoma data on the full registration cohort of 60
patients and interim data in other cohorts that have surpassed futility from this trial in the second half of
2018;
submit our first NDA submission, for the treatment of epithelioid sarcoma, in the fourth quarter of 2018
and begin preparing for a confirmatory study in epithelioid sarcoma;
complete enrollment of patients in our Phase 2 monotherapy study of tazemetostat in adults with
relapsed or refractory NHL and present updated monotherapy data from this trial at individual medical
meetings in the mid-to second half of 2018;
continue to refine our regulatory strategy in FL, with a planned FL NDA submission in 2019, and
determine next development steps for DLBCL monotherapy in EZH2 mutant patients;
complete enrollment in the dose expansion phase of our Phase 1 monotherapy study of tazemetostat in
children with molecularly defined solid tumors in the second half of 2018;
complete enrollment in the combination trial of tazemetostat and atezolizumab in patients with relapsed
or refractory DLBCL, as well as evaluate the opportunity with our partner Genentech in regard to the
appropriate timing and forum for data presentation;
advance our Phase 1b combination trial of tazemetostat and R-CHOP in first line patients with DLBCL
to determine the recommended Phase 2 dose and advance into the Phase 2 expansion portion of the
study as well as evaluate the opportunity with our partner, the Lymphoma Study Association, to present
the phase 1b dose escalation data at a future medical meeting;
complete enrollment in the additional arm of our ongoing Phase 2 NHL study to investigate
tazemetostat in combination with prednisolone for patients with relapsed or refractory DLBCL and
evaluate the opportunity to present data at a future medical meeting;
initiate a combination trial of tazemetostat in FL in the second half of 2018 designed to support
registration strategy; and
present Phase 2 study data of tazemetostat in patients with mesothelioma characterized by a loss-of-
function of BAP1 at a medical meeting in mid-2018.
We also plan to complete IND-enabling studies of development candidate EZM8266, targeted for SCD, to enable a
first in human study in early 2019.
We have recently begun building the infrastructure necessary to support the successful commercial launch and
marketing of tazemetostat or other product candidates that may receive marketing approval. We own the global
development and commercialization rights to tazemetostat outside of Japan. Eisai Co. Ltd, or Eisai, holds the rights
to develop and commercialize tazemetostat in Japan. Tazemetostat is covered by claims of U.S. and European
composition of matter patents, which are expected to expire in 2032, not including extensions. We have announced
that the FDA has granted tazemetostat Fast Track designation in patients with relapsed or refractory FL, with or
without activating EZH2 mutations, and relapsed or refractory DLBCL with EZH2 activating mutations. The FDA
has granted tazemetostat orphan drug designation for the treatment of patients with follicular lymphoma, malignant
rhabdoid tumors, or MRT, soft tissue sarcoma and mesothelioma. The orphan drug designation for the treatment of
MRT applies to INI1-negative MRT as well as SMARCA4-negative malignant rhabdoid tumor of ovary. We also
own global rights to EZM8266 targeting G9a.
We have retained commercialization rights in the United States to all of our other programs, except two programs
that are the subject of our collaboration with Glaxo Group Limited (GlaxoSmithKline or GSK, and two of the
preclinical programs that are the subject of our collaboration with Celgene. We plan to retain commercialization
rights in the United States and possibly in select foreign jurisdictions in connection with any future collaborations.
We intend to build a focused field presence and marketing capabilities to commercialize any of our product
candidates that receive regulatory approval in the United States, as well as the capabilities to lead global commercial
strategy. As of December 31, 2017, we had received $217.8 million in non-equity funding under these
collaborations
Through December 31, 2017, we have raised an aggregate of $891.6 million to fund our operations, of which $217.8
million was non-equity funding through our collaboration agreements, $597.8 million was from the sale of common
stock in our public offerings and $76.0 million was from the sale of redeemable convertible preferred stock. As of
December 31, 2017, we had $276.4 million in cash, cash equivalents and marketable securities.
We commenced active operations in early 2008, and since inception, have incurred significant operating losses. As
of December 31, 2017, our accumulated deficit totaled $488.1 million. As a clinical stage company, we expect to
continue to incur significant expenses and operating losses over the next several years. Our net losses may fluctuate
significantly from quarter to quarter and year to year. We expect our expenses to increase in connection with our
ongoing activities, including our continued execution on our clinical development and commercialization plans for
tazemetostat.
Collaborations
Refer to Item 1, Business--Our Collaborations and Note 9, Collaborations, of the notes to our consolidated financial
statements in Item 15 of this Annual Report on Form 10-K for a description of the key terms of our arrangements
with Eisai, Celgene and GSK, as well as the related accounting and revenue recognition considerations.
Results of Operations for the Years Ended December 31, 2017, 2016 and 2015
Collaboration Revenue
The following is a comparison of collaboration revenue for the years ended December 31, 2017, 2016, and 2015:
Collaboration revenue
Collaboration revenue
Year Ended December 31,
2017
2016
Change
%
(In millions)
$
10.0
$
8.0
$
2.0
25.0%
Year Ended December 31,
2016
2015
Change
%
(In millions)
$
8.0
$
2.6
$
5.4
207.7%
Our revenue consists of collaboration revenue, including amounts recognized from deferred revenue related to
upfront payments for licenses or options to obtain licenses in the future, research and development services revenue
earned and milestone payments earned under collaboration and license agreements with our collaboration partners.
The following tables summarize our collaboration revenue, by collaboration partner, for the years ended
December 31, 2017, 2016, and 2015:
Collaboration Partner
GSK:
Milestone revenue
Celgene:
Upfront revenue
Other
Collaboration Partner
GSK:
Upfront revenue
Milestone revenue
Research and development revenue
Celgene:
Upfront revenue
Other
Year Ended December 31,
2017
2016
Change
%
(In millions)
$
10.0
$
6.0
$
4.0
66.7%
—
—
10.0
$
$
1.9
0.1
8.0
(1.9)
(0.1)
2.0
-100.0
-100.0
25.0%
$
Year Ended December 31,
2016
2015
Change
%
(In millions)
$
$
—
6.0
—
1.9
0.1
8.0
$
$
1.0
—
0.4
1.1
0.1
2.6
$ (1.0)
6.0
(0.4)
-100.0%
100.0
-100.0
0.8
—
5.4
$
72.7
0.0
207.7%
Collaboration revenue for the year ended December 31, 2017 increased $2.0 million as compared to the year ended
December 31, 2016, primarily as a result of the achievement of a $10.0 million milestone under our agreement with
GSK during 2017 as compared to the achievement of a $6.0 million milestone with GSK and $1.9 million in upfront
revenue under our agreement with Celgene in 2016. Collaboration revenue for the year ended December 31, 2016
increased $5.4 million as compared to the year ended December 31, 2015, primarily as a result of the achievement
of a $6.0 million milestone under our agreement with GSK during 2016.
GSK. Through December 31, 2017, we have earned a total of $69.0 million under the GSK agreement, which we
recognized as collaboration revenue in the condensed consolidated statements of operations and comprehensive loss,
including $10.0 million of preclinical and research and development milestone revenue earned in May 2017 related
to the second target in the collaboration, upon GSK’s initiation of good laboratory practices toxicology studies for
a first-in-class methyltransferase inhibitor discovered by us and licensed to GSK. In the year ended December 31,
2016, revenue attributable to the GSK collaboration reflects the $6.0 million milestone earned upon GSK’s initiation
of patient dosing in a Phase 1 clinical trial of GSK3326595, a PRMT5 inhibitor discovered by us and licensed to
GSK under the collaboration agreement. Upfront revenue of $1.0 million in the year ended December 31, 2015
reflects the recognition of deferred revenue related to upfront payments for licenses under the agreement. Research
and development revenue of $0.4 million in the year ended December 31, 2015 relates to research and development
services performed during the year. Since we have no further performance obligations under the GSK collaboration,
future revenues under the collaboration will relate to milestone payments and royalties received under the
agreement, if any. Upfront and research and development revenue decreased each year as a result of the completion
of a significant portion of our performance obligations during 2014.
Celgene. In the year ended December 31, 2017, no collaboration revenue was recognized as part of our Celgene
collaboration. Collaboration revenue attributed to the Celgene collaboration increased in the year ended
December 31, 2016, as compared to the year ended December 31, 2015, primarily due to the recognition of deferred
revenue attributed to the pinometostat clinical trial services as part of the accounting for the amended and restated
Celgene agreement, which was entered into during the third quarter of 2015. Upfront revenue of $1.1 million in the
year ended December 31, 2015 reflects the recognition of deferred revenue related to upfront payments for licenses
under the agreement.
As of December 31, 2017, we have deferred revenue of $28.8 million, all of which relates to our Celgene
collaboration and is attributable to the non-pinometostat targets that are subject to the collaboration. We satisfied all
of our obligations related to pinometostat under the collaboration as of December 31, 2016. We expect our deferred
revenue balance to change upon the adoption of new revenue accounting guidance, ASC 606, Revenue From
Contracts with Customers, in the first quarter of 2018, as described in Note 2, Summary of Significant Accounting
Policies—Recent Accounting Pronouncements, in the accompanying Notes to Consolidated Financial Statements
included in Item 15. of Part IV of this Annual Report on Form 10-K.
Research and Development
Research and development expenses consist of expenses incurred in performing research and development activities,
including clinical trials and related clinical manufacturing expenses, fees paid to external providers of research and
development services, third party clinical research organizations, or CROs, compensation and benefits for full-time
research and development employees, facilities expenses, overhead expenses, and other outside expenses. Most of
our research and development costs are external costs, which we track on a program-by-program basis. Our internal
research and development costs are primarily compensation expenses for our full-time research and development
employees, including stock-based compensation expense.
In our early-stage research, we identify and prioritize novel CMPs that are implicated in cancer and other diseases,
and seek to develop potent and selective small molecule inhibitors of these targets. During this phase of research,
our external costs primarily relate to lead discovery, biology, drug metabolism and pharmacokinetics and chemistry
services from a multinational network of third party providers of research and development services. As our product
candidates progress into preclinical and clinical development, external costs are driven by clinical trial costs,
manufacturing expenses, and third-party research and development expenses.
In circumstances where our collaboration and license agreements provide for equally co-funded global development
under joint risk sharing collaborations, and where we are the study sponsor, such as our Celgene collaboration,
amounts received for co-funding are recorded as a reduction to research and development expense.
The following is a comparison of research and development expenses for the years ended December 31, 2017, 2016,
and 2015:
Research and development
Year Ended December 31,
2017
2016
Change
%
(In millions)
$
$ 109.7
91.5
$ 18.2
19.9%
Year Ended December 31,
2016
2015
Change
%
(In millions)
Research and development
$
91.5
$ 111.2
$ (19.7)
-17.7%
During the year ended December 31, 2017, total research and development expenses increased by $18.2 million
compared to the year ended December 31, 2016, primarily due to increased tazemetostat manufacturing activities,
tazemetostat clinical development, expansion of activities related to our drug platform and target families, and
research activities related to advancing our next development candidate.
During the year ended December 31, 2016 total research and development expenses decreased by $19.7 million
compared to the year ended December 31, 2015, primarily due to the $40.0 million upfront payment that we made to
Eisai to reacquire the worldwide rights, excluding Japan, to the EZH2 program, including tazemetostat, and the
related costs to accelerate the development of tazemetostat. The impact of the prior year upfront payment was
partially offset by higher spending on the tazemetostat program and discovery/preclinical and internal research and
development costs in the year ended December 31, 2016 compared to the year ended December 31, 2015.
The following table illustrates the components of our research and development expenses:
Product Program
External research and development expenses:
Tazemetostat and related EZH2 programs
Pinometostat and related DOT1L programs
Discovery and preclinical stage product
programs, collectively
Unallocated personnel and other expenses
Total research and development expenses
Product Program
External research and development expenses:
Tazemetostat and related EZH2 programs
Pinometostat and related DOT1L programs
Discovery and preclinical stage product
programs, collectively
Unallocated personnel and other expenses
Total research and development expenses
Year Ended December 31,
2017
2016
Change
%
(In millions)
$
54.2
0.8
17.9
36.8
$ 109.7
$
$
39.9
2.6
$ 14.3
(1.8)
35.8%
-69.2
18.9
30.1
91.5
(1.0)
6.7
$ 18.2
-5.3
22.3
19.9%
Year Ended December 31,
2016
2015
Change
%
(In millions)
$
39.9
2.6
$
63.1
5.3
$ (23.2)
(2.7)
-36.8%
-50.9
18.9
30.1
91.5
16.3
26.5
$ 111.2
2.6
3.6
$ (19.7)
16.0
13.6
-17.7%
$
External research and development costs include external manufacturing costs related to the acquisition of active
pharmaceutical ingredient and manufacturing of clinical drug supply, ongoing clinical trial costs, discovery and
preclinical research in support of the tazemetostat program and expenses associated with our companion diagnostic
program.
External research and development expenses for tazemetostat and related EZH2 programs increased $14.3 million
for the year ended December 31, 2017 compared to the year ended December 31, 2016. The increase in tazemetostat
related spending in the year ended December 31, 2017 is primarily a result of a significant increase in tazemetostat
manufacturing and clinical trial activities in 2017 as compared to 2016.
External research and development expenses for tazemetostat decreased $23.2 million during the year ended
December 31, 2016 compared to the year ended December 31, 2015. The decrease in tazemetostat related spending
in the year ended December 31, 2016 is primarily a result of the $40.0 million upfront payment made to Eisai in the
prior year, offset by a significant increase in tazemetostat clinical trial activities in the year ended December 31,
2016.
External research and development expenses for tazemetostat during 2015 include the costs associated with our
reacquisition of worldwide rights, excluding Japan, to the EZH2 program, including tazemetostat, from Eisai during
the first quarter of 2015 (including the $40.0 million upfront payment made to Eisai). External research and
development expenses for tazemetostat in 2015 also include Phase 1/2 clinical trial costs, discovery and preclinical
research in support of the tazemetostat program, expenses associated with our companion diagnostic program, and
external manufacturing costs related to the acquisition of active pharmaceutical ingredient and manufacturing of
clinical drug supply.
External research and development expenses for pinometostat and related DOT1L programs for the year ended
December 31, 2017 decreased $1.8 million when compared to the year ended December 31, 2016. The decline in
program spending reflects our completion of the pinometostat Phase 1 clinical trials during the fourth quarter of
2016 and the associated reduction in costs. The costs incurred related to pinometostat in the year ended
December 31, 2017 are primarily associated with costs attributed to the CRADA with the NCI. External research
and development expenses for pinometostat decreased by $2.7 million for the year ended December 31, 2016
compared to 2015. The decline in program spending reflects our completion of enrollment in the pinometostat adult
and pediatric clinical trials and the associated reduction in costs. We completed enrollment in our pinometostat adult
Phase 1 clinical trial in the third quarter of 2015 and the pediatric Phase 1 clinical trial in the first quarter of 2016.
The costs incurred related to pinometostat in year ended December 31, 2016 are primarily associated with study
closeout and final reporting activities on the Phase 1 clinical trials, as well as costs attributed to the CRADA with
the NCI.
External research and development expenses for discovery and preclinical stage product programs decreased
$1.0 million for the year ended December 31, 2017 compared to the year ended December 31, 2016, primarily
related to a greater focus on more mature existing targets and reduced efforts on the discovery of new chemical
matter. External research and development expenses for discovery and preclinical stage product programs increased
$2.6 million for the year ended December 31, 2016 as compared to the year ended December 31, 2015, due to
increased spending on high priority discovery programs.
Unallocated personnel and other expenses are comprised of compensation expenses for our full-time research and
development employees and other general research and development expenses. Unallocated personnel and other
expenses for the year ended December 31, 2017 increased $6.7 million compared to the year ended December 31,
2016. The increase in unallocated personnel and other expenses in the year ended December 31, 2017 was primarily
due to the expansion of our development organization to support expanded tazemetostat clinical trials, chemistry,
manufacturing and controls, translational medicine, data analytics and regulatory activities. Unallocated personnel
and other expenses increased $3.6 million for year ended December 31, 2016 as compared to the year ended
December 31, 2015. The increase in unallocated personnel and other expenses in the year ended December 31, 2016
was primarily due to the expansion of our development organization to support expanded tazemetostat clinical trials,
chemistry, manufacturing and controls, translational medicine, data analytics and regulatory activities.
We expect research and development expenses to increase significantly in 2018, as we progress and expand our
development program for tazemetostat, expand our regulatory activities, and advance a preclinical program G9a into
later stage preclinical testing.
General and Administrative
General and administrative expenses consist primarily of salaries and related benefits, including stock-based
compensation, related to our executive, finance, intellectual property, business development and support functions.
Other general and administrative expenses include allocated facility-related costs not otherwise included in research
and development expenses, travel expenses and professional fees for auditing, tax and legal services, including
intellectual property and general legal services.
The following is a comparison of general and administrative expenses for the years ended December 31, 2017, 2016,
and 2015:
General and administrative
Year Ended December 31,
2017
2016
Change
%
(In millions)
$
37.2
$
28.4
$
8.8
31.0%
General and administrative
Year Ended December 31,
2016
2015
Change
%
(In millions)
$
28.4
$
23.9
$
4.5
18.8%
For the year ended December 31, 2017, our general and administrative expenses increased $8.8 million compared to
the year ended December 31, 2016, primarily due to an increase in consulting services as a result of rapid
organizational development, including preparation for commercialization, and increased intellectual property legal
fees associated with potential drug research candidates. For the year ended December 31, 2016, our general and
administrative expenses increased $4.5 million compared to the year ended December 31, 2015, primarily due to
higher compensation-related expenses associated with additions to the senior leadership team in the first half of
2016, as well as increased investment in business development activities and pre-commercial activities related to
tazemetostat.
We expect that general and administrative expenses will increase in 2018, as we plan to increase our pre-commercial
activities, including the continued build out of our medical affairs and commercial organizations.
Other Income, Net
The following is a comparison of other income, net for the years ended December 31, 2017, 2016, and 2015:
Other income, net
Interest income, net
Other income, net
Other income, net
Other income, net
Interest income, net
Other income, net
Other income, net
Year Ended December 31,
2017
2016
Change
%
(In millions)
$
$
2.2
—
2.2
$
$
1.5
0.1
1.6
0.7
(0.1)
0.6
46.7%
-100.0
37.5%
$
Year Ended December 31,
2016
2015
Change
%
(In millions)
$
$
1.5
0.1
1.6
$
$
0.1
0.1
0.2
$
1.4
—
1.4
$
1400.0%
0.0
700.0%
Other income, net consists of interest income earned on our cash equivalents and marketable securities, net of
imputed interest expense paid under our capital lease obligation, and other income recorded from a tax incentive
award received in 2013. Other income is mainly comprised of net interest income, which increased $0.7 million for
the year ended December 31, 2017 compared to the year ended December 31, 2016, primarily due to an increased
cash balance as a result of the September 2017 follow-on offering. Net interest income increased $1.4 million for the
year ended December 31, 2016 compared to the year ended December 31, 2015, primarily due to an increased cash
balance as a result of the January 2016 follow-on offering and the purchases of short term interest bearing securities
in 2016.
Income Tax Benefit
We evaluated the expected recoverability of our net deferred tax assets as of December 31, 2017 and determined
that, with the exception of the deferred tax asset related to alternative minimum tax, or AMT, credits, there was
insufficient positive evidence to support the recoverability of these net deferred tax assets. The AMT credit becomes
refundable no later than 2022 under the Tax Cuts and Jobs Act, and as such, the related deferred tax asset will be
able to be realized. The corresponding valuation allowance of $368,000 has been reversed as of December 31, 2017
and recognized as tax benefit.
We evaluated the expected recoverability of our net deferred tax assets as of December 31, 2016 and 2015 and
determined that there was insufficient positive evidence to support the recoverability of these net deferred tax assets,
concluding it is more likely than not that our net deferred tax assets would not be realized in the future; therefore, we
provided a full valuation allowance against our net deferred tax asset balance as of December 31, 2016 and 2015 and
did not recognize any tax benefit for the years ended December 31, 2016 and 2015, respectively.
Liquidity and Capital Resources
In September 2017, we raised $151.3 million, net of underwriting discounts and commissions, but before direct and
incremental costs from the sale of 10,557,000 shares of our common stock in a public offering at a price to the
public of $15.25 per share. Through December 31, 2017, we have raised an aggregate of $891.6 million to fund our
operations, of which $217.8 million was non-equity funding through our collaboration agreements, $597.8 million
was from the sale of common stock in our public offerings and $76.0 million was from the sale of redeemable
convertible preferred stock. As of December 31, 2017, we had $276.4 million in cash, cash equivalents and
marketable securities.
On April 15, 2016, we entered into a Sales Agreement with Cowen and Company, LLC, or Cowen, to sell, from
time to time, shares of our common stock having an aggregate sales price of up to $50.0 million through an “at the
market offering” as defined in Rule 415 under the Securities Act of 1933, as amended, under which Cowen would
act as sales agent, which we refer to as the ATM Offering. Through March 10, 2017, we sold 155,834 shares of
Common Stock under the Sales Agreement, resulting in net proceeds of $1.9 million related to the ATM Offering.
We terminated the Sales Agreement with Cowen, effective March 10, 2017.
In addition to our existing cash, cash equivalents and marketable securities, we may receive research and
development co-funding and are eligible to earn a significant amount of option exercise and milestone payments
under our collaboration agreements. Our ability to earn these payments and the timing of earning these payments is
dependent upon the outcome of our research and development activities and is uncertain at this time.
Funding Requirements
Our primary uses of capital are, clinical trial costs, third party research and development services, expenses related
to preparation for commercialization, compensation and related expenses, laboratory and related supplies, our
potential future milestone payment obligations to Eisai and Roche Molecular under the amended Eisai collaboration
agreement and Roche Molecular companion diagnostic agreement, legal and other regulatory expenses and general
overhead costs.
Because our product candidates are in various stages of clinical and preclinical development and the outcome of
these efforts is uncertain, we cannot estimate the actual amounts necessary to successfully complete the
development and commercialization of our product candidates or whether, or when, we may achieve profitability.
Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs
through a combination of equity or debt financings and collaboration arrangements. Except for any obligations of
our collaborators to make license, milestone or royalty payments under our agreements with them, we do not have
any committed external sources of liquidity. To the extent that we raise additional capital through the future sale of
equity or debt, the ownership interest of our stockholders may be diluted, and the terms of these securities may
include liquidation or other preferences that adversely affect the rights of our existing common stockholders. Debt
financing and preferred equity financing, if available, may involve agreements that include covenants limiting or
restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or
declaring dividends. If we raise additional funds through collaboration arrangements in the future, we may have to
relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on
terms that may not be favorable to us. If we are unable to raise any additional funds that may be needed through
equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product
development or future commercialization efforts or grant rights to develop and market product candidates that we
would otherwise prefer to develop and market ourselves.
Outlook
Based on our research and development plans and our timing expectations related to the progress of our programs,
we expect that our existing cash, cash equivalents and marketable securities as of December 31, 2017, will be
sufficient to fund our planned operating expenses and capital expenditure requirements into the third quarter of
2019, without giving effect to any potential option exercise fees or milestone payments we may receive under our
collaboration agreements. We have based this estimate on assumptions that may prove to be wrong, particularly as
the process of testing product candidates in clinical trials is costly and the timing of progress in these trials is
uncertain. As a result, we could use our capital resources sooner than we expect.
Cash Flows
The following is a summary of cash flows for the years ended December 31, 2017, 2016 and 2015:
Net cash used in operating activities
Net cash provided by (used in) investing activities
Net cash provided by financing activities
$ (120.4)
113.3
155.9
$ (96.4)
(165.4)
131.4
(24.0)
278.7
24.5
24.9%
-168.5
18.6
Year Ended December 31,
2017
2016
Change
%
(In millions)
Net cash used in operating activities
Net cash used in investing activities
Net cash provided by financing activities
Net Cash Used in Operating Activities
Year Ended December 31,
2016
2015
Change
%
(In millions)
$ (96.4)
(165.4)
131.4
$ (72.9) $ (23.5)
(125.2)
0.1
(40.2)
131.3
32.2%
311.4
—
Net cash used in operating activities was $120.4 million during the year ended December 31, 2017 compared to
$96.4 million during the year ended December 31, 2016. The increase in net cash used in operating activities
primarily relates to the increase in net loss in the period compared to 2016, partially offset by changes in working
capital.
Net cash used in operating activities was $96.4 million during the year ended December 31, 2016 compared to $72.9
million during the year ended December 31, 2015. The increase in net cash used in operating activities during year
ended December 31, 2016 as compared to 2015 primarily relates to the net loss in the period, after adjusting for the
$40.0 million payment made to Eisai in the prior year, which is classified as an investing cash outflow.
Net Cash Used in Investing Activities
Net cash provided by investing activities during the year ended December 31, 2017 reflects $126.4 million of
purchases of available-for-sale securities, maturities of available-for-sale securities of $240.7 million and purchases
of property and equipment of $1.0 million.
Net cash used in investing activities during the year ended December 31, 2016 reflects $229.9 million of purchases
of available for sale securities, maturities/sales of available for sale securities of $65.1 million and $0.6 million of
purchases of property and equipment during the period.
Net cash used in investing activities during the year ended December 31, 2015, reflects the $40.0 million upfront
payment made to Eisai upon the execution of our amended and restated collaboration and license agreement, under
which we reacquired worldwide rights, excluding Japan, to tazemetostat, as well as purchases of property and
equipment.
Net Cash Provided by Financing Activities
Net cash provided by financing activities of $155.9 million during the year ended December 31, 2017 primarily
reflects net cash received from the sale of common stock in public offerings in the first quarter and third quarter of
2017 of $152.5 million, cash received from stock option exercises of $3.3 million, and the purchases of shares under
our employee stock purchase plan of $0.7 million, partially offset by the payments under our capital lease obligation
of $0.6 million.
Net cash provided by financing activities of $131.4 million during the year ended December 31, 2016 primarily
reflects net cash received from our January 2016 public offering of our common stock of $129.7 million as well as
cash received from stock option exercises, cash proceeds from our ATM Offering and purchase of shares under our
employee stock purchase plan. This amount was offset in part by the payment of $0.6 million of principal on our
capital lease obligation.
Net cash provided by financing activities of $131.3 million during the year ended December 31, 2015 primarily
reflects net cash received from our March 2015 public offering of our common stock of $130.3 million as well as
cash received from stock option exercises and the purchase of shares under our employee stock purchase plan. This
amount was offset in part by the payment of $0.4 million of principal on our capital lease obligation during the year
ended December 31, 2015.
Contractual Obligations and Contingent Liabilities
The following summarizes our significant contractual obligations as of December 31, 2017:
Contractual Obligations
Real estate leases (1)
Capital leases (2)
Total obligations
Less than
1
Year
Total
1 to 3 Year
s
3 to 5 Year
s
(In thousands)
More than
5
Years
$17,262 $
111
$17,373 $
3,270 $
111
3,381 $
7,121 $
—
7,121 $
6,871 $
—
6,871 $
—
—
—
(1) Real Estate Leases. Real estate leases represent future minimum lease payments under non-cancelable
operating leases in effect as of December 31, 2017. The minimum lease payments above do not include
common area maintenance charges or real estate taxes to the extent applicable.
(2) Capital Leases. Capital leases relate to lease of computer hardware and related equipment.
In addition to commitments under leasing arrangements described in the table above, as of December 31, 2017, we
have committed to fund $10.5 million of remaining development costs payable to Roche Molecular, expected to be
paid through 2019 upon certain development and regulatory milestones, under an amended companion diagnostic
agreement. The agreement was further amended in March 2018. Under the amended agreement, we are responsible
for remaining development costs of $10.4 million due under the agreement and Eisai has agreed to reimburse us for
$0.9 million of this amount related to a regulatory milestone for Japan. We expect the remaining development costs
under the amended agreement to be incurred and paid through 2019. In addition, the contractual obligations table
does not include potential future milestones or royalties that we may be required to make under license and
collaboration agreements, including potential future milestones or royalties payable to Eisai under the amended
collaboration and license agreement, due to the uncertainty of the occurrence of the events requiring payment under
these agreements. Upon the execution of the amended and restated collaboration agreement in March 2015, we
agreed to pay Eisai a $40.0 million upfront payment. We also agreed to pay Eisai up to $20.0 million in clinical
development milestone payments, including a $10.0 million milestone upon the earlier of initiation of a phase 3
clinical trial of any EZH2 product or the first submission of an NDA or MAA, up to $50.0 million in regulatory
milestone payments, including a $25.0 million milestone payment upon regulatory approval of the first NDA or
MAA, and royalties at a percentage in the mid-teens on worldwide net sales of any EZH2 product, excluding net
sales in Japan.
We enter into contracts in the normal course of business with CROs for clinical and preclinical research studies,
external manufacturers for product for use in our clinical trials, and other research supplies and other services as part
of our operations. These contracts generally provide for termination on notice, and therefore are cancelable contracts
and not included in the table of contractual obligations and commitments.
Critical Accounting Policies and Use of Estimates
Our management’s discussion and analysis of financial condition and results of operations is based upon our
consolidated financial statements, which have been prepared in accordance with accounting principles generally
accepted in the United States of America. The preparation of these consolidated financial statements requires us to
make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosures
of contingent assets and liabilities as of the date of the balance sheets and the reported amounts of collaboration
revenue and expenses during the reporting periods. We base our estimates on historical experience and on various
other assumptions that we believe to be reasonable under the circumstances at the time such estimates are made.
Actual results and outcomes may differ materially from our estimates, judgments and assumptions. We periodically
review our estimates in light of changes in circumstances, facts and experience. The effects of material revisions in
estimates are reflected in the consolidated financial statements prospectively from the date of the change in estimate.
We define our critical accounting policies as those accounting principles generally accepted in the United States of
America that require us to make subjective estimates and judgments about matters that are uncertain and are likely
to have a material impact on our financial condition and results of operations as well as the specific manner in which
we apply those principles. We believe the critical accounting policies used in the preparation of our financial
statements which require significant estimates and judgments are as follows:
Revenue Recognition
We recognize revenue when all of the following criteria are met: persuasive evidence of an arrangement exists;
delivery has occurred or services have been rendered; our price to the customer is fixed or determinable and
collectability is reasonably assured. The terms of our collaboration and license agreements typically contain multiple
deliverables, which may include licenses, or options to obtain licenses, to compounds directed to specific HMT
targets, referred to as exclusive licenses, as well as research and development activities to be performed by us on
behalf of the collaboration partner related to the licensed HMT targets. Payments that we may receive under these
agreements include non-refundable license fees, option fees, extension fees, payments for research activities,
payments based upon the achievement of specified milestones and royalties on any resulting net product sales.
Multiple-Element Revenue Arrangements. Our collaborations primarily represent multiple-element revenue
arrangements. To account for these transactions, we determine the elements, or deliverables, included in the
arrangement and allocate arrangement consideration to the various elements based on each element’s relative selling
price. The identification of individual elements in a multiple-element arrangement and the estimation of the selling
price of each element involve significant judgment, including consideration as to whether each delivered element
has standalone value to the collaborator. We determine the estimated selling price for deliverables within each
agreement using vendor-specific objective evidence of selling price, if available, or third party evidence of selling
price if vendor-specific objective evidence is not available, or our best estimate of selling price, if neither vendor-
specific objective evidence nor third party evidence is available. Determining the best estimate of selling price for a
deliverable requires significant judgment. We typically use our best estimate of selling price to estimate the selling
price for licenses to our proprietary technology, since we do not have vendor-specific objective evidence or third
party evidence of selling price for these deliverables. In those circumstances where we apply our best estimate of
selling price to determine the estimated selling price of a license to our proprietary technology, we consider market
conditions as well as entity-specific factors, including those factors contemplated in negotiating the agreements as
well as internally developed estimates that include assumptions related to the market opportunity, estimated
development costs, probability of success and the time needed to commercialize a product candidate pursuant to the
license. In validating our best estimate of selling price, we evaluate whether changes in the key assumptions used to
determine our best estimate of selling price will have a significant effect on the allocation of arrangement
consideration between deliverables. We recognize consideration allocated to an individual element when all other
revenue recognition criteria are met for that element.
Our multiple-element revenue arrangements generally include the following:
•
•
•
Exclusive Licenses. The deliverables under our collaboration agreements generally include exclusive
licenses to discover, develop, manufacture and commercialize compounds with respect to one or more
specified HMT targets. To account for this element of the arrangement, we evaluate whether the
exclusive license has standalone value from the undelivered elements to the collaboration partner based
on the consideration of the relevant facts and circumstances of each arrangement, including the research
and development capabilities of the collaboration partner and other market participants. Arrangement
consideration allocated to licenses may be recognized upon delivery of the license if facts and
circumstances indicate that the license has standalone value apart from the undelivered elements, which
generally include research and development services. Arrangement consideration allocated to licenses is
deferred if facts and circumstances indicate that the delivered license does not have standalone value
from the undelivered elements.
We have determined that some of our exclusive licenses lack standalone value apart from the related
research and development services, and in those circumstances we recognize collaboration revenue from
non-refundable exclusive license fees on a straight-line basis over the contracted or estimated period of
performance, which is generally the period over which the research and development services are to be
provided.
Research and Development Services. The deliverables under our collaboration and license agreements
generally include deliverables related to research and development services to be performed on behalf of
the collaboration partner. As the provision of research and development services is a part of our central
operations, when we are principally responsible for the performance of these services under the
agreements, we recognize revenue on a gross basis for research and development services as those
services are performed.
Option Arrangements. Our arrangements may provide a collaborator with the right to select a target for
licensing either at the inception of the arrangement or within an initial pre-defined selection period,
which may, in certain cases, include the right of the collaborator to extend the selection period. Under
these agreements, fees may be due to us at the inception of the arrangement as an upfront fee or
payment, upon the exercise of an option to acquire a license or upon extending the selection period as an
extension fee or payment.
The accounting for option arrangements is dependent on the nature of the options granted to the
collaboration partner. Options are considered substantive if, at the inception of the arrangement, we are
at risk as to whether the collaboration partner will choose to exercise the options to secure exclusive
licenses. Factors that are considered in evaluating whether options are substantive include the overall
objective of the arrangement, the benefit the collaborator might obtain from the arrangement without
exercising the options, the cost to exercise the options relative to the total upfront consideration and the
additional financial commitments or economic penalties imposed on the collaborator as a result of
exercising the options. For arrangements under which the option to secure licenses is considered
substantive, we do not consider the licenses to be deliverables at the inception of the arrangement. For
arrangements where the option to secure licenses is not considered substantive, we consider the license
to be a deliverable at the inception of the arrangement and, upon delivery of the license, would apply the
multiple-element revenue arrangement criteria to the license and any other deliverables to determine the
appropriate revenue recognition. None of the options to secure exclusive licenses included in our
collaborative arrangements have been determined to be substantive.
Milestone Revenue. Our collaboration and license agreements generally include contingent milestone payments
related to specified preclinical research and development milestones, clinical development milestones, regulatory
milestones and sales-based milestones. Preclinical research and development milestones are typically payable upon
the selection of a compound candidate for the next stage of research and development. Clinical development
milestones are typically payable when a product candidate initiates or advances in clinical trial phases or achieves
defined clinical events, such as proof-of-concept. Regulatory milestones are typically payable upon submission for
marketing approval with regulatory authorities, upon receipt of actual marketing approvals for a compound or for
additional indications or upon the first commercial sale. Sales-based milestones are typically payable when annual
sales reach specified levels.
At the inception of each arrangement that includes milestone payments, we evaluate whether each milestone is
substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes
an assessment of whether:
•
•
•
the consideration is commensurate with either the entity’s performance to achieve the milestone or the
enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the
entity’s performance to achieve the milestone;
the consideration relates solely to past performance; and
the consideration is reasonable relative to all of the deliverables and payment terms within the
arrangement.
We evaluate factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve
the respective milestone, the level of effort and investment required to achieve the respective milestone and whether
the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in
making this assessment.
Non-refundable preclinical research and development, clinical development and regulatory milestones that are
expected to be achieved as a result of our efforts during the period of our performance obligations under the
collaboration and license agreements are generally considered to be substantive and are recognized as revenue upon
the achievement of the milestone, assuming all other revenue recognition criteria are met. If not considered to be
substantive, revenue from achievement of milestones is initially deferred and recognized over the remaining term of
our performance obligations. Milestones that are not considered substantive because we do not contribute effort to
their achievement are recognized as revenue upon achievement, assuming all other revenue recognition criteria are
met, as there are no undelivered elements remaining and no continuing performance obligations on our part.
We are required to adopt new revenue accounting guidance in the first quarter of 2018, which we expect will impact
this policy, the amount and timing of our future revenue recognition, and the amount of revenue previously
recognized in our published financial statements. For further discussion, see Note 2, Summary of Significant
Accounting Policies—Recent Accounting Pronouncements, in the accompanying Notes to Consolidated Financial
Statements included in Item 15. of Part IV of this Annual Report on Form 10-K.
Research and Development Expenses
Research and development expenses consist of expenses incurred in performing research and development activities,
including compensation and benefits, facilities expenses, overhead expenses, clinical trial and related clinical
manufacturing expenses, fees paid to clinical research organizations and other outside expenses. Research and
development costs are expensed as incurred if no planned alternative future use exists for the technology and if the
payment is not payment for future services. We defer and capitalize our nonrefundable advance payments that are
for research and development activities until the related goods are delivered or the related services are performed. In
circumstances where our collaboration and license agreements provide for equally co-funded global development
under joint risk sharing collaborations, amounts received from collaboration partners for such co-funding are
recorded as a reduction to research and development expense.
Accrued Research and Development Expenses
As part of the process of preparing our financial statements, we are required to estimate our accrued expenses as of
each balance sheet date. This process involves reviewing open contracts and purchase orders, communicating with
our personnel to identify services that have been performed on our behalf and estimating the level of service
performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified
of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or
when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in
our financial statements based on facts and circumstances known to us at that time. We periodically confirm the
accuracy of our estimates with the service providers and make adjustments if necessary. Examples of estimated
accrued research and development expenses include fees paid to:
•
•
•
•
contract research organizations in connection with clinical trials;
investigative sites in connection with clinical trials;
vendors in connection with non-clinical development activities; and
vendors related to product manufacturing, development and distribution of clinical supplies.
We generally accrue expenses related to research and development activities based on the services received and
efforts expended pursuant to contracts with multiple contract research organizations that conduct and manage
clinical trials on our behalf as well as other vendors that provide research and development services. The financial
terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven
payment flows. There may be instances in which payments made to our vendors will exceed the level of services
provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such
as the successful enrollment of subjects and the completion of clinical trial milestones. In accruing service fees, we
estimate the time period over which services will be performed and the level of effort to be expended in each period.
If the actual timing of the performance of services or the level of effort varies from our estimate, we would adjust
the accrual or prepaid accordingly.
Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates
of the status and timing of services performed differ from the actual status and timing of services performed we may
report amounts that are too high or too low in any particular period. To date, there have been no material differences
from our estimates to the amount actually incurred.
Stock-Based Compensation
We issue stock-based compensation awards to employees, including stock options and restricted stock, and offer an
employee stock purchase plan. We measure stock-based compensation expense related to these awards based on the
fair value of the award on the date of grant and recognize stock-based compensation expense on a straight-line basis
over the requisite service period of the awards, which generally equals the vesting period. We have selected the
Black-Scholes option pricing model to determine the fair value of stock option awards which requires the input of
various assumptions that require management to apply judgment and make assumptions and estimates, including:
•
•
•
•
the expected life of the stock option award, which we calculate using the simplified method as we have
insufficient historical information regarding our stock options to provide a basis for estimate;
the expected volatility of the underlying common stock, which we estimate using a blended approach
encompassing our historical experience and the historical volatility of a peer group of comparable
publicly traded companies with product candidates in similar stages of development;
the expected risk-free interest rate based on the U.S. Treasury zero coupon rate with a remaining term
approximating the expected term; and
the expected dividend yield of zero.
Our assumptions may differ from those used in prior periods, and changes in the assumptions may have a significant
impact on the fair value of future equity awards, which could have a material impact on our consolidated financial
statements.
We recognize forfeitures for employee and non-employee grants at the time they occur. The actual expense
recognized over the vesting period will only represent those options that vest.
Since our initial public offering, the exercise price per share of all option grants has been set at the closing price of
our common stock on The NASDAQ Global Market on the applicable date of grant, which our board of directors
believes represents the fair value of our common stock.
Going Concern
We continually evaluate our ability to continue as a going concern within one year of the date of issuance of
financial statements in both our Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Our evaluation
entails analyzing forward looking budgets and forecasts for expectations of our cash needs, and comparing those
needs to our current cash, cash equivalent and marketable security balances.
Acquired In-Process Research and Development
We record upfront payments that relate to the acquisition of a development-stage product candidate as research and
development expense in the period in which they are incurred, provided that the acquired development-stage product
candidate did not also include processes or activities that would constitute a business, the product candidate has not
achieved regulatory approval for marketing and, absent obtaining such approval, has no alternative future use. In the
first quarter of 2015, we accounted for the upfront payment paid to Eisai in connection with the amended and
restated collaboration and license agreement, pursuant to which we reacquired the worldwide rights, excluding
Japan, to tazemetostat, as an acquisition of in-process research and development.
Recent Accounting Pronouncements
For detailed information regarding recently issued accounting pronouncements and the expected impact on our
consolidated financial statements, see Note 2, Summary of Significant Accounting Policies—Recent Accounting
Pronouncements, in the accompanying Notes to Consolidated Financial Statements included in Item 15. of Part IV
of this Annual Report on Form 10-K.
Item 7A. Quantitative and Qualitative Disclosures about Market Risk
The market risk inherent in our financial instruments and in our financial position represents the potential loss
arising from adverse changes in interest rates. As of December 31, 2017, we had cash equivalents and available for
sale securities of $276.4 million consisting of money market funds, corporate bonds, commercial paper and
government-related obligations. Our primary exposure to market risk is interest rate sensitivity, which is affected by
changes in the general level of U.S. interest rates. We estimate that a hypothetical 100-basis point change in market
interest rates would impact the fair value of our investment portfolio as of December 31, 2017 by $0.1 million.
We contract with CROs and manufacturers globally. Transactions with these providers are predominantly settled in
U.S. dollars and, therefore, we believe that we have only minimal exposure to foreign currency exchange risks. We
do not hedge against foreign currency risks.
Item 8.
Financial Statements and Supplementary Data
The information required by this item may be found on pages F-2 through F-32 as listed below, including the
quarterly information required by this item.
INDEX
Report of Independent Registered Public Accounting Firm ...............................................................................
Consolidated Balance Sheets ..............................................................................................................................
Consolidated Statements of Operations and Comprehensive Loss .....................................................................
Consolidated Statements of Cash Flows .............................................................................................................
Consolidated Statements of Stockholders’ Equity ..............................................................................................
Notes to Consolidated Financial Statements .......................................................................................................
Page
F-2
F-3
F-4
F-5
F-6
F-7
Item 9.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
None.
Item 9A. Controls and Procedures
Disclosure Controls and Procedures
Our management, with the participation of our principal executive officer and principal financial officer, evaluated
the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the
Securities Exchange Act of 1934, as amended, or the Exchange Act) as of December 31, 2017. In designing and
evaluating our disclosure controls and procedures, management recognized that any controls and procedures, no
matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and our
management necessarily applied its judgment in evaluating the cost-benefit relationship of possible controls and
procedures. Based on this evaluation, our principal executive officer and principal financial officer concluded that as
of December 31, 2017, our disclosure controls and procedures were (1) designed to ensure that material information
relating to us is made known to our management including our principal executive officer and principal financial
officer by others, particularly during the period in which this report was prepared and (2) effective, in that they
provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under
the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s
rules and forms.
Management’s Annual Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting.
Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the
Exchange Act as a process designed by, or under the supervision of, our principal executive and principal financial
officers and effected by our board of directors, management and other personnel, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles and includes those policies and procedures that:
•
•
•
pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the
transactions and dispositions of the assets of our company;
provide reasonable assurance that transactions are recorded as necessary to permit preparation of
financial statements in accordance with generally accepted accounting principles, and that receipts and
expenditures of our company are being made only in accordance with authorizations of our management
and directors; and
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use
or disposition of our assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.
Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to
financial statement preparation and presentation. Projections of any evaluation of effectiveness to future periods are
subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of
compliance with the policies or procedures may deteriorate. Our management assessed the effectiveness of our
internal control over financial reporting as of December 31, 2017. In making this assessment, management used the
criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO, in Internal
Control—Integrated Framework (2013). Based on its assessment, management believes that, as of December 31,
2017, our internal control over financial reporting is effective based on those criteria.
Changes in Internal Control over Financial Reporting
No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the
Exchange Act) occurred during the three months ended December 31, 2017 that has materially affected, or is
reasonably likely to materially affect, our internal control over financial reporting.
Item 9B. Other Information
Election of Director
On March 8, 2018, the Board of Directors (the “Board”) of Epizyme, Inc., a Delaware corporation (the “Company”)
elected Michael F. Giordano, M.D. to the Board as a Class III Director, with a term expiring at the 2019 annual
meeting of stockholders. Dr. Giordano has not been elected to any committees of the Board.
Michael F. Giordano, M.D., has served as a clinical advisor to the company since December 2017. From 1999 to
2017, Dr. Giordano was with Bristol-Myers Squibb (BMS), most recently serving as senior vice president and head
of development, oncology and immuno-oncology. In this role, he was responsible for the development strategy for
this therapeutic area, as well as for the direction of eight teams working on innovative medicines to improve the
standard of care for patients, including Opdivo®, Yervoy®, Empliciti™, Ixempra®, and Sprycel®. Dr. Giordano
also held positions of increasing responsibility within the BMS research and development organization, leading the
development of more than a dozen molecules in the United States, Europe and Asia. From 1990 to 1999, he served
as assistant professor of medicine and founding director of the Cornell Clinical Trials Unit, a National Institutes of
Health and Industry-supported AIDS clinical trials center at New York Hospital-Cornell University Medical Center.
He earned his M.D. and completed his residency and fellowship training at New York Presbyterian-Weill Cornell
Medical Center, and received his B.A. in natural sciences from The Johns Hopkins University.
There are no arrangements or understandings between Dr. Giordano and any other person pursuant to which he was
elected as a director of the Company. Dr. Giordano has served as a consultant to the Company since December 1,
2017. He has been providing guidance, advice and strategic oversight in regard to the clinical development program
for the Company. Dr. Giordano has been compensated at a rate of twelve thousand dollars ($12,000) a week, which
was expanded to eighteen thousand dollars ($18,000) a week based on enhanced services. His consulting
arrangement is scheduled to terminate on March 31, 2018, with the ability to be extended for an appropriate period
to wind-down the consulting services.
In accordance with the Company’s director compensation program, Dr. Giordano will receive an annual cash
retainer of $35,000 for service on the Board, which is payable quarterly in arrears. Under the Company’s director
compensation program, Dr. Giordano may elect to receive such retainer in shares of common stock of the Company.
In addition, under the Company’s director compensation program, upon his election as a director, Dr. Giordano was
granted an option on March 8, 2018 to purchase 25,000 shares of the Company’s common stock at an exercise price
per share of $17.60. This option vests as to 25% of the shares on the first anniversary of the grant date and as to an
additional 2.0833% of the shares at the end of each successive month following the first anniversary of the grant
date until the fourth anniversary of the grant date and becomes exercisable in full upon the occurrence of a change in
control of the Company. For a full description of the Company’s director compensation program, see the section
entitled “Corporate Governance—Director Compensation—2017 Director Compensation Program” in the
Company’s definitive proxy statement for the 2017 Annual Meeting of Stockholders.
Also in connection with Dr. Giordano’s election to the Board, Dr. Giordano will enter into the Company’s standard
form of indemnification agreement, a copy of which was filed as Exhibit 10.16 to Amendment No. 1 to the
Company’s Registration Statement on Form S-1 (File No. 333- 187982) filed with the SEC on April 26, 2013.
Pursuant to the terms of this agreement, the Company may be required, among other things, to indemnify Dr.
Giordano for some expenses, including attorneys’ fees, judgments, fines and settlement amounts incurred by him in
any action or proceeding arising out of his service as one of our directors.
Date of 2018 Annual Meeting
The Company intends to hold its annual meeting of stockholders on Friday, May 18, 2018 (the “2018 Annual
Meeting”). Because the expected date of the 2018 Annual Meeting represents a change of more than 30 calendar
days from the date of the anniversary of the Company’s 2017 annual meeting of stockholders, the Company is
providing revised deadlines for receipt of stockholder proposals and nominations with respect to the 2018 Annual
Meeting.
Pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), stockholders
may present proposals for inclusion in the Company’s proxy statement for the 2018 Annual Meeting by submitting
their proposals to the Company a reasonable time before the Company begins to print and send its proxy materials.
The Company will consider any such proposal must be provided not later than the close of business on or prior to
March 24, 2018, the date corresponding to the deadline for stockholder proposals under the Company’s bylaws
described below, to be timely. Any such proposals must comply with the applicable requirements of Rule 14a-8 of
the Exchange Act regarding the inclusion of stockholder proposals in company-sponsored proxy materials and other
applicable laws and must be received in writing by the Company at the following address: Epizyme, Inc., 400
Technology Square, Cambridge, Massachusetts 02139, Attention: IR.
Under the Company’s bylaws, stockholders may also propose a director nomination or present a proposal at the
2018 Annual Meeting if advance written notice is timely given to the Secretary of the Company, at the Company’s
principal executive offices, in accordance with the Company’s bylaws. To be timely, notice by a stockholder of any
proposal or nomination must be provided not later than the close of business on or prior to March 24, 2018. The
Company’s bylaws specify requirements relating to the content of the notice that stockholders much provide, and
any such notices should be received in writing at the following address: Epizyme, Inc., 400 Technology Square,
Cambridge, Massachusetts 02139, Attention: Corporate Secretary.
PART III
Certain information required by Part III is omitted from this Annual Report on Form 10-K and is incorporated by
reference from our definitive proxy statement relating to our 2018 annual meeting of stockholders, pursuant to
Regulation 14A of the Securities Exchange Act of 1934, as amended, also referred to in this Annual Report on Form
10-K as our 2018 Proxy Statement, which we expect to file with the SEC within 120 days of the end of the fiscal
year ended December 31, 2017.
Item 10. Directors, Executive Officers and Corporate Governance
Information regarding our directors, including the audit committee and audit committee financial experts, and
executive officers and compliance with Section 16(a) of the Exchange Act will be included in our 2018 Proxy
Statement and is incorporated herein by reference.
We have adopted a Code of Business Conduct and Ethics for all of our directors, officers and employees as required
by NASDAQ governance rules and as defined by applicable SEC rules. Stockholders may locate a copy of our Code
of Business Conduct and Ethics on our website at www.epizyme.com or request a copy without charge from:
Epizyme, Inc.
Attention: Investor Relations
400 Technology Square, 4th Floor
Cambridge, MA 02139
We will post to our website any amendments to the Code of Business Conduct and Ethics, and any waivers that are
required to be disclosed by the rules of either the SEC or NASDAQ.
Item 11.
Executive Compensation
The information required by this item regarding executive compensation will be included in our 2018 Proxy
Statement and is incorporated herein by reference.
Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder
Matters
The information required by this item regarding security ownership of certain beneficial owners and management
and securities authorized for issuance under equity compensation plans will be included in our 2018 Proxy
Statement and is incorporated herein by reference.
Item 13. Certain Relationships and Related Transactions, and Director Independence
The information required by this item regarding certain relationships and related transactions and director
independence will be included in our 2018 Proxy Statement and is incorporated herein by reference.
Item 14.
Principal Accounting Fees and Services
The information required by this item regarding principal accounting fees and services will be included in our 2018
Proxy Statement and is incorporated herein by reference.
PART IV
Item 15.
Exhibits, Financial Statement Schedules
(a)
The following documents are included in this Annual Report on Form 10-K:
1.
The following Report and Consolidated Financial Statements of the Company are included in this
Annual Report:
Report of Independent Registered Public Accounting Firm
Consolidated Balance Sheets
Consolidated Statements of Operations and Comprehensive Loss
Consolidated Statements of Cash Flows
Consolidated Statements of Stockholders’ Equity
Notes to Consolidated Financial Statements
All financial schedules have been omitted because the required information is either presented in
the consolidated financial statements or the notes thereto or is not applicable or required.
Exhibits:1
Description of Exhibit
Restated Certificate of Incorporation of the Registrant (1)
Amended and Restated Bylaws of the Registrant (2)
Amended and Restated Investor Rights Agreement dated as of April 2, 2012 (4)
2008 Stock Incentive Plan (4)
Form of Incentive Stock Option Agreement under 2008 Stock Incentive Plan (4)
Form of Nonstatutory Stock Option Agreement under 2008 Stock Incentive Plan (4)
Form of Restricted Stock Agreement under 2008 Stock Incentive Plan (4)
2013 Stock Incentive Plan (2)
Form of Incentive Stock Option Agreement under 2013 Stock Incentive Plan (2)
Form of Nonstatutory Stock Option Agreement under 2013 Stock Incentive Plan (2)
Form of Restricted Stock Agreement under 2013 Stock Incentive Plan (2)
Form of Restricted Stock Unit Agreement under 2013 Stock Incentive Plan (12)
2013 Employee Stock Purchase Plan (2)
Executive Severance and Change in Control Plan (as amended February 25, 2016) (16)
Employment Offer Letter dated January 28, 2015 by and between the Registrant and Andrew E.
Singer (11)
Employment Offer Letter dated between the Registrant and Robert Bazemore, dated August 5,
2015 (14)
2.
3.
Exhibit
Number
3.1
3.2
4.2
10.1+
10.2+
10.3+
10.4+
10.5+
10.6+
10.7+
10.8+
10.9+
10.10+
10.11+
10.12+
10.13+
10.14+
Employment Offer Letter between the Company and Matthew E. Ros, dated April 15, 2016 (18)
Exhibit
Number
10.15+
10.16
10.17†
10.18†
10.19†
10.20†
10.21☐
10.22
10.23
10.24†
10.25
10.26
10.27
10.28
10.29†
10.30†
10.31†
10.32†
10.33†
10.34†
Description of Exhibit
Employment Offer Letter between the Company and Susan Graf, dated April 25, 2016 (21)
Form of Director and Officer Indemnification Agreement (2)
Collaboration and License Agreement dated as of April 1, 2011 by and between the Registrant and
Eisai Co., Ltd. (3)
License and Collaboration Agreement dated as of April 2, 2012 by and between the Registrant and
Celgene International Sàrl and Celgene Corporation (3)
Companion Diagnostics Agreement dated as of December 18, 2012 between the Registrant and
Eisai Co., Ltd. on the one side and Roche Molecular Systems, Inc. on the other side (3)
First Amendment to the Companion Diagnostics Agreement dated October 23, 2013 between the
Registrant and Eisai Co. Ltd. on the one side and Roche Molecular Systems, Inc. on the other
side (6)
Second Amendment to the Companion Diagnostics Agreement dated November 16, 2015 between
the Registrant and Eisai Co. Ltd. on the one side and Roche Molecular Systems, Inc. on the other
side (16)
Letter Agreement by and between the Registrant and Eisai Co., Ltd. dated as of December 21,
2012 relating to Companion Diagnostics Agreement (4)
Amended and Restated Letter Agreement dated as of March 12, 2015 by and between the
Registrant and Eisai Co., Ltd. relating to the Companion Diagnostics Agreement (13)
Amended and Restated Collaboration and License Agreement dated as of March 12, 2015, by and
between the Registrant and Eisai Co. Ltd. (13)
Lease Agreement dated as of June 15, 2012 between the Registrant and ARE-TECH Square,
LLC (4)
Non-Employee Director Compensation Program (19)
First Amendment to Lease Agreement dated as of September 30, 2013 between the Registrant and
ARE-TECH Square, LLC (5)
Second Amendment to Lease Agreement dated as of May 18, 2016 between the Registrant and
ARE-TECH Square, LLC (20)
Amended and Restated Collaboration and License Agreement dated as of July 8, 2015 by and
between the Registrant and Celgene Corporation and Celgene RIVOT Ltd. (15)
Collaboration and License Agreement dated as of January 8, 2011 by and between the Registrant
and Glaxo Group Limited (3)
Amendment to Collaboration and License Agreement dated as of July 23, 2013 by and between the
Registrant and Glaxo Group Limited (7)
Amendment to Collaboration and License Agreement dated as of February 24, 2014 by and
between the Registrant and Glaxo Group Limited (8)
Amendment to Collaboration and License Agreement dated as of March 18, 2014 by and between
the Registrant and Glaxo Group Limited (8)
Amendment to Collaboration and License Agreement dated as of April 17, 2014 by and between
the Registrant and Glaxo Group Limited (9)
Exhibit
Number
10.35†
10.36
10.37
21.1
23.1
31.1
31.2
32.1
Description of Exhibit
Amendment to Collaboration and License Agreement dated as of October 1, 2014 by and between
the Registrant and Glaxo Group Limited (12)
Third Amendment to Lease Agreement, entered into May 25, 2017 and effective May 18, 2017, by
and between the Company and ARE-TECH Square, LLC (22)
Fourth Amendment to Lease Agreement, entered into May 25, 2017 and effective May 18, 2017,
by and between the Company and ARE-TECH Square, LLC (22)
Subsidiaries of the Registrant (4)
Consent of Ernst & Young LLP (23)
Certification of Principal Executive Officer pursuant to Rules 13a-14(a) or 15d-14(a) of the
Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of
2002. (23)
Certification of Principal Financial Officer pursuant to Rules 13a-14(a) or 15d-14(a) of the
Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of
2002. (23)
Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of The
Sarbanes-Oxley Act of 2002, by Robert B. Bazemore, President and Chief Executive Officer of the
Company, and Susan Graf, Chief Business Officer and Treasurer of the Company. (23)
101.INS
101.SCH
101.CAL
101.LAB
101.PRE
101.DEF
XBRL Instance Document
XBRL Schema Document
XBRL Calculation Linkbase Document
XBRL Labels Linkbase Document
XBRL Presentation Linkbase Document
XBRL Definition Linkbase Document
_____________________________
Management compensatory agreement.
Confidential treatment has been granted as to portions of the exhibit. Confidential materials omitted and filed
separately with the Securities and Exchange Commission.
+
†
☐
Confidential treatment requested as to portions of the exhibit. Confidential materials omitted and filed
separately with the Securities and Exchange Commission.
Incorporated by reference to the Registrant’s Current Report on Form 8-K (File No. 001-35945) filed with
(1)
the Securities and Exchange Commission on June 7, 2013.
(2)
the Securities and Exchange Commission on April 26, 2013.
(3)
the Securities and Exchange Commission on May 13, 2013.
Incorporated by reference to the Registration Statement on Form S-1/A (File No. 333-187892) filed with
Incorporated by reference to the Registration Statement on Form S-1/A (File No. 333-187982) filed with
Incorporated by reference to the Registration Statement on Form S-1 (File No. 333-187982) filed with the
Incorporated by reference to the Quarterly Report on Form 10-Q (File No. 001-35945) filed with the
Incorporated by reference to the Registration Statement on Form S-1 (File No. 333-193569) filed with the
Incorporated by reference to the Registration Statement on Form S-1/A (File No. 333-193569) filed with
Incorporated by reference to the Registrant’s Current Report on Form 8-K (File No. 001-35945) filed with
Incorporated by reference to the Quarterly Report on Form 10-Q (File No. 001-35945) filed with the
Incorporated by reference to the Quarterly Report on Form 10-Q (File No. 001-35945) filed with the
Incorporated by reference to the Registrant’s Current Report on Form 8-K (File No. 001-35945) filed with
Incorporated by reference to the Registrant’s Annual Report on Form 10-K (File No. 001-35945) filed with
Incorporated by reference to the Registrant’s Current Report on Form 8-K (File No. 001-35945) filed with
Incorporated by reference to the Registrant’s Current Report on Form 8-K (File No. 001-35945) filed with
Incorporated by reference to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-35945) filed
Incorporated by reference to the Registrant’s Annual Report on Form 10-K (File No. 001-35945) filed with
Incorporated by reference to the Registration Statement on Form S-3 (File No. 333-210774) filed with the
Incorporated by reference to the Registrant’s Current Report on Form 8-K (File No. 001-35945) filed with
(4)
Securities and Exchange Commission on April 18, 2013.
(5)
Securities and Exchange Commission on October 23, 2013.
(6)
Securities and Exchange Commission on January 27, 2014.
(7)
the Securities and Exchange Commission on January 28, 2014.
(8)
the Securities and Exchange Commission on April 22, 2014.
(9)
Securities and Exchange Commission on May 14, 2014.
(10)
Securities and Exchange Commission on November 6, 2014.
(11)
the Securities and Exchange Commission on February 3, 2015.
(12)
the Securities and Exchange Commission on March 12, 2015.
(13)
the Securities and Exchange Commission on March 16, 2015.
(14)
the Securities and Exchange Commission on August 6, 2015.
(15)
with the Securities and Exchange Commission on August 6, 2015.
(16)
the Securities and Exchange Commission on March 9, 2016.
(17)
Securities and Exchange Commission on April 15, 2016.
(18)
the Securities and Exchange Commission on May 6, 2016.
(19)
Securities and Exchange Commission on May 9, 2016.
(20)
Securities and Exchange Commission on August 8, 2016.
(21)
Securities and Exchange Commission on March 3, 2017.
(22)
and Exchange Commission on May 30, 2017.
(23)
Filed with this Annual Report on Form 10-K.
Incorporated by reference to the Quarterly Report on Form 10-Q (File No. 001-35945) filed with the
Incorporated by reference to the Quarterly Report on Form 10-Q (File No. 001-35945) filed with the
Incorporated by reference to the Annual Report on Form 10-K (File No. 001-35945) filed with the
Incorporated by reference to the Current Report on Form 8-K (File No. 001-35945) filed with the Securities
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
SIGNATURES
Epizyme, Inc.
By:
/s/ Robert B. Bazemore
Robert B. Bazemore
President and Chief Executive Officer
Dated: March 13, 2018
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the
following persons on behalf of the registrant and in the capacities and on the dates indicated:
Name
Title
/s/ Robert B. Bazemore
Robert B. Bazemore
President, Chief Executive Officer, Director
(Principal Executive Officer)
/s/ Susan E. Graf
Susan E. Graf
Chief Business Officer
(Principal Financial Officer)
/s/ Suzanne Fleming
Suzanne Fleming
Senior Vice President, Finance and Treasurer
(Principal Accounting Officer)
/s/ Andrew R. Allen
Andrew R. Allen, M.D., Ph.D.
/s/ Kenneth Bate
Kenneth Bate
/s/ Kevin T. Conroy
Kevin T. Conroy
/s/ Michael Giordano
Michael Giordano, M.D.
/s/ Carl Goldfischer
Carl Goldfischer, M.D.
/s/ David M. Mott
David M. Mott
/s/ Richard F. Pops
Richard F. Pops
/s/ Beth Seidenberg
Beth Seidenberg, M.D.
Director
Director
Director
Director
Director
Director
Director
Director
Date
March 13, 2018
March 13, 2018
March 13, 2018
March 13, 2018
March 13, 2018
March 13, 2018
March 13, 2018
March 13, 2018
March 13, 2018
March 13, 2018
March 13, 2018
EPIZYME, INC.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
Report of Independent Registered Public Accounting Firm ...............................................................................
Consolidated Balance Sheets ..............................................................................................................................
Consolidated Statements of Operations and Comprehensive Loss .....................................................................
Consolidated Statements of Cash Flows .............................................................................................................
Consolidated Statements of Stockholders’ Equity ..............................................................................................
Notes to Consolidated Financial Statements .......................................................................................................
F-2
F-3
F-4
F-5
F-6
F-7
F-1
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Stockholders and Board of Directors of Epizyme, Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Epizyme, Inc. (the Company) as of December
31, 2017 and 2016, the related consolidated statements of operations and comprehensive loss, cash flows, and
stockholders’ equity for each of the three years in the period ended December 31, 2017, and the related notes
(collectively, the “consolidated financial statements”). In our opinion, the consolidated financial statements
present fairly, in all material respects, the financial position of the Company at December 31, 2017 and 2016, and
the results of its operations and its cash flows for each of the three years in the period ended December 31, 2017,
in conformity with U.S. generally accepted accounting principles.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express
an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered
with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be
independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether the financial statements are free of material
misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to
perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an
understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the
effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such
opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial
statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures
included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audits also included evaluating the accounting principles used and significant estimates made by
management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.
/s/ Ernst & Young LLP
We have served as Epizyme, Inc.’s auditor since 2009.
Boston, Massachusetts
March 13, 2018
F-2
EPIZYME, INC.
CONSOLIDATED BALANCE SHEETS
(Amounts in thousands except per share data)
ASSETS
Current assets:
Cash and cash equivalents
Marketable securities
Accounts receivable
Prepaid expenses and other current assets (Note 4)
Total current assets
Property and equipment, net (Note 3)
Restricted cash and other assets
Total assets
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable
Accrued expenses (Note 5)
Current portion of capital lease obligation
Other current liabilities
Total current liabilities
Capital lease obligation, net of current portion
Deferred revenue, net of current portion
Other long-term liabilities
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 5,000 shares authorized; no shares
issued and outstanding
Common stock, $0.0001 par value; 125,000 shares authorized; 69,302 shares
and 58,050 shares issued and outstanding, respectively
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Total stockholders’ equity
Total liabilities and stockholders’ equity
December 31,
2017
December 31,
2016
$
$
$
$
$
$
226,664
49,775
382
8,983
285,804
2,527
1,028
289,359
7,001
17,549
110
4
24,664
—
28,809
515
77,895
164,297
23
6,457
248,672
3,124
645
252,441
4,994
16,007
620
—
21,621
110
28,809
201
—
—
7
723,510
(49)
(488,097)
235,371
289,359
6
555,473
(106)
(353,673)
201,700
252,441
$
$
See notes to consolidated financial statements.
F-3
EPIZYME, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Amounts in thousands except per share data)
Collaboration revenue
Operating expenses:
Research and development
General and administrative
Total operating expenses
Operating loss
Other income, net:
Interest income, net
Other income, net
Other income, net
Loss before income taxes
Income tax benefit
Net loss
Other comprehensive income (loss):
Unrealized gain on available for sale securities
Comprehensive loss
Loss per share allocable to common stockholders:
Basic
Diluted
Weighted average shares outstanding:
Basic
Diluted
2017
10,000
$
Year Ended December 31,
2016
2015
$
8,007
$
2,560
109,661
37,181
146,842
(136,842)
91,461
28,372
119,833
(111,826)
111,209
23,900
135,109
(132,549)
2,165
32
2,197
(134,645)
336
$ (134,309)
1,531
83
1,614
(110,212)
—
$ (110,212)
94
79
173
(132,376)
—
$ (132,376)
57
$ (134,252)
(106)
$ (110,318)
—
$ (132,376)
$
$
(2.18)
(2.18)
$
$
(1.93)
(1.93)
$
$
(3.32)
(3.32)
61,471
61,471
57,126
57,126
39,839
39,839
See notes to consolidated financial statements.
F-4
EPIZYME, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands)
Year Ended December 31,
2016
2015
2017
$ (134,309)
$ (110,212)
$ (132,376)
—
1,639
11,431
265
—
(368)
(359)
(2,525)
1,967
1,523
—
(17)
320
(120,433)
(126,356)
240,670
—
(984)
113,330
—
1,589
10,568
(51)
—
—
239
(1,542)
341
4,673
(1,900)
106
(182)
(96,371)
(229,887)
65,097
—
(624)
(165,414)
130,438
(483)
(561)
1,589
374
131,357
(130,428)
208,323
77,895
40,000
1,419
9,849
—
27
—
1,813
(1,638)
(3,647)
4,292
7,558
(178)
(44)
(72,925)
—
—
(40,000)
(183)
(40,183)
130,712
(367)
(441)
996
436
131,336
18,228
190,095
$ 208,323
—
—
—
—
$
$
$
$
1,732
—
—
—
$
$
$
$
$
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
Adjustments to reconcile net loss to net cash used in operating
activities:
Acquired in-process research and development
Depreciation and amortization
Stock-based compensation
Amortization of discount on investments
Loss on disposal of property and equipment
Deferred income taxes
Changes in operating assets and liabilities:
Accounts receivable
Prepaid expenses and other current assets
Accounts payable
Accrued expenses
Deferred revenue
Restricted cash and other assets
Other long-term liabilities
Net cash used in operating activities
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of available for sale securities
Proceeds from sales/maturities of available for sale securities
Acquisition of in-process research and development
Purchases of property and equipment
Net cash provided by (used in) investing activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from public offering of common stock, net of commissions
Payment of common stock offering costs
Payment under capital lease obligation
Proceeds from stock options exercised
Issuance of shares under employee stock purchase plan
Net cash provided by financing activities
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
SUPPLEMENTAL DISCLOSURES OF CASH FLOW
INFORMATION:
Equipment acquired under capital lease
Cumulative catch up related to the adoption of ASU 2016-09
Property and equipment included in accounts payable or accruals
Cash paid for income taxes
152,922
(388)
(620)
3,281
677
155,872
148,769
77,895
$ 226,664
$
$
$
$
—
115
58
33
See notes to consolidated financial statements.
F-5
.
C
N
I
,
E
M
Y
Z
I
P
E
Y
T
I
U
Q
E
’
S
R
E
D
L
O
H
K
C
O
T
S
F
O
S
T
N
E
M
E
T
A
T
S
D
E
T
A
D
I
L
O
S
N
O
C
)
a
t
a
d
e
r
a
h
s
t
p
e
c
x
e
s
d
n
a
s
u
o
h
t
n
i
s
t
n
u
o
m
A
(
l
a
t
o
T
d
e
t
a
l
u
m
u
c
c
A
r
e
h
t
O
’
s
r
e
d
l
o
h
k
c
o
t
S
e
v
i
s
n
e
h
e
r
p
m
o
C
d
e
t
a
l
u
m
u
c
c
A
s
s
o
L
t
i
c
i
f
e
D
l
a
n
o
i
t
i
d
d
A
n
I
-
d
i
a
P
l
a
t
i
p
a
C
y
r
u
s
a
e
r
T
k
c
o
t
S
t
n
u
o
m
A
s
e
r
a
h
S
k
c
o
t
S
n
o
m
m
o
C
y
t
i
u
q
E
2
8
2
,
0
6
1
$
6
9
9
9
4
8
,
9
6
3
4
5
4
3
,
0
3
1
)
6
7
3
,
2
3
1
(
2
3
5
,
9
6
1
$
9
8
5
,
1
8
6
5
,
0
1
5
5
9
,
9
2
1
4
7
3
)
6
0
1
(
)
2
1
2
,
0
1
1
(
—
—
—
—
—
—
—
—
—
—
—
—
)
6
0
1
(
$
)
5
8
0
,
1
1
1
(
$
4
6
3
,
1
7
2
$
—
—
—
—
)
6
7
3
,
2
3
1
(
6
9
9
9
4
8
,
9
—
6
3
4
4
4
3
,
0
3
1
$
)
1
6
4
,
3
4
2
(
$
9
8
9
,
2
1
4
$
—
—
—
—
—
)
2
1
2
,
0
1
1
(
—
—
4
7
3
9
8
5
,
1
8
6
5
,
0
1
3
5
9
,
9
2
1
0
0
7
,
1
0
2
$
)
6
0
1
(
$
)
3
7
6
,
3
5
3
(
$
3
7
4
,
5
5
5
$
—
7
5
7
7
6
1
8
2
,
3
1
3
4
,
1
1
4
3
5
,
2
5
1
)
9
0
3
,
4
3
1
(
—
—
—
—
—
7
5
—
)
5
1
1
(
5
1
1
—
—
—
—
—
)
9
0
3
,
4
3
1
(
—
—
7
7
6
1
8
2
,
3
1
3
4
,
1
1
3
3
5
,
2
5
1
1
7
3
,
5
3
2
$
)
9
4
(
$
)
7
9
0
,
8
8
4
(
$
0
1
5
,
3
2
7
$
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
$
$
$
$
3
1
—
—
—
—
4
2
—
—
—
—
—
6
—
1
—
—
—
—
—
7
$
2
1
0
,
6
2
4
,
4
3
4
1
0
2
,
1
3
r
e
b
m
e
c
e
D
t
a
e
c
n
a
l
a
B
g
n
i
r
e
f
f
o
d
n
a
s
n
o
i
s
s
i
m
m
o
c
f
o
t
e
n
(
k
c
o
t
s
n
o
m
m
o
c
f
o
e
c
n
a
u
s
s
I
—
—
4
5
5
,
3
2
0
6
7
,
4
3
6
8
4
4
,
1
0
7
,
6
$
4
7
7
,
5
8
7
,
1
4
—
—
—
9
8
1
,
6
5
7
9
0
,
8
8
7
0
2
2
,
0
2
4
,
5
1
$
0
8
2
,
0
5
0
,
8
5
—
—
—
7
8
6
,
3
8
—
1
7
4
,
8
7
4
3
5
2
,
9
8
6
,
0
1
$
1
9
6
,
1
0
3
,
9
6
g
n
i
r
e
f
f
o
d
n
a
s
n
o
i
s
s
i
m
m
o
c
f
o
t
e
n
(
k
c
o
t
s
n
o
m
m
o
c
f
o
e
c
n
a
u
s
s
I
n
a
l
p
e
s
a
h
c
r
u
p
k
c
o
t
s
e
e
y
o
l
p
m
e
r
e
d
n
u
s
e
r
a
h
s
f
o
e
c
n
a
u
s
s
I
5
1
0
2
,
1
3
r
e
b
m
e
c
e
D
t
a
e
c
n
a
l
a
B
s
s
o
l
t
e
N
n
o
i
t
a
s
n
e
p
m
o
c
d
e
s
a
b
-
k
c
o
t
S
s
n
o
i
t
p
o
k
c
o
t
s
f
o
e
s
i
c
r
e
x
E
)
3
8
4
$
f
o
s
t
s
o
c
9
0
-
6
1
0
2
U
S
A
f
o
n
o
i
t
p
o
d
a
e
h
t
o
t
d
e
t
a
l
e
r
p
u
h
c
t
a
c
e
v
i
t
a
l
u
m
u
C
)
2
e
t
o
N
(
g
n
i
r
e
f
f
o
d
n
a
s
n
o
i
s
s
i
m
m
o
c
f
o
t
e
n
(
k
c
o
t
s
n
o
m
m
o
c
f
o
e
c
n
a
u
s
s
I
)
8
8
3
$
f
o
s
t
s
o
c
s
t
i
n
u
k
c
o
t
s
d
e
t
c
i
r
t
s
e
r
f
o
g
n
i
t
s
e
v
d
n
a
s
n
o
i
t
p
o
k
c
o
t
s
f
o
e
s
i
c
r
e
x
E
n
a
l
p
e
s
a
h
c
r
u
p
k
c
o
t
s
e
e
y
o
l
p
m
e
r
e
d
n
u
s
e
r
a
h
s
f
o
e
c
n
a
u
s
s
I
s
e
i
t
i
r
u
c
e
s
e
l
a
s
r
o
f
e
l
b
a
l
i
a
v
a
n
o
n
i
a
g
d
e
z
i
l
a
e
r
n
U
n
o
i
t
a
s
n
e
p
m
o
c
d
e
s
a
b
-
k
c
o
t
S
n
a
l
p
e
s
a
h
c
r
u
p
k
c
o
t
s
e
e
y
o
l
p
m
e
r
e
d
n
u
s
e
r
a
h
s
f
o
e
c
n
a
u
s
s
I
s
e
i
t
i
r
u
c
e
s
e
l
a
s
r
o
f
e
l
b
a
l
i
a
v
a
n
o
s
s
o
l
d
e
z
i
l
a
e
r
n
U
6
1
0
2
,
1
3
r
e
b
m
e
c
e
D
t
a
e
c
n
a
l
a
B
s
s
o
l
t
e
N
7
1
0
2
,
1
3
r
e
b
m
e
c
e
D
t
a
e
c
n
a
l
a
B
s
s
o
l
t
e
N
n
o
i
t
a
s
n
e
p
m
o
c
d
e
s
a
b
-
k
c
o
t
S
s
n
o
i
t
p
o
k
c
o
t
s
f
o
e
s
i
c
r
e
x
E
)
7
6
3
$
f
o
s
t
s
o
c
F-6
.
s
t
n
e
m
e
t
a
t
s
l
a
i
c
n
a
n
i
f
d
e
t
a
d
i
l
o
s
n
o
c
o
t
s
e
t
o
n
e
e
S
EPIZYME, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. The Company
Epizyme, Inc. (collectively referred to with its wholly owned, controlled subsidiary, Epizyme Securities
Corporation, as “Epizyme” or the “Company”) is a clinical-stage biopharmaceutical company that is committed to
rewriting treatment for cancer and other serious diseases through discovering, developing, and commercializing
novel epigenetic medicines. By focusing on the genetic drivers of disease, the Company’s science seeks to match
targeted medicines with the patients who need them. The Company is broadly developing its lead product candidate,
tazemetostat, an oral, first-in-class selective inhibitor of the EZH2 histone methyltransferase (HMT), in a range of
cancer types and settings, and developing the lead development candidate in the Company’s novel G9a program,
EZM8266, for the treatment of sickle cell disease.
Through December 31, 2017, the Company has raised, including amounts received under collaboration agreements,
an aggregate of $891.6 million to fund its operations, of which $217.8 million was non-equity funding through its
collaboration agreements, $597.8 million was from the sale of common stock in the Company’s public offerings and
$76.0 million was from the sale of redeemable convertible preferred stock in private financings prior to the
Company’s initial public offering in May 2013. As of December 31, 2017, the Company had $276.4 million in cash,
cash equivalents and marketable securities.
The Company commenced active operations in early 2008. Since its inception, the Company has generated an
accumulated deficit of $488.1 million through December 31, 2017 and will require substantial additional capital to
fund its research and development. The Company is subject to risks common to companies in the biotechnology
industry, including, but not limited to, risks of failure of clinical trials and preclinical studies, the need to obtain
additional financing to fund the future development and commercialization of tazemetostat and the rest of its
pipeline, the need to obtain marketing approval for its product candidates, the need to successfully commercialize
and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary
technology, compliance with government regulations, development by competitors of technological innovations and
ability to transition from clinical-stage manufacturing to commercial-stage production of products.
2. Summary of Significant Accounting Policies
Principles of Consolidation
The consolidated financial statements include the accounts of the Company and its wholly owned, controlled
subsidiary, Epizyme Securities Corporation. All intercompany transactions and balances of subsidiaries have been
eliminated in consolidation.
Use of Estimates
The preparation of these consolidated financial statements in accordance with accounting principles generally
accepted in the United States requires management to make estimates, judgments and assumptions that affect the
reported amounts of assets and liabilities and disclosures of contingent assets and liabilities, as of the date of the
consolidated financial statements, and the reported amounts of collaboration revenue and expenses during the
reporting period. Actual results and outcomes may differ materially from management’s estimates, judgments and
assumptions.
Subsequent Events
The Company considers events or transactions that occur after the balance sheet date but before the consolidated
financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that
require additional disclosure. The Company evaluated all events and transactions through the date these financial
statements were filed with the Securities and Exchange Commission.
F-7
Cash and cash equivalents
The Company considers all highly liquid securities with original final maturities of three months or less from the
date of purchase to be cash equivalents. Cash and cash equivalents are comprised of funds in money market
accounts, commercial paper and corporate notes.
Marketable securities
The Company classifies marketable securities with a remaining maturity when purchased of greater than three
months as available-for-sale. The Company considers all available-for-sale securities, including those with maturity
dates beyond 12 months, as available to support current operational liquidity needs and therefore classifies all
securities with maturity dates beyond 90 days at the date of purchase as current assets within the consolidated
balance sheets. Available-for-sale securities are maintained by the Company’s investment managers and may consist
of commercial paper, high-grade corporate notes, U.S. Treasury securities, and U.S. government agency securities.
Available-for-sale securities are carried at fair value with the unrealized gains and losses included in other
comprehensive income (loss) as a component of stockholders’ equity until realized. Any premium or discount
arising at purchase is amortized and/or accreted to interest income and/or expense over the life of the instrument.
Realized gains and losses are determined using the specific identification method and are included in other income
(expense).
The aggregate fair value of securities held by the Company in an unrealized loss position for less than twelve
months as of December 31, 2017 was $42,783,000, which consisted of 4 commercial paper securities, 14 corporate
notes securities and 1 U.S. government agency security. The aggregate fair value of securities held by the Company
in an unrealized loss position for less than twelve months as of December 31, 2016 was $134,860,000, which
consisted of 11 commercial paper securities and 23 corporate notes securities. If any adjustment to fair value reflects
a decline in value of the investment, the Company considers all available evidence to evaluate the extent to which
the decline is “other-than-temporary” and, if so, mark the investment to market through a charge to the Company’s
statement of operations and comprehensive loss.
The Company does not intend to sell and it is unlikely that the Company will be required to sell the above
investments before recovery of their amortized cost bases, which may be maturity. The Company determined there
was no material change in the credit risk of the above investments, and as a result, the Company determined it did
not hold any investments with an other-than-temporary impairment as of December 31, 2017 and 2016.
The following table summarizes the available for sale securities held at December 31, 2017 (in thousands):
Description
Commercial paper
Corporate notes
U.S. government agency securities and U.S.
Treasuries
Total
Amortized Cos
t
16,964
31,610
$
1,250
49,824
$
Unrealized
Gains
Unrealized
Losses
Fair
Value
$
$
—
—
—
—
$
$
(6) $ 16,958
31,567
(43)
—
1,250
(49) $ 49,775
The following table summarizes the available for sale securities held at December 31, 2016 (in thousands):
Description
Commercial paper
Corporate notes
U.S. government agency securities and U.S.
Treasuries
Total
Amortized Cos
t
68,407
70,489
$
25,507
164,403
$
F-8
Unrealized
Gains
Unrealized
Losses
$
$
—
—
7
7
$
$
Fair Value
(32) $ 68,375
70,408
(81)
—
25,514
(113) $164,297
The Company did not hold any available-for-sale securities prior to the second quarter of 2016. Certain short-term
debt securities with original maturities of less than 90 days are included in cash and cash equivalents within the
consolidated balance sheets and are not included in the tables above.
All marketable securities held at December 31, 2017 and 2016 have maturities of less than one year.
The amortized cost of available-for-sale securities is adjusted for amortization of premiums and accretion of
discounts to maturity. At December 31, 2017, the balance in the Company’s accumulated other comprehensive loss
was composed solely of activity related to the Company’s available-for-sale marketable securities. There were no
realized gains or losses recognized on the sale or maturity of available-for-sale securities during the year ended
December 31, 2017 and as a result, the Company did not reclassify any amounts out of accumulated other
comprehensive loss for the same period.
The aggregate fair value of available-for-sale securities held by the Company in an unrealized loss position for less
than twelve months as of December 31, 2017 was $42.8 million. The aggregate unrealized loss for those securities in
an unrealized loss position for less than twelve months as of December 31, 2017 was less than $0.1 million. The
Company determined that there was no material change in the credit risk of any of its investments. As a result, the
Company determined it did not hold any investments with any other-than-temporary impairment as of December 31,
2017. The weighted-average maturity of the Company’s portfolio was approximately one month at December 31,
2017.
Fair Value Measurements
The Financial Accounting Standards Board, or FASB, Codification Topic 820, Fair Value Measurements and
Disclosures, requires the use of valuation techniques that are consistent with the market approach, the income
approach and/or the cost approach. The market approach uses prices and other relevant information generated by
market transactions involving identical or comparable assets and liabilities. The income approach uses valuation
techniques to convert future amounts, such as cash flows or earnings, to a single present amount on a discounted
basis. The cost approach is based on the amount that currently would be required to replace the service capacity of
an asset (replacement cost). Valuation techniques should be consistently applied. GAAP also establishes a fair value
hierarchy which requires an entity to maximize the use of observable inputs, where available, and minimize the use
of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to
measure fair value:
Level 1
Quoted prices in active markets for identical assets or liabilities.
Level 2
Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted
prices in markets that are not active; or other inputs that are observable or can be corroborated by
observable market data for substantially the full term of the assets or liabilities.
Level 3
Unobservable inputs that are supported by little or no market activity and that are significant to the fair
value of the assets or liabilities.
F-9
The Company’s financial instruments as of December 31, 2017 consisted primarily of cash and cash equivalents,
marketable securities and accounts receivable and accounts payable. The Company’s financial instruments as of
December 31, 2016 consisted primarily of cash and cash equivalents, marketable securities, accounts receivable and
accounts payable. As of December 31, 2017 and December 31, 2016, the Company’s financial assets recognized at
fair value consisted of the following:
Cash equivalents
Marketable securities:
Commercial paper
Corporate notes
U.S. government agency securities and
treasuries
Total
Cash equivalents
Marketable securities:
Commercial paper
Corporate notes
U.S. government agency securities and
treasuries
Total
Fair Value as of December 31, 2017
Total
Level 1
Level 2
Level 3
$207,251
$207,251
$
—
$
(In thousands)
16,958
31,567
—
—
16,958
31,567
1,250
$257,026
—
$207,251
1,250
$ 49,775
$
—
—
—
—
—
Fair Value as of December 31, 2016
Total
Level 1
Level 2
Level 3
$ 62,854
$ 59,862
$
2,992
$
(In thousands)
68,375
70,408
—
—
68,375
70,408
25,514
$227,151
—
$ 59,862
25,514
$167,289
$
—
—
—
—
—
Cash equivalents and marketable securities have been initially valued at the transaction price and subsequently
valued, at the end of each reporting period, utilizing third-party pricing services or other market observable data.
The Company measures its cash equivalents at fair value on a recurring basis. The Company classifies the majority
of its cash equivalents within Level 1 of the fair value hierarchy because they are valued using observable inputs that
reflect quoted prices for identical assets in active markets. The Company measures its marketable securities at fair
value on a recurring basis and classifies those instruments within Level 2 of the fair value hierarchy. The pricing
services used by management utilize industry standard valuation models, including both income and market based
approaches and observable market inputs to determine the fair value of marketable securities.
Going Concern
At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt
about the Company’s ability to continue as a going concern within one year after the date that the financial
statements are issued. The Company is required to make certain additional disclosures if it concludes substantial
doubt exists and it is not alleviated by the Company’s plans or when its plans alleviate substantial doubt about the
Company’s ability to continue as a going concern.
The Company’s evaluation entails analyzing prospective operating budgets and forecasts for expectations of the
Company’s cash needs, and comparing those needs to the current cash, cash equivalent and marketable security
balances. After considering the Company’s current research and development plans and the timing expectations
related to the progress of its programs, and after considering its existing cash, cash equivalents and marketable
securities as of December 31, 2017, the Company did not identify conditions or events that raise substantial doubt
about the Company’s ability to continue as a going concern within one year from the date these financial statements
were issued.
F-10
Accounts Receivable
Accounts receivable are amounts due from collaboration partners as a result of research and development services
provided, reimbursements under equally co-funded global development arrangements or milestones achieved but not
yet paid. The Company considered the need for an allowance for doubtful accounts and has concluded that no
allowance was needed as of December 31, 2017 or 2016, as the estimated risk of loss on its accounts receivable was
determined to be minimal.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk include cash, cash
equivalents, marketable securities and accounts receivable. The Company attempts to minimize the risks related to
cash, cash equivalents and marketable securities by working with highly rated financial institutions that invest in a
broad and diverse range of financial instruments as defined by the Company. The Company has established
guidelines relative to credit ratings and maturities intended to safeguard principal balances and maintain liquidity.
The Company maintains its funds in accordance with its investment policy, which defines allowable investments,
specifies credit quality standards and is designed to limit the Company’s credit exposure to any single issuer.
Accounts receivable represent amounts due from collaboration partners. The Company monitors economic
conditions to identify facts or circumstances that may indicate that any of its accounts receivable are at risk of
collection.
Acquired In-Process Research and Development
The Company records upfront payments that relate to the acquisition of a development-stage product candidate as
research and development expense in the period in which they are incurred, provided that the acquired development-
stage product candidate did not also include processes or activities that would constitute a business, the product
candidate has not achieved regulatory approval for marketing and, absent obtaining such approval, has no alternative
future use. In the first quarter of 2015, the Company accounted for the upfront payment paid to Eisai Co., Ltd.,
(‘Eisai”), in connection with the amended and restated collaboration and license agreement, pursuant to which the
Company reacquired the worldwide rights, excluding Japan, to tazemetostat, as in-process research and development
expense.
Property and Equipment
The Company records property and equipment at cost. Property and equipment acquired under a capital lease is
recorded at the lesser of the present value of the minimum lease payments under the capital lease or the fair value of
the leased property at lease inception. The Company calculates depreciation and amortization using the straight-line
method over the following estimated useful lives:
Asset Category
Laboratory equipment
Office furniture and equipment
Leasehold improvements
Useful Lives
5 - 10 years
3 - 10 years
3 - 10 years or term of respective lease, if shorter
Amortization of capital lease assets is included in depreciation expense. The Company capitalizes expenditures for
new property and equipment and improvements to existing facilities and charges the cost of maintenance to expense.
The Company eliminates the cost of property retired or otherwise disposed of, along with the corresponding
accumulated depreciation, from the related accounts, and the resulting gain or loss is reflected in the results of
operations.
F-11
Impairment of Long-Lived Assets
The Company reviews long-lived assets to be held and used, including property and equipment, for impairment
whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not
be recoverable.
Evaluation of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the
asset or asset group and its eventual disposition. In the event that such cash flows are not expected to be sufficient to
recover the carrying amount of the asset or asset group, the assets are written down to their estimated fair values. No
such impairments were recorded during 2017, 2016 or 2015.
Income Taxes
The Company records deferred income taxes to recognize the effect of temporary differences between tax and
financial statement reporting. The Company calculates the deferred taxes using enacted tax rates expected to be in
place when the temporary differences are realized and records a valuation allowance to reduce deferred tax assets if
it is determined that it is more likely than not that all or a portion of the deferred tax asset will not be realized. The
Company considers many factors when assessing the likelihood of future realization of deferred tax assets, including
recent earnings results, expectations of future taxable income, carryforward periods available and other relevant
factors. The Company records changes in the required valuation allowance in the period that the determination is
made.
The Company assesses its income tax positions and records tax benefits for all years subject to examination based
upon management’s evaluation of the facts, circumstances and information available as of the reporting date. For
those tax positions where it is more likely than not that a tax benefit will be sustained, the Company records the
largest amount of tax benefit with a greater than 50.0% likelihood of being realized upon ultimate settlement with a
taxing authority having full knowledge of all relevant information. For those income tax positions where it is not
more likely than not that a tax benefit will be sustained, the Company does not recognize a tax benefit in the
financial statements. The Company records interest and penalties related to uncertain tax positions, if applicable, as
a component of income tax expense. Refer to Note 6, Income Taxes, for additional information regarding the
Company’s income taxes.
On December 22, 2017, the President of the United States signed into law the Tax Cuts and Jobs Act (“TCJA”). This
legislation makes broad and complex changes to the U.S. tax code, including, but not limited to, (i) reducing the
U.S. federal statutory tax rate from 35% to 21%; (ii) eliminating the corporate alternative minimum tax (AMT) and
changing how existing AMT credits can be realized; (iii) changing rules related to uses and limitations of net
operating loss carryforwards created in tax years beginning after December 31, 2017, and (iv) modifying the
officer’s compensation limitation. The Company recognizes the effects of changes in tax law, including the TCJA,
in the period the law is enacted. Accordingly, the effects of the TCJA have been recognized in the financial
statements for the year ended December 31, 2017.
Revenue Recognition
The Company recognizes revenue when all of the following criteria are met: persuasive evidence of an arrangement
exists; delivery has occurred or services have been rendered; the Company’s price to the customer is fixed or
determinable and collectability is reasonably assured.
The Company has entered into collaboration and license agreements to discover, develop, manufacture and
commercialize compounds directed to specific HMT targets. The terms of these agreements typically contain
multiple deliverables, which may include: (i) licenses, or options to obtain licenses, to compounds directed to
specific HMT targets (referred to as “exclusive licenses”) and (ii) research and development activities to be
performed on behalf of the collaboration partner related to the licensed HMT targets. Payments to the Company
under these agreements may include non-refundable license fees, option fees, exercise fees, payments for research
activities, payments based upon the achievement of certain milestones and royalties on any resulting net product
sales.
F-12
Multiple-Element Revenue Arrangements. The Company’s collaborations primarily represent multiple-element
revenue arrangements. To account for these transactions, the Company determines the elements, or deliverables,
included in the arrangement and allocates arrangement consideration to the various elements based on each
element’s relative selling price. The identification of individual elements in a multiple-element arrangement and the
estimation of the selling price of each element involves significant judgment, including consideration as to whether
each delivered element has standalone value to the collaborator. The Company determines the estimated selling
price for deliverables within each agreement using vendor-specific objective evidence (“VSOE”) of selling price, if
available, or third party evidence of selling price if VSOE is not available, or the Company’s best estimate of selling
price, if neither VSOE nor third party evidence is available. Determining the best estimate of selling price for a
deliverable requires significant judgment. The Company typically uses its best estimate of a selling price to estimate
the selling price for licenses to its proprietary technology, since it often does not have VSOE or third party evidence
of selling price for these deliverables. In those circumstances where the Company applies its best estimate of selling
price to determine the estimated selling price of a license to its proprietary technology, it considers market
conditions as well as entity-specific factors, including those factors contemplated in negotiating the agreements as
well as internally developed estimates that include assumptions related to the market opportunity, estimated
development costs, probability of success and the time needed to commercialize a product candidate pursuant to the
license. In validating its best estimate of selling price, the Company evaluates whether changes in the key
assumptions used to determine its best estimate of selling price will have a significant effect on the allocation of
arrangement consideration between deliverables. The Company recognizes consideration allocated to an individual
element when all other revenue recognition criteria are met for that element.
The Company’s multiple-element revenue arrangements generally include the following:
•
•
•
Exclusive Licenses—The deliverables under the Company’s collaboration agreements generally include
exclusive licenses to discover, develop, manufacture and commercialize compounds with respect to one
or more specified HMT targets. To account for this element of the arrangement, management evaluates
whether the exclusive license has standalone value from the undelivered elements to the collaboration
partner based on the consideration of the relevant facts and circumstances of each arrangement,
including the research and development capabilities of the collaboration partner. The Company may
recognize arrangement consideration allocated to licenses upon delivery of the license if facts and
circumstances indicate that the license has standalone value from the undelivered elements, which
generally include research and development services. The Company defers arrangement consideration
allocated to licenses if facts and circumstances indicate that the delivered license does not have
standalone value from the undelivered elements. The Company has determined that certain of its
exclusive licenses lack standalone value apart from the related research and development services and is
therefore recognizing collaboration revenue from non-refundable exclusive license fees on a straight-
line basis over the contracted or estimated period of performance, which is generally the period over
which the research and development services are to be provided.
Research and Development Services—The deliverables under the Company’s collaboration and license
agreements generally include deliverables related to research and development services to be performed
by the Company on behalf of the collaboration partner. As the provision of research and development
services is a part of the Company’s central operations, when the Company is principally responsible for
the performance of these services under the agreements, the Company recognizes revenue on a gross
basis for research and development services as those services are performed.
Option Arrangements—The Company’s arrangements may provide a collaborator with the right to
select a target for licensing either at the inception of the arrangement or within an initial pre-defined
selection period, which may, in certain cases, include the right of the collaborator to extend the selection
period. Under these agreements, fees may be due to the Company (i) at the inception of the arrangement
as an upfront fee or payment, (ii) upon the exercise of an option to acquire a license or (iii) upon
extending the selection period as an extension fee or payment.
The accounting for option arrangements is dependent on the nature of the options granted to the
collaboration partner. Options are considered substantive if, at the inception of the arrangement, the
Company is at risk as to whether the collaboration partner will choose to exercise the options to secure
exclusive licenses. Factors that the Company considers in evaluating whether options are substantive
include the overall objective of the arrangement, the benefit the collaborator might obtain from the
F-13
arrangement without exercising the options, the cost to exercise the options relative to the total upfront
consideration and the additional financial commitments or economic penalties imposed on the
collaborator as a result of exercising the options. For arrangements under which the option to secure
licenses is considered substantive, the Company does not consider the licenses to be deliverables at the
inception of the arrangement. For arrangements under which the option to secure licenses is not
considered substantive, the Company considers the license to be a deliverable at the inception of the
arrangement and, upon delivery of the license, would apply the multiple-element revenue arrangement
criteria to the license and any other deliverables to determine the appropriate revenue recognition. None
of the options to secure exclusive licenses included in the Company’s collaborative arrangements have
been determined to be substantive.
Milestone Revenue. The Company’s collaboration and license agreements generally include contingent milestone
payments related to specified preclinical research and development milestones, clinical development milestones,
regulatory milestones and sales-based milestones. Preclinical research and development milestones are typically
payable upon the selection of a compound candidate for the next stage of research and development. Clinical
development milestones are typically payable when a product candidate initiates or advances in clinical trial phases
or achieves defined clinical events such as proof-of-concept. Regulatory milestones are typically payable upon
submission for marketing approval with regulatory authorities or upon receipt of actual marketing approvals for a
compound, approvals for additional indications, or upon the first commercial sale. Sales-based milestones are
typically payable when annual sales reach specified levels.
At the inception of each arrangement that includes milestone payments, the Company evaluates whether each
milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This
evaluation includes an assessment of whether (a) the consideration is commensurate with either (i) the entity’s
performance to achieve the milestone or (ii) the enhancement of the value of the delivered item(s) as a result of a
specific outcome resulting from the entity’s performance to achieve the milestone; (b) the consideration relates
solely to past performance; and (c) the consideration is reasonable relative to all of the deliverables and payment
terms within the arrangement. The Company evaluates factors such as the scientific, regulatory, commercial and
other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to
achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables
and payment terms in the arrangement in making this assessment.
The Company generally considers non-refundable preclinical research and development, clinical development and
regulatory milestones that the Company expects to be achieved as a result of the Company’s efforts during the
period of the Company’s performance obligations under the collaboration and license agreements to be substantive
and recognizes them as revenue upon the achievement of the milestone, assuming all other revenue recognition
criteria are met. If not considered to be substantive, the Company initially defers milestones and recognizes them
over the remaining term of the Company’s performance obligations. Milestones that are not considered substantive
because the Company does not contribute effort to the achievement of such milestones are generally achieved after
the period of the Company’s performance obligations and are recognized as revenue upon achievement, assuming
all other revenue recognition criteria are met, as there are no undelivered elements remaining and no continuing
performance obligations.
The Company is required to adopt new revenue accounting guidance in the first quarter of 2018, which it expects
will impact this policy, the amount and timing of future revenue recognition, and the amount of revenue previously
recognized in our published financial statements. For further discussion, see Recent Accounting Pronouncements in
this note below.
Research and Development Expenses
Research and development expenses are expensed as incurred. Research and development expenses are comprised
of costs incurred in providing research and development activities, including salaries and benefits, facilities costs,
overhead costs, contract research and development services, and other outside costs. Nonrefundable advance
payments for goods and services that will be used in future research and development activities are expensed when
the activity has been performed or when the goods have been received rather than when the payment is made.
F-14
External research and development expenses associated with the Company’s programs include clinical trial site
costs, clinical manufacturing costs, costs incurred for consultants and other outside services, such as data
management and statistical analysis support, and materials and supplies used in support of the clinical and
preclinical programs. Internal costs of the Company’s clinical programs include salaries, stock-based compensation,
and the portion of the Company’s facility costs allocated to research and development expense. When third-party
service providers’ billing terms do not coincide with the Company’s period-end, the Company is required to make
estimates of its obligations to those third parties, including clinical trial and pharmaceutical development costs,
contractual services costs and costs for supply of its product candidates incurred in a given accounting period and
record accruals at the end of the period. The Company bases its estimates on its knowledge of the research and
development programs, services performed for the period, past history for related activities and the expected
duration of the third-party service contract, where applicable.
The Company generally accrues expenses related to research and development activities based on the services
received and efforts expended pursuant to contracts with multiple contract research organizations that conduct and
manage clinical trials, as well as other vendors that provide research and development services. The financial terms
of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment
flows. There may be instances in which payments made to vendors will exceed the level of services provided and
result in a prepayment of the clinical expense. Payments under some of these contracts depend on factors such as the
successful enrollment of subjects and the completion of clinical trial milestones. In accruing service fees, the
Company estimates the time period over which services will be performed and the level of effort to be expended in
each period. If the actual timing of the performance of services or the level of effort varies from estimates, the
Company would adjust the accrual or prepaid accordingly in future periods.
Stock-Based Compensation
The Company measures employee stock-based compensation based on the grant date fair value of the stock-based
compensation award. The Company grants stock options at exercise prices equal to the fair value of the Company’s
common stock on the date of grant, based on observable market prices.
The Company recognizes employee stock-based compensation expense on a straight-line basis over the requisite
service period of the awards. The Company recognizes forfeitures for employee and non-employee grants at the time
they occur. The actual expense recognized over the vesting period will only represent those options that vest.
Refer to Note 10, Employee Benefit Plans, for additional information regarding the measurement and recognition of
expense related to the Company’s stock-based compensation awards.
Earnings (Loss) per Share
The Company computes basic earnings (loss) per share by dividing income (loss) allocable to common stockholders
by the weighted average number of shares of common stock outstanding. During periods of income, the Company
allocates participating securities a proportional share of income determined by dividing total weighted average
participating securities by the sum of the total weighted average common shares and participating securities (the
“two-class method”). The Company’s restricted stock and, prior to its automatic conversion, redeemable convertible
preferred stock participate in any dividends declared by the Company and are therefore considered to be
participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share
during periods of income. During periods of loss, the Company allocates no loss to participating securities because
they have no contractual obligation to share in the losses of the Company. The Company computes diluted earnings
(loss) per share after giving consideration to the dilutive effect of stock options that are outstanding during the
period, except where such non-participating securities would be anti-dilutive. Refer to Note 11, Loss per Share, for
the Company’s calculation of loss per share for the periods presented.
Segment Information
The Company operates as one reportable business segment: the discovery and development of novel epigenetic
therapies for patients with cancer and other diseases.
F-15
Pending Accounting Pronouncements
In May 2014, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or
ASU, 2014-09, Revenue From Contracts With Customers. ASU 2014-09 amends Accounting Standards
Codification, or ASC, 605, Revenue Recognition (“ASC 605”), by outlining a single comprehensive model for
entities to use in accounting for revenue arising from contracts with customers. In addition, the FASB issued
ASUs 2016-10 and 2016-12, which provide clarifying amendments to ASU 2014-09. ASU 2014-09 and its related
amendments will be effective for the Company for interim and annual periods beginning after December 15,
2017. The Company will adopt ASU 2014-09, as amended, effective January 1, 2018. The new standards are
codified under ASC 606, Revenue From Contracts with Customers (“ASC 606”). The Company will utilize the
modified retrospective approach to implement this standard. The Company is in the process of evaluating its
collaboration agreements with Celgene Corporation (“Celgene”), Glaxo Group Limited (“GSK”) and Eisai Co. Ltd.
(“Eisai”) (as the amended and restated agreement with Eisai provides for the receipt of royalties on Eisai’s sales of
any EZH2 product in Japan) to determine the impact the adoption of this standard may have on its consolidated
financial statements and internal control over financial reporting.
The Company has not yet completed its assessment of the impact the adoption of this standard may have on its
consolidated financial statements and internal control, but expects that the adoption will impact the amount and
timing of revenues recognized related to its collaboration agreement with Celgene and the impact may be material.
With regard to the collaboration agreements with GSK and Eisai, the Company currently does not expect the impact
of adoption of this standard to be material.
The Company is still assessing its collaboration agreement with Celgene; however, it currently expects that (a) the
number of performance obligations identified under ASC 606 will be different from the number of units of
accounting identified under ASC 605 and (b) the transaction price under ASC 606 will be different from the
transaction price determined under ASC 605. In particular, the Company currently expects that the accounting
treatment for Celgene’s option rights that were determined to be non-substantive options under ASC 605 will be
different under ASC 606. The licenses and research and development services underlying Celgene’s options will not
be identified as promised goods or services (or performance obligations) under ASC 606 and the consideration that
would be received upon exercise of the options will not be included in the transaction price at contract inception.
The Company may identify additional differences as it completes its assessment.
The Company also expects the accounting for contingent milestone payments under its collaboration agreements to
change under ASC 606. ASC 606 does not contain guidance specific to milestone payments, thereby requiring
contingent milestone payments to be considered in accordance with the overall model of ASC 606 as variable
consideration. Revenue from contingent milestone payments may be recognized earlier under ASC 606 than under
ASC 605, based on an assessment at each reporting date of the probability of achievement of the underlying
milestone event. This assessment may, in certain circumstances, result in the recognition of revenue related to a
contingent milestone payment before the milestone event has been achieved.
ASC 606 requires more robust disclosures than required by previous guidance, including disclosures related to
disaggregation of revenue into appropriate categories, performance obligations, the judgments made in revenue
recognition determinations, adjustments to revenue which relate to activities from previous quarters or years, any
significant reversals of revenue, and costs to obtain or fulfill contracts.
Expected impacts from the adoption of this standard could differ upon the final adoption and implementation of the
standard. In connection with the adoption of the standard, the Company is implementing several new internal
controls, including controls to monitor the probability of achievement of contingent milestone payments and the
pattern of performance of certain performance obligations.
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which requires lessees to recognize a right-
of-use asset and lease liability for most lease arrangements. The new standard is effective for annual reporting
periods beginning after December 15, 2018 with early adoption permitted. The Company is currently evaluating the
potential changes from this ASU, but expects that all of its lease commitments will be subject to the new standard.
F-16
In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain
Cash Receipts and Cash Payments. The new standard clarifies certain aspects of the statement of cash flows,
including the classification of debt prepayment or debt extinguishment costs, settlement of zero-coupon debt
instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective
interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from
the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies,
distributions received from equity method investees and beneficial interests in securitization transactions. The new
standard also clarifies that an entity should determine each separately identifiable source or use within the cash
receipts and cash payments on the basis of the nature of the underlying cash flows. In situations in which cash
receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use,
the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash
flows for the item. The new standard will be effective for the Company on January 1, 2018. The adoption of this
standard is not expected to have a material impact on the Company’s consolidated statements of cash flows.
In November 2016, the FASB issued ASU 2016-18, Restricted Cash, or ASU 2016-18, which requires an entity to
reconcile and explain the period-over-period change in total cash, cash equivalents and restricted cash within its
statements of cash flows. ASU 2018-18 is effective for fiscal years, and interim periods within, beginning after
December 15, 2017. Early adoption is permitted. A reporting entity must apply the amendments in ASU 2016-18
using a full retrospective approach. The adoption of ASU 2016-18 is not expected to have a material effect on the
Company’s consolidated financial statements or disclosures.
In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of
Modification Accounting, which clarifies when to account for a change to the terms or conditions of a share-based
payment award as a modification. The new standard does not change the accounting for modifications but clarifies
that modification accounting guidance should only be applied if the fair value, vesting conditions, or classification
of the award changes as a result of the change in terms or conditions. The new standard is effective for fiscal years,
and interim periods within, beginning after December 15, 2017. Early adoption is permitted. A reporting entity must
apply the amendments in the ASU prospectively to an award modified on or after the adoption date. The adoption of
ASU 2017-09 is not expected to have a material effect on the Company’s consolidated financial statements or
disclosures.
Recently Adopted Accounting Pronouncements
As of January 1, 2017, the Company adopted ASU 2016-09, Improvements to Employee Share-
Based Payment Accounting. The standard revised the accounting for share-based compensation arrangements,
including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as
classification in the statement of cash flows. Under this guidance, a company recognizes all excess tax benefits and
tax deficiencies as income tax expense or benefit in the income statement when the awards vest or are settled. The
amendments also removed the requirement to delay the recognition of an excess tax benefit until it reduces current
taxes payable. In addition, cash flows related to excess tax benefits will no longer be separately classified as a
financing activity apart from other income tax cash flows. The standard also allows the Company to repurchase
more of an employee’s shares for tax withholding purposes without triggering liability accounting, clarifies that all
cash payments made on an employee’s behalf for withheld shares should be presented as a financing activity on the
cash flows statement, and provides an accounting policy election to account for forfeitures as they occur. Upon
adoption, the Company recognized previously unrecognized excess tax benefits using the modified retrospective
transition method, which increased deferred tax assets and the valuation allowance by $25.7 million and charged
$0.1 million to retained earnings, with a corresponding credit to additional paid-in-capital related to the Company’s
election to account for forfeitures as they occur. The adoption of the standard did not materially impact the
Company’s stock-based compensation expense.
F-17
3. Property and Equipment, net
Property and equipment, net consists of the following:
Laboratory equipment
Computer and office equipment, furniture (1)
Leasehold improvements
Construction in progress
Property and equipment
Less: accumulated depreciation and amortization
Property and equipment, net
December 31,
2017
2016
(In thousands)
$ 4,138
4,807
354
71
9,370
(6,843)
$ 2,527
$ 3,691
4,495
464
—
8,650
(5,526)
$ 3,124
(1)
In 2015, the Company acquired $1.7 million of computer hardware and equipment, pursuant to a capital lease,
the term of which expires in February 2018. Accumulated depreciation related to these assets totaled $1.6
million and $1.1 million as of December 31, 2017 and 2016, respectively.
Depreciation and amortization expense was $1.6 million, $1.6 million and $1.4 million for the years ended
December 31, 2017, 2016, and 2015, respectively.
4. Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consisted of the following:
Prepaid clinical and manufacturing costs
Interest receivable on available for sale securities
Other prepaid expenses and other receivables
Total prepaid expenses and other current assets
5. Accrued Expenses
Accrued expenses consisted of the following:
Employee compensation and benefits
Research and development expenses
Professional services and other
Accrued expenses
December 31,
2017
2016
(In thousands)
$ 5,724
249
3,010
$ 8,983
$ 3,666
295
2,496
$ 6,457
December 31,
2017
2016
(In thousands)
$ 4,628
11,658
1,263
$ 17,549
$ 4,100
10,925
982
$ 16,007
F-18
6. Income Taxes
The Company’s losses before income taxes consist solely of domestic losses.
The provision for (benefit from) income taxes for the years ended December 31, 2017, 2016, and 2015 is as follows:
Current
Deferred
Total
Income tax provision (benefit)
2017
2016
2015
(In thousands)
$
$
32.0 $
(368.0)
(336.0)
(336.0) $
— $
—
—
— $
—
—
—
—
A reconciliation of the federal statutory income tax rate and the Company’s effective income tax rate is as follows:
Federal statutory income tax rate
State income taxes
Research and development and other tax credits
Permanent items
Change in valuation allowance
Return-to-provision adjustments
Change in deferred taxes
Rate Change
Other
Effective income tax rate
Year Ended December 31,
2016
2015
2017
34.0%
4.8
4.2
(2.0)
5.7
(0.7)
—
(45.7)
—
0.3%
34.0%
4.5
3.3
(1.9)
(40.1)
—
0.2
—
0.0
0.0%
34.0%
5.2
1.8
(1.2)
(40.0)
—
0.2
—
—
0.0%
Deferred Tax Assets (Liabilities)
The Company’s deferred tax assets (liabilities) consist of the following:
December 31,
2017
2016
(In thousands)
$ 116,869 $ 94,390
24,257
1,175
36
7,766
1,250
8,985
4,702
165,040
(164,607)
433
18,055
1,899
154
11,231
1,435
14,035
5,607
146,806
(146,548)
258
(65)
(65)
368 $
(258)
(258)
—
$
Deferred tax assets:
Net operating loss carryforwards
Research and development and other credit
carryforwards
Capitalized start-up costs
Capitalized research and development costs
Deferred revenue
Accruals and allowances
Eisai license payment
Other
Gross deferred tax assets
Deferred tax asset valuation allowance
Total deferred tax assets
Deferred tax liabilities:
Depreciation and other
Total deferred tax liabilities
Net deferred tax asset (liability)
F-19
The Company evaluated the expected recoverability of our net deferred tax assets as of December 31, 2017 and
determined that, with the exception of the deferred tax asset related to alternative minimum tax, or AMT, credits,
there was insufficient positive evidence to support the recoverability of these net deferred tax assets, concluding it is
more likely than not that our net deferred tax assets would not be realized in the future; therefore, the Company
provided a full valuation allowance against its net deferred tax asset balance as of December 31, 2017, with the
exception of the deferred tax asset related to the AMT credit. The AMT credit becomes refundable beginning in
2018 through no later than 2022 under the Tax Cuts and Jobs Act, or TCJA, tax reform legislation, and as such, the
related deferred tax asset will be able to be realized and the corresponding valuation allowance of $368,000 has been
reversed as of December 31, 2017 and recognized as tax benefit.
The Company evaluated the expected recoverability of its net deferred tax assets as of December 31, 2016 and 2015
and determined that there was insufficient positive evidence to support the recoverability of these net deferred tax
assets, concluding it is more likely than not that the Company’s net deferred tax assets would not be realized in the
future; therefore, the Company provided a full valuation allowance against its net deferred tax asset balance as of
December 31, 2016 and 2015 and did not recognize any tax benefit for the years ended December 31, 2016 and
2015.
On December 22, 2017, the President of the United States signed into law the TCJA. The TCJA makes significant
changes in U.S. tax law including a reduction in the corporate tax rates, changes to net operating loss carryforwards
and carrybacks, and a repeal of the corporate alternative minimum tax. The TCJA reduced the U.S. corporate tax
rate from the current rate of 34 percent down to 21 percent starting on January 1, 2018. As a result of the enacted
law, the Company was required to revalue deferred tax assets and liabilities at 21 percent. This revaluation resulted
in a provision of $61.6 million to income tax expense in continuing operations related to the reduction in the
carrying value of the Company’s deferred tax assets, offset by a corresponding reduction in the valuation
allowance. The Company’s preliminary estimate of the effects of the TCJA, including the remeasurement of
deferred tax assets and liabilities and the evaluation of the recoverability of the deferred tax assets related to AMT
credits, is subject to the finalization of management’s analysis related to certain matters, such as developing
interpretations of the provisions of the TCJA, changes to certain estimates and the filing of the Company’s tax
returns. U.S. Treasury regulations, administrative interpretations or court decisions interpreting the TCJA may
require further adjustments and changes in the Company’s estimates. The final determination of the TCJA and the
remeasurement of deferred assets and liabilities will be completed as additional information becomes available, but
no later than one year from the enactment of the TCJA. In all cases, the Company will continue to make and refine
its calculations as additional analysis is completed. In addition, the Company’s estimates may also be affected as it
gains a more thorough understanding of the tax law.
As of December 31, 2017, the Company had operating loss carryforwards of approximately $428.5 million and
$428.7 million available to offset future taxable income for United States federal and state income tax purposes,
respectively. The U.S. federal tax operating loss carryforwards expire commencing in 2029. The state tax operating
loss carryforwards expire commencing in 2030.
Additionally, as of December 31, 2017, the Company had research and development tax credit carryforwards of
approximately $7.2 million and $2.5 million available to be used as a reduction of federal income taxes and state
income taxes, respectively, which expire at various dates from 2028 through 2037, as well as federal orphan drug tax
credit carryforwards of $14.7 million, which would expire at various dates from 2033 through 2037, and a $0.4
million federal alternative minimum tax credit carryforward. The Company’s ability to use its operating loss
carryforwards and tax credits to offset future taxable income is subject to restrictions under Section 382 of the U.S.
Internal Revenue Code, (“the Internal Revenue Code”). These restrictions may limit the future use of the operating
loss carryforwards and tax credits if certain ownership changes described in the Internal Revenue Code occur.
Future changes in stock ownership may occur that would create further limitations on the Company’s use of the
operating loss carryforwards and tax credits. In such a situation, the Company may be required to pay income taxes,
even though significant operating loss carryforwards and tax credits exist.
F-20
Uncertain Tax Positions
The following is a rollforward of the Company’s unrecognized tax benefits:
Unrecognized tax benefits - as of beginning of year
Gross increases - tax positions of prior periods
Gross increases - current period tax positions
Unrecognized tax benefits - as of end of year
December 31,
2017
2016
(In thousands)
$ 4,206
—
1,017
$ 5,223
$ 3,480
—
726
$ 4,206
None of the Company’s unrecognized tax benefits would result in income tax expense or impact the Company’s
effective tax rate if recognized. The Company had no accrued tax-related interest or penalties as of December 31,
2017 or 2016.
The Company files income tax returns in the U.S. federal tax jurisdiction and Colorado, Indiana, Massachusetts, and
North Carolina state tax jurisdictions. Since the Company is in a loss carryforward position, the Company is
generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which
a loss carryforward is available.
7. Commitments and Contingencies
Commitments
The Company leases office and laboratory space at Technology Square in Cambridge, Massachusetts under a Lease
Agreement, dated as of June 15, 2012, as amended (the “Lease”) with ARE-TECH Square, LLC, a Delaware limited
liability company (the “Landlord”), with a term that originally continued through May 31, 2018, and a Company
option to extend the term of the lease at the then-current market rent, as defined in the Lease, through November 30,
2022.
In May 2017, the Company entered into a Third Amendment to Lease (the “Third Amendment”) with the Landlord,
and a Fourth Amendment to Lease with the Landlord (the “Fourth Amendment,” and, together with the Third
Amendment, the “Amendments”).
Under the Amendments, the Company extended the term of the lease to November 30, 2022 but retained the right to
terminate the Lease effective as of December 31, 2018, by giving written notice to the Landlord by December 31,
2017 and paying an early termination fee. The Company did not exercise this right. Under the Lease as amended, the
Company has agreed to pay a monthly base rent of approximately $0.2 million for the period commencing
December 1, 2017 through May 31, 2018, with an increase on June 1, 2018 and annual increases December 1 of
each subsequent year until December 1, 2021.
The Company has a $0.5 million letter of credit as a security deposit for this lease and has recorded cash held to
secure this letter of credit as restricted cash in restricted cash and other assets on the consolidated balance sheet. The
Company recognizes rent expense, including escalation charges, on a straight-line basis over the initial term of the
lease agreement.
In addition, the Company has a capital lease related to computer hardware equipment, an operating lease for storage
space in Colorado and an operating lease for office space in North Carolina.
F-21
Rent expense was $3.3 million, $2.8 million and $2.7 million for the years ended December 31, 2017, 2016, and
2015, respectively.
The Company’s contractual commitments under these leases, excluding common area maintenance charges and real
estate taxes, as of December 31, 2017 are as follows:
Operating leases
Capital lease, including amounts representing interest
Total commitments
$17,262 $ 3,270 $ 3,516 $ 3,605
111 — —
$17,373 $ 3,381 $ 3,516 $ 3,605
111
$ 3,538 $ 3,333
— —
$ 3,538 $ 3,333
Total
2018
2019
(In thousands)
2020
2021
2022
In addition to commitments under leasing arrangements, as of December 31, 2017, the Company has committed to
$10.4 million of remaining development costs payable to Roche Molecular, expected to be paid through 2019 upon
certain development and regulatory milestones, under the amended companion diagnostic agreement.
Developmental costs of $1.5 million were paid in 2017 upon the achievement of a milestone under the companion
diagnostic agreement with Roche Molecular. In addition, the contractual commitments table above does not include
potential future milestones or royalties that the Company may be required to make under license and collaboration
agreements, including potential future milestones or royalties payable to Eisai under the amended collaboration and
license agreement, due to the uncertainty of the occurrence of the events requiring payment under these agreements.
Refer to Note 9, Collaborations.
Additionally, the Company enters into contracts in the normal course of business with clinical research
organizations for clinical and preclinical research studies, external manufacturers for product for use in clinical
trials, and other research supplies and other services as part of the Company’s operations. These contracts generally
provide for termination on notice, and therefore are cancelable contracts and not included in the contractual
commitments table above.
8. Stockholders’ (Deficit) Equity
Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s
stockholders. Common stockholders are entitled to dividends when and if declared by the board of directors.
In September 2017 and January 2016, the Company issued 10,557,000 and 15,333,334 shares of Common Stock,
respectively, in connection with public offerings. The issuance of these shares contributed to significant increases in
the Company’s shares outstanding as of December 31, 2017 and 2016 and in the weighted average shares
outstanding for the years ended December 31, 2017 and 2016 when compared to the comparable prior year periods.
The Company sold 132,253 shares and 23,581 shares, of Common Stock during the years ended December 31, 2017
and December 31, 2016, respectively, under an “at the market” program (“ATM Facility”) with Cowen and
Company, LLC (“Cowen”) acting as sales agent under a sales agreement that the Company and Cowen entered into
in April 2016. Cowen was compensated at a fixed commission rate of 3.0%. Transactions under the ATM Facility
resulted in net proceeds of $1.6 million and $0.3 million in the years ended December 31, 2017 and 2016,
respectively. The Company also incurred other issuance related costs of $0.1 million associated with the ATM
Facility in the fourth quarter of 2016, which have been accounted for as an offset to additional paid in capital.
Through March 10, 2017, including sales in the year ended December 31, 2016, the Company sold 155,834 shares
of Common Stock under the sales agreement with Cowen. The Company terminated the sales agreement with
Cowen, effective March 10, 2017.
As of December 31, 2017, a total of 8,890,201 shares of common stock were reserved for issuance upon (i) the
exercise of outstanding stock options and vesting of restricted stock units and (ii) the issuance of stock awards under
the Company’s 2013 Stock Incentive Plan and 2013 Employee Stock Purchase Plan.
F-22
9. Collaborations
Celgene
In April 2012, the Company entered into a collaboration and license agreement with Celgene. On July 8, 2015, the
Company entered into an amendment and restatement of the collaboration and license agreement with Celgene.
Original Agreement Structure
Under the original agreement, the Company granted Celgene an exclusive license, for all countries other than the
United States, to small molecule HMT inhibitors targeting the DOT1L HMT, including pinometostat, and an option,
on a target-by-target basis, to exclusively license, for all countries other than the United States, rights to small
molecule HMT inhibitors targeting any HMT targets, other than the EZH2 HMT, including tazemetostat, and targets
covered by the Company’s collaboration and license agreement dated January 8, 2011 with GlaxoSmithKline
(“GSK”). Under the original agreement, Celgene’s option was exercisable during an option period that would have
expired on July 9, 2015.
Under the original agreement, the Company received a $65.0 million upfront payment and $25.0 million from the
sale of its series C redeemable convertible preferred stock to an affiliate of Celgene, of which $3.0 million was
considered a premium and included as collaboration arrangement consideration for a total upfront payment of $68.0
million. In addition, the Company has received a $25.0 million clinical development milestone payment and $7.0
million of global development co-funding through December 31, 2017. The Company was also eligible to receive
$35.0 million in an additional clinical development milestone payment and up to $100.0 million in regulatory
milestone payments related to DOT1L as well as up to $65.0 million in payments, including a combination of
clinical development milestone payments and an option exercise fee for each available target to which Celgene had
the right to exercise its option during an initial option period that would have ended in July 2015 but was extended
pursuant to the amended and restated agreement as discussed below under “Amended and Restated Agreement
Structure” (each a “selected target”), and up to $100.0 million in regulatory milestone payments for each selected
target. As to DOT1L and each selected target, the Company retained all product rights in the United States and was
eligible to receive royalties for each target at defined percentages ranging from the mid-single digits to the mid-teens
on net product sales outside of the United States subject to reduction in specified circumstances.
The Company was obligated to conduct and solely fund research and development costs of the Phase 1 clinical trials
for pinometostat. For all remaining DOT1L program development costs, Celgene and the Company were to equally
co-fund global development and each party was to solely fund territory-specific development costs for its territory.
Amended and Restated Agreement Structure
Under the amended and restated collaboration and license agreement:
•
•
•
•
•
Celgene retained its exclusive license to small molecule HMT inhibitors targeting DOT1L, including
pinometostat,
Celgene’s other option rights were narrowed to small molecule HMT inhibitors targeting three
predefined targets (the “Option Targets”),
The exclusive licenses to HMT inhibitors targeting two of the Option Targets that Celgene may acquire
were expanded to include the United States, with the exclusive license to HMT inhibitors targeting the
third Option Target continuing to be for all countries other than the United States,
Celgene’s option period was extended for each of the Option Targets and Celgene’s option is
exercisable at the time of the Company’s investigational new drug application, or IND, filing for an
HMT inhibitor targeting the applicable Option Target, upon the payment by Celgene at such time of a
pre-specified development milestone-based license payment,
Celgene’s license may be maintained beyond the end of Phase 1 clinical development for each of the
Option Targets, upon payment by Celgene at such time of a pre-specified development milestone-based
license payment, and
F-23
•
The Company’s research and development obligations with respect to each Option Target under the
amended and restated agreement were extended for at least an additional three years, subject to Celgene
exercising its option with respect to such Option Target at IND filing. Subject to the Company’s opt-out
rights, the Company’s research and development obligations were expanded to include the completion
of a Phase 1 clinical trial as to each Option Target following Celgene’s exercise of its option at IND
filing.
Under the amended and restated agreement, the Company received a $10.0 million upfront payment in exchange for
the Company’s extension of Celgene’s option rights to the Option Targets and the Company’s research and
development obligations. In addition, the Company is eligible to earn an aggregate of up to $75.0 million in
development milestones and license payments, up to $365.0 million in regulatory milestone payments and up to
$170.0 million in sales milestone payments related to the three Option Targets. The Company is also eligible to
receive royalties on each of the Option Targets as specified in the amended and restated agreement. The Company is
also eligible to earn $35.0 million in an additional clinical development milestone payment and up to $100.0 million
in regulatory milestone payments related to DOT1L. Due to the uncertainty of pharmaceutical development and the
high historical failure rates generally associated with drug development, the Company may not receive any
additional milestone payments or royalty payments from Celgene. Due to the varying stages of development of each
target, the Company is not able to determine the next milestone that might be earned, if any.
The amended and restated agreement eliminated the right of first negotiation that the Company had granted to
Celgene under the original agreement with respect to business combination transactions that the Company may
desire to pursue with third parties.
The Company is primarily responsible for the research strategy under the collaboration. During each applicable
option period the Company is required to use commercially reasonable efforts to carry out a mutually agreed-upon
research plan for each Option Target. Subject to the Company’s opt-out right, for the DOT1L target and each of the
Option Targets, the Company is required to conduct and solely fund development costs of the Phase 1 clinical trials
for HMT inhibitors directed to such targets, including for pinometostat. After the completion of Phase 1
development, as to DOT1L and the Option Target for which the Company retains U.S. rights, Celgene and the
Company will equally co-fund global development and each party will solely fund territory-specific development
costs for its respective territory; and, as to the other two Option Targets, after the completion of Phase 1
development, Celgene will solely fund all development costs on a worldwide basis.
Accounting Considerations of the Amended and Restated Agreement
The Company determined that the amended and restated agreement represented a modification of the original
agreement. Accordingly, the Company determined that the remaining deferred revenue of $21.6 million attributable
to the original agreement should be combined with the $10.0 million upfront payment received from Celgene upon
execution of the amended and restated agreement. This combined amount, along with any development milestone-
based license fees associated with those Option Targets where Celgene’s option rights are determined to be non-
substantive, will be recognized on a prospective basis after (i) identifying the deliverables and units of accounting
included in the amended and restated agreement, (ii) allocating the total arrangement fee among the units of
accounting and (iii) determining the revenue recognition for each unit of accounting.
The Company evaluated the deliverables in the amended and restated agreement and determined that the
deliverables included its obligation to provide research and development services for DOT1L and the three Option
Targets. In addition, the Company concluded that Celgene’s option rights are not substantive and the licenses to
HMT inhibitors targeting each Option Target were therefore considered to be deliverables. As a result, the Company
has determined the deliverables in the amended and restated arrangement to be:
•
•
Research and development services for DOT1L and the three Option Targets
Licenses to HMT inhibitors targeting the Option Targets
F-24
The Company evaluated the nature of the deliverables to determine the units of accounting. At a program level (that
is, for DOT1L and each Option Target), the Company believes there is standalone value. Therefore, the identified
deliverables were evaluated on a program by program basis to determine the units of accounting.
The Company determined the research services related to DOT1L have stand-alone value as the services are
delivered and therefore represent a single unit of accounting. There are no other deliverables related to the DOT1L
program. For two of the Option Targets, the Company concluded the licenses and related research services should be
accounted for as a combined unit of accounting up until an IND filing. Prior to an IND filing, the delivered research
services do not have standalone value from the remaining undelivered elements because Celgene could not resell the
research services and no other vendor has the specialized skills and know-how related to HMT inhibitors necessary
to provide the research services. After an IND filing, for these two Option Targets, the Company concluded the
delivered pre-IND research services and licenses, once delivered, would have standalone value from the remaining
research services because Celgene, or other market participants, would have the ability to execute human clinical
trials on the identified compound. After an IND filing, the remaining research services represent a separate unit of
accounting which has standalone value upon delivery. With respect to the third Option Target where the Company
retains U.S. rights, because the license terms restrict Celgene’s access to information through the completion of a
Phase 1 trial that would otherwise be necessary for Celgene, or other market participants, to execute human clinical
trials on the identified compound, the Company determined the licenses did not have standalone value apart from
the research services Accordingly, for the third Option Target, the licenses and research services will be accounted
for as a combined unit of accounting.
Because Celgene’s option rights with respect to the Option Targets are not considered substantive, any development
milestone-based license fees associated with the Option Targets would be considered to be part of the total
consideration for purposes of allocating the arrangement consideration. Accordingly, the Company has identified the
total allocable arrangement consideration to be $106.6 million, as follows: (i) the remaining $21.6 million of
deferred revenue under the original agreement, (ii) the $10.0 million upfront payment made in connection with the
amended and restated agreement, and (iii) the $75.0 million of aggregate development milestone-based license fees
associated with the Option Targets.
The allocable arrangement consideration has been allocated to the identified deliverables using the relative selling
price method. The Company estimated the selling price of the license deliverable for each Option Target using
management’s best estimate of selling price after considering potential future cash flows under each license and
industry benchmarks on the probability of achieving development milestones. The Company then discounted these
probability-weighted cash flows to their present value. The Company estimated the selling price of the research
services to be provided in connection with the DOT1L Phase 1 clinical trial and related to each Option Target using
management’s best estimate of selling price based on the Company’s estimated cost of providing the services plus
an applicable profit margin of 10%, which is commensurate with observable market data for similar services.
The Company expects to recognize the allocated arrangement consideration as follows, subject to the limitation
described in ASC 605-25-30-5:
•
•
•
Research and development services for DOT1L: The arrangement consideration allocated to the DOT1L
program was recognized as the research and development services were performed. The Company
allocated $2.8 million to the remaining research services under the DOT1L program, and this amount
was recognized through December 31, 2016, the period over which the related research services were
provided.
Two Option Targets: The arrangement consideration allocated to these Option Targets of $70.2 million
in the aggregate will be deferred until an IND filing. The Company did not recognize any revenue
related to the Option Targets during 2017.
Third Option Target: The licenses and the research services provided through completion of a Phase 1
trial represent a single combined unit of accounting. Therefore, because a license is the last delivered
item in this unit of accounting, the Company will defer all consideration allocated to this unit of
accounting, $33.6 million, until the delivery of the license upon completion of a Phase 1 clinical trial.
The Company did not recognize any revenue related to the Option Target during 2017.
F-25
•
If any of the programs are terminated in accordance with the amended and restated agreement, any
remaining deferred revenue will be reallocated among the undelivered items based upon their relative
selling prices.
Collaboration Revenue
Through December 31, 2017, the Company has recognized $74.3 million of total collaboration revenue since the
inception of the collaboration, including $1.9 million and $1.1 million in the years ended December 31, 2016 and
2015, respectively. In addition, the Company has recognized $0.1 million and $1.1 million of total global
development co-funding as a reduction to research and development expense in the years ended December 31, 2016
and 2015, respectively. The Company recognized no revenue and no global development co-funding under this
collaboration for the year ended December 31, 2017. As of December 31, 2017 and December 31, 2016, the
Company had deferred revenue of $28.8 million related to this agreement.
GSK
In January 2011, the Company entered into a collaboration and license agreement with GSK, to discover, develop
and commercialize novel small molecule HMT inhibitors directed to available targets from the Company’s platform.
Under the terms of the agreement, the Company granted GSK exclusive worldwide license rights to HMT inhibitors
directed to three targets. Additionally, as part of the research collaboration, the Company agreed to provide research
and development services related to the licensed targets pursuant to agreed upon research plans during a research
term that ended January 8, 2015. In March 2014, the Company and GSK amended certain terms of this agreement
for the third licensed target, revising the license terms with respect to candidate compounds and amending the
corresponding financial terms, including reallocating milestone payments and increasing royalty rates as to the third
target. Subsequent to a GSK strategic portfolio prioritization, the Company received notice in October 2017 that
GSK terminated the agreement with respect to the third target, effective December 31, 2017, which returned all
rights to that target to the Company. The two other targets continue to be subject to the agreement and were not
impacted by the termination with respect to the third target. The Company substantially completed all research
obligations under this agreement by the end of the first quarter of 2015 and completed the transfer of the remaining
data and materials for these programs to GSK in the second quarter of 2015.
Agreement Structure
Under the agreement, the Company has received and recognized as collaboration revenue a $20.0 million upfront
payment, a $3.0 million payment upon the execution of the March 2014 agreement amendment, $6.0 million of
fixed research funding, $9.0 million for research and development services and $31.0 million of preclinical research
and development milestone payments. The preclinical and research and development milestone payments total
includes a $10.0 million milestone payment earned in May 2017 related to the second target in the collaboration,
upon GSK’s initiation of good laboratory practices toxicology studies, as well as a $6.0 million clinical milestone
following GSK’s initiation of patient dosing in a Phase 1 clinical trial of a PRMT5 inhibitor that the Company
discovered and licensed to GSK. As of December 31, 2017, for the two remaining targets, the Company is eligible to
receive up to $70.0 million in clinical development milestone payments, up to $197.0 million in regulatory
milestone payments and up to $128.0 million in sales-based milestone payments. As a result of the termination of
the agreement as it relates to the third target, the Company will receive no additional payments related to that target.
In addition, GSK is required to pay the Company royalties, at percentages from the mid-single digits to the low
double-digits, on a licensed product-by-licensed product basis, on worldwide net product sales, subject to reduction
in specified circumstances. The Company determined the next milestone that might be achieved under this
agreement is for $8.0 million due at the first dosing of a patient for an undisclosed target under a Phase 1 study. Due
to the uncertainty of pharmaceutical development and the high historical failure rates generally associated with drug
development, the Company may not receive any additional milestone payments or royalty payments from GSK.
GSK became solely responsible for development and commercialization for each licensed target in the collaboration
when the research term ended on January 8, 2015.
F-26
Collaboration Revenue
Through December 31, 2017, the Company has earned a total of $69.0 million under the GSK agreement, which the
Company recognized as collaboration revenue in the condensed consolidated statements of operations and
comprehensive loss, including $10.0 million of milestone revenue in the year ended December 31, 2017 and $6.0
million of milestone revenue in the year ended December 31, 2016. The Company did not have any deferred
revenue related to this agreement as of December 31, 2017 or December 31, 2016 and any future revenues will
relate to any milestone payments and royalties received under the agreement with respect to the two remaining
targets.
Eisai
In April 2011, the Company entered into a collaboration and license agreement with Eisai under which the Company
granted Eisai an exclusive worldwide license to its small molecule HMT inhibitors directed to the EZH2 HMT,
including the Company’s product candidate tazemetostat, while retaining an opt-in right to co-develop, co-
commercialize and share profits with Eisai as to licensed products in the United States.
As of December 31, 2014, the Company had completed its performance obligations under the original agreement.
In March 2015, the Company entered into an amended and restated collaboration and license agreement with Eisai,
under which the Company reacquired worldwide rights, excluding Japan, to its EZH2 program, including
tazemetostat. Under the amended and restated agreement, the Company is responsible for global development,
manufacturing and commercialization outside of Japan of tazemetostat and any other EZH2 product candidates, with
Eisai retaining development and commercialization rights in Japan, as well as a right to elect to manufacture
tazemetostat and any other EZH2 product candidates in Japan and waived the right of first negotiation for the rest of
Asia.
Under the original agreement, Eisai was solely responsible for funding all research, development and
commercialization costs for EZH2 compounds. Under the amended and restated agreement, the Company is solely
responsible for funding global development, manufacturing and commercialization costs for EZH2 compounds
outside of Japan, including the remaining development costs due under a Roche Molecular companion diagnostic
agreement, and Eisai is solely responsible for funding Japan-specific development and commercialization costs for
EZH2 compounds.
The Company recorded the reacquisition of worldwide rights, excluding Japan, to the EZH2 program, including
tazemetostat, under the amended and restated agreement with Eisai as an acquisition of an in-process research and
development asset. As this asset was acquired without corresponding processes or activities that would constitute a
business, had not achieved regulatory approval for marketing and, absent obtaining such approval, had no alternative
future use, the Company recorded the $40.0 million upfront payment made to Eisai in March 2015 as research and
development expense in the consolidated statements of operations and comprehensive loss. The Company has also
agreed to pay Eisai up to $20.0 million in clinical development milestone payments, including a $10.0 million
milestone upon the earlier of initiation of a first phase 3 clinical trial of any EZH2 product or the first submission of
an NDA or MAA, up to $50.0 million in regulatory milestone payments, including a $25.0 million milestone
payment upon regulatory approval of the first NDA or MAA, and royalties at a percentage in the mid-teens on
worldwide net sales of any EZH2 product, excluding net sales in Japan. The Company is eligible to receive from
Eisai royalties at a percentage in the mid-teens on net sales of any EZH2 product in Japan.
F-27
LYSA
In May 2016, the Company entered into a collaboration agreement with the Lymphoma Academic Research
Organisation, or LYSARC, for the first planned combination trial of tazemetostat. LYSARC is the operational arm
of the Lymphoma Study Association, or LYSA, a premier cooperative group in France dedicated to clinical and
translational research for lymphoma. This Phase 1b/2 study is evaluating tazemetostat in combination with R-
CHOP, the standard of care first line combination treatment for diffuse large B-cell lymphoma, or DLBCL, as a first
line treatment in elderly, high-risk patients with DLBCL and is being sponsored by LYSARC. LYSA is managing
the study operations for the trial, and the Company is recognizing its share of the related expenses as those costs are
incurred over the duration of the trial.
Genentech
In June 2016, the Company entered into a collaboration agreement with Genentech Inc. (“Genentech”), a member of
the Roche Group, to conduct a Phase 1b clinical trial to investigate the anti-cancer effects of the Company’s EZH2
inhibitor, tazemetostat, and Genentech’s anti-PD-L1 cancer immunotherapy, atezolizumab, when used in
combination. The trial is evaluating this combination regimen for the treatment of patients with relapsed or
refractory DLBCL. Under the agreement, each company is supplying its respective anti-cancer agent to support the
trial and sharing equally in the trial costs. Genentech is managing the study operations for the trial, and the Company
is recognizing its share of the related expenses as those costs are incurred over the duration of the trial.
In June 2017, the Company announced an expansion of the clinical collaboration with Genentech to investigate the
combination of tazemetostat with atezolizumab in a Phase 1b/2 clinical trial for the treatment of patients with
relapsed or refractory metastatic non-small cell lung cancer, or NSCLC. The trial will be part of MORPHEUS,
Genentech’s open-label, multi-center, randomized umbrella trial evaluating the efficacy and safety of multiple
immunotherapy-based treatment combinations for metastatic NSCLC. Under the agreement, each company is
supplying its respective anti-cancer agent to support the trial and sharing equally in the trial costs. Genentech is
managing the study operations for the trial, and the Company is recognizing its share of the related expenses as
those costs are incurred over the duration of the trial.
Companion Diagnostics
Roche Molecular. In December 2012, Eisai and the Company entered into an agreement with Roche Molecular
under which Eisai and the Company engaged Roche Molecular to develop a companion diagnostic to identify
patients who possess certain activating mutations of EZH2. In October 2013, this agreement was amended to include
additional mutations in EZH2. The development costs due under the amended agreement with Roche Molecular
were the responsibility of Eisai until the execution of the amended and restated collaboration and license agreement
with Eisai in March 2015, at which time the Company assumed responsibility for the remaining development costs
due under the agreement. In December 2015, the Company entered into a second amendment to the companion
diagnostic agreement with Roche Molecular. As of December 31, 2017, the Company is responsible for the
remaining development costs of $10.5 million due under the agreement. The agreement was further amended in
March 2018. Under the amended agreement, the Company is responsible for remaining development costs of $10.4
million due under the agreement and Eisai has agreed to reimburse the Company $0.9 million of this amount related
to a regulatory milestone for Japan. We expect the remaining development costs under the amended agreement to be
incurred and paid through 2019.
Under the agreement with Roche Molecular, Roche Molecular is obligated to use commercially reasonable efforts to
develop and to make commercially available the companion diagnostic. Roche Molecular has exclusive rights to
commercialize the companion diagnostic.
F-28
The agreement with Roche Molecular will expire when the Company is no longer developing or commercializing
tazemetostat. The Company may terminate the agreement by giving Roche Molecular 90 days’ written notice if the
Company discontinues development and commercialization of tazemetostat or determines, in conjunction with
Roche Molecular, that the companion diagnostic is not needed for use with tazemetostat. Either the Company or
Roche Molecular may also terminate the agreement in the event of a material breach by the other party, in the event
of material changes in circumstances that are contrary to key assumptions specified in the agreement or in the event
of specified bankruptcy or similar circumstances. Under specified termination circumstances, Roche Molecular may
become entitled to specified termination fees.
10. Employee Benefit Plans
Stock Incentive Plans
In 2008, the Company’s board of directors adopted and the Company’s stockholders approved the 2008 Stock
Incentive Plan (the “2008 Plan”), which provided for the granting of certain defined stock incentive awards to
employees, members of the Company’s board of directors and non-employee consultants, advisors or other service
providers. In April 2013, the Company’s board of directors adopted and the Company’s stockholders approved the
2013 Stock Incentive Plan (the “2013 Plan”), which provides for the granting of certain defined stock incentive
awards to employees, members of the Company’s board of directors and non-employee consultants, advisors or
other service providers. Additionally, in May 2013, the Company’s board of directors adopted and the Company’s
stockholders approved the 2013 Employee Stock Purchase Plan (the “2013 ESPP”), which provides participating
employees the option to purchase shares of the Company’s common stock at defined purchase prices over six month
offering periods.
Stock incentive awards granted under the 2013 Plan may be incentive stock options, non-qualified stock options,
restricted stock awards, restricted stock units, stock appreciation rights and other stock-based awards under the
applicable provisions of the Internal Revenue Code. Incentive stock options are granted only to employees of the
Company. Non-qualified stock options and restricted stock may be granted to officers, employees, consultants,
advisors and other service providers. Incentive and non-qualified stock options and restricted stock granted to
employees generally vest over four years, with 25.0% vesting upon the one-year anniversary of the grant and the
remaining 75.0% vesting monthly over the following three years. Non-qualified stock options granted to consultants
and other non-employees generally vest over the period of service to the Company. Initial non-qualified stock
options granted to members of the Company’s board of directors generally vest over the recipient’s term of board
service. Annual non-qualified stock options granted to members of the Company’s board of directors vest on the
one-year anniversary of the grant. Incentive and non-qualified stock options expire ten years from the date of grant.
Stock-Based Compensation
Stock-based compensation expense is classified in the consolidated statements of operations and comprehensive loss
as follows:
2017
Year Ended December 31,
2016
(In thousands)
$ 5,352
5,216
$10,568
$ 5,613
5,818
$11,431
2015
$ 5,155
4,694
$ 9,849
Research and development
General and administrative
Total
F-29
Stock Options
The Company uses the Black-Scholes option-pricing model to measure the fair value of stock option awards. Key
weighted average assumptions used in this pricing model on the date of grant for options granted to employees are
as follows:
Risk-free interest rate
Expected life of options
Expected volatility of underlying stock
Expected dividend yield
Year Ended December 31,
2016
2015
2017
1.8%
1.2%
6.0 year
s
74.2%
0.0%
6.0 year
s
78.5%
0.0%
1.6%
6.0 year
s
83.6%
0.0%
There were no stock option awards granted to non-employees in the years ended December 31, 2017, 2016 or 2015.
The risk-free interest rate is based upon the U.S. Treasury yield curve in effect at the time of grant, with a term that
approximates the expected life of the option. The Company calculates the expected life of options granted to
employees using the simplified method as the Company has insufficient historical information to provide a basis for
estimate. The Company determines the expected volatility using a blended approach encompassing its historical
experience and the historical volatility of a peer group of comparable publicly traded companies with product
candidates in similar stages of development to the Company’s product candidates. The Company has applied an
expected dividend yield of 0.0% as the Company has not historically declared a dividend and does not anticipate
declaring a dividend during the expected life of the options.
The following is a summary of stock option activity for the year ended December 31, 2017:
Outstanding at December 31, 2016
Granted
Exercised
Forfeited or expired
Outstanding at December 31, 2017
Exercisable at December 31, 2017
Weighted
Average
Exercise
Price per
Share
Weighted
Average
Remaining
Contractual
Term
(In years)
Aggregate
Intrinsic
Value
(In thousands
)
Number of
Options
(In thousands
)
4,059 $ 14.32
13.50
2,332
7.15
(459)
(1,356)
14.49
4,576 $ 14.57
1,640 $ 16.90
7.9
6.4
$
$
5,814
3,379
During the years ended December 31, 2017, 2016 and 2015, the Company granted stock options to purchase an
aggregate of 2,331,500 shares, 2,212,668 shares, and 1,289,755 shares, respectively, at weighted average grant date
fair values per option share of $8.85, $6.42, and $14.57, respectively. The total grant date fair value of options that
vested during the years ended December 31, 2017, 2016 and 2015 was $12.0 million, $12.0 million, and $9.3
million, respectively. The aggregate intrinsic value of stock options exercised was $4.1 million in 2017, $7.1 million
in 2016 and $11.9 million in 2015.
As of December 31, 2017, there was $22.5 million of unrecognized stock-based compensation related to stock
options that are expected to vest. These costs are expected to be recognized over a weighted average remaining
vesting period of 2.7 years.
F-30
Restricted Stock
The following is a summary of restricted stock unit activity for the year ended December 31, 2017:
Number
of
Units
Weighted
Average Grant
Date Fair Value
per Unit
Outstanding at December 31, 2016
Granted
Vested
Forfeited
Outstanding at December 31, 2017
(In thousands)
$
64
—
(20)
(44)
—
$
12.20
—
12.20
12.20
—
In February 2016, the Company granted 80,732 restricted stock units with a grant date fair value of $9.29 per unit, in
accordance with a former chief financial officer’s employment agreement. Of the total restricted stock awards
granted, 73,779 shares vested through the termination of the officer’s employment in August 2017. As of
December 31, 2017 there was no unrecognized compensation cost related to restricted stock units, which were
cancelled upon termination for the remaining unvested awards. The intrinsic value of restricted stock that vested
during the years ended December 31, 2017, 2016 and 2015 was 0.3 million, $0.5 million and $0.0 million,
respectively.
401(k) Savings Plan
The Company has a defined contribution 401(k) savings plan (the “401(k) Plan”). The 401(k) Plan covers
substantially all employees, and allows participants to defer a portion of their annual compensation on a pretax basis.
Company contributions to the 401(k) Plan may be made at the discretion of the board of directors. During the year
ended December 31, 2014, the Company implemented a matching contribution to the 401(k) Plan, matching 50% of
an employee’s contribution up to a maximum of 3% of the participant’s compensation. Company contributions to
the 401(k) plan totaled $0.5 million, $0.4 million and $0.4 million in the years ended December 31, 2017, 2016 and
2015, respectively.
11. Loss per Share
As described in Note 2, Summary of Significant Accounting Policies, the Company computes basic and diluted
earnings (loss) per share using a methodology that gives effect to the impact of outstanding participating securities
(the “two-class method”). The two-class method was not applied for the years ended December 31, 2017, 2016, and
2015 due to the net loss recognized in each of those periods.
Basic and diluted loss per share allocable to common stockholders are computed as follows:
Year Ended December 31,
2017
2015
2016
(In thousands except per share data)
$(134,309) $(110,212) $(132,376)
39,839
57,126
61,471
$
(2.18) $
(1.93) $
(3.32)
Net loss
Weighted average shares outstanding
Basic and diluted loss per share allocable to common
stockholders
F-31
The following common stock equivalents were excluded from the calculation of diluted loss per share allocable to
common stockholders because their inclusion would have been antidilutive:
Stock options
Unvested restricted stock
Shares issuable under employee stock purchase plan
2015
2017
Year Ended December 31,
2016
(In thousands)
4,059
64
46
4,169
4,576
—
23
4,599
3,100
37
8
3,145
12. Related Party Transactions
Celgene has made a series of equity investments in the Company, owning 3,674,640 shares of common stock
representing 5.3% of the Company’s outstanding common stock as of December 31, 2017. Refer to Note
9, Collaborations, for additional information regarding the Company’s original agreement with Celgene entered into
in April 2012 and the amended and restated agreement with Celgene entered into in July 2015.
Under the Celgene collaboration agreement, the Company recognized $1.9 million and $1.1 million of collaboration
revenue in the years ended December 31, 2016 and 2015, respectively. The Company recognized no revenue under
the Celgene collaboration agreement for the year ended December 31, 2017 As of December 31, 2017 and 2016, the
Company had recorded $28.8 million and $28.8 million of deferred revenue related to the Celgene collaboration
arrangement, respectively. Additionally, in the years ended December 31, 2017, 2016 and 2015, the Company
recorded $0.0 million, $0.1 million and $1.1 million, respectively, in global development co-funding from Celgene.
As of December 31, 2017 and 2016, the Company had no accounts receivable and less than $0.1 million,
respectively, related to this collaboration arrangement.
F-32
13. Unaudited Quarterly Results
The results of operations on a quarterly basis for the years ended December 31, 2017 and 2016 are set forth below:
Collaboration revenue
Operating expenses:
Research and development
General and administrative
Total operating expenses
Operating loss
Other income, net
Income tax benefit
Net loss
Loss per share allocable to common stockholders:
Basic
Diluted
Weighted average shares outstanding:
Basic
Diluted
Collaboration revenue
Operating expenses:
Research and development
General and administrative
Total operating expenses
Operating loss
Other income, net
Net loss
Loss per share allocable to common stockholders:
Basic
Diluted
Weighted average shares outstanding:
Basic
Diluted
Quarter Ended
March 31,
2017
June 30,
2017
September 30
,
2017
December 31
,
2017
(In thousands, except per share data)
— $
— $ 10,000 $
$
24,695
8,269
32,964
(32,964)
442
—
27,292
11,170
38,462
(28,462)
438
—
$(32,522) $(28,024) $
28,741
9,311
38,052
(38,052)
455
—
(37,597) $
—
28,933
8,431
37,364
(37,364)
862
336
(36,166)
$
$
(0.56) $
(0.56) $
(0.48) $
(0.48) $
(0.63) $
(0.63) $
(0.52)
(0.52)
58,219
58,219
58,377
58,377
59,899
59,899
69,287
69,287
Quarter Ended
March 31,
2016
June 30,
2016
September 30
,
2016
December 31
,
2016
(In thousands, except per share data)
6,584 $
473 $
472 $
$
17,740
5,846
23,586
(23,114)
235
21,450
7,424
28,874
(28,401)
420
$(22,879) $(27,981) $
23,888
7,522
31,410
(24,826)
490
(24,336) $
478
28,383
7,580
35,963
(35,485)
469
(35,016)
$
$
(0.41) $
(0.41) $
(0.49) $
(0.49) $
(0.42) $
(0.42) $
(0.60)
(0.60)
55,149
55,149
57,352
57,352
57,970
57,970
58,016
58,016
F-33
SENIOR LEADERSHIP
BOARD OF DIRECTORS
Robert Bazemore
President and Chief Executive Officer
Richard Cheswort h, Ph.D.
Senior Vice President, Discovery Research
Andrea Edwards
Head of Human Resources &
Organizational Development
Susan Graf, R. Ph., MBA
Chief Business Officer
Mat t hew Ros
Chief Operating Officer
Pamela St rode
Senior Vice President, Regulatory Affairs &
Quality Assurance
John Weidenbruch
General Counsel
David M. Mot t
Chairman of the Board
New Enterprise Associates, Inc.
Andrew R. Allen, M.D., Ph.D.
Gritstone Oncology
Ken Bat e
Biopharmaceutical Consultant
Robert Bazemore
Epizyme, Inc.
Kevin T. Conroy
Exact Sciences
Michael F. Giordano, M.D.
Biopharmaceutical Consultant
Carl Goldfisher, M.D.
Bay City Capital LLC
Richard F. Pops
Alkermes plc
Bet h Seidenberg, M.D.
Kleiner Perkins Caufield & Byers
ANNUAL MEETING
TRANSFER AGENT
SEC FORM 10-K
The Annual Meeting of
Stockholders will be held at
10:00 a.m. ET on
May 18, 2018, at:
WilmerHale
60 State Street
Boston, MA 02109
CORPORATE COUNSEL
WilmerHale
INDEPENDENT AUDITORS
Ernst & Young LLP
200 Clarendon Street
Boston, MA 02116
The transfer agent is responsible, among
other things, for handling stockholder
questions regarding lost stock
certificates, address changes, including
duplicate mailings and changes in
ownership or name in which shares are
held. These requests may be directed to
the transfer agent at the following
addresses or telephone numbers:
Computershare Investor Services
P.O. Box 505000
Louisville, KY 40233-5000
Tel: 877-373-6374 or 781-575-2879
www.computershare.com/investor
A copy of Epizyme's annual report
on Form 10-K filed with the
Securities and Exchange
Commission is available free of
charge from the company's
Investor Relations Department by
calling 617-500-0623, sending a
request by email to
ir@epizyme.com or sending a
written request by mail to:
INVESTOR RELATIONS
Jason Fredette
Vice President, Investor Relations
400 Technology Square
Cambridge, MA 02139
400 Technology Square | Cambridge, MA | 02139
www.epizyme.com
NASDAQ: EPZM